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 Defects within the apoptotic pathway are thought to contribute to 
tumorigenesis and therapeutic resistance.  Most cytotoxic anti-cancer 
drugs are thought to activate the mitochondria-mediated apoptotic 
pathway; however, the precise mechanistic details remain unclear and, in 
some instances, controversial.  The prevailing view of mitochondria-
mediated apoptosis is that the process occurs through a series of events 
that are orchestrated in a linear step-wise fashion.  From this perspective, 
initiating events include the activation of a BH3-only family member which 
then activates Bax and/or Bak resulting in their homo-oligomerization and 
pore formation spanning the outer mitochondrial membrane to induce 
mitochondrial outer membrane permeabilization (MOMP).  Subsequently, 
cytochrome c and other pro-apoptotic factors are released from the 
intermembrane space of the mitochondria into the cytosol through this 
pore.  Cytosolic cytochrome c interacts with Apoptotic protease activating 
factor-1 (Apaf-1) and initiator caspase-9 where this complex serves as the 
activating platform for initiator caspase-9.  Active caspase-9 then activates 
downstream effector caspase-3 and -7, which produce the biochemical 
and morphological features associated with apoptosis. 
 For my dissertation research, I have investigated the underlying 
molecular requirements necessary for mitochondria-mediated apoptosis 
 xviii
induced by a DNA topoisomerase II inhibitor, a novel heat shock protein 
90 (Hsp90) inhibitor, and elevated temperature in Jurkat T-lymphocytes.  
Combined, the data suggest that different cytotoxic stressors use similar 
as well as distinct mechanisms to execute mitochondria-mediated 
apoptosis.  In addition, the data provide new insights into the mechanistic 
details utilized by these three different stressors, which may prove useful 
for future drug design and therapeutic approaches.   
 In the first Specific Aim, I investigated the molecular requirements 
necessary for mitochondria-mediated apoptosis in response to the DNA-
damaging drug etoposide.  The data suggest that the BH3-only family 
member Bid is important during DNA-damage induced apoptosis where it 
functions to facilitate MOMP.  These studies also found that the active 
form of the protein, tBid, is generated downstream of initiator caspase-9 
activation by executioner caspase-3 and/or -7.  Taken together, these data 
suggest that effector caspases, Bid, and mitochondria forge an 
amplification loop to irreversibly commit a cell to apoptosis. 
 The antiproliferative effects of a novel C-terminal inhibitor of Hsp90, 
designated KU135, were characterized in the second Specific Aim.  This 
study compared the effects of an N-terminal Hsp90 inhibitor, 17-AAG, to 
the effects of the C-terminal Hsp90 inhibitor, KU135.  KU135 was found to 
have more potent antiproliferative effects than 17-AAG, and KU135 
activated the mitochondria-mediated apoptotic pathway, whereas 17-AAG 
 xix
was primarily cytostatic.  Finally, 17-AAG caused robust induction of the 
cytoprotective proteins Hsp90 and Hsp70 which could account for its lack 
of an apoptotic response. 
 The molecular requirements for heat-induced apoptosis were 
examined in the third Specific Aim.  The data showed that heat-induced 
apoptosis is a mitochondria-mediated event and that caspase-9, and not 
caspase-2, is the most apically activated caspase.  The BH3-only protein, 
Bid, was found to be important during heat-induced apoptosis where it 
was needed to facilitate MOMP.  However, we found that tBid was 
generated downstream of caspase-9 suggesting that it may function to 
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Chapter 1: Introduction and Background 
 
1.1 The Relationship Between Apoptosis and Cancer 
 
It is estimated that there were 1,479,350 new cancer cases and 
562,340 new cancer-related deaths during 2009 in the United States.  
There are currently over 100 types of known cancers with lung, breast, 
colon, and prostate being the most common (American Cancer Society).  
These cancers are thought to develop through a series of events 
eventually causing healthy cells to develop into a cancerous cells.  Events 
that contribute toward tumorigenesis include genetic modifications to the 
cell that favor uncontrolled proliferation and a lack of cell death.  In this 
way, a cancerous cell possesses a survival advantage.  It has been 
suggested that the large variety of genotypes of different cancer cells fall 
into one of six categories, with one genotype from each category being 
necessary for cell transformation.  These categories include: self-
sufficiency in growth signals, insensitivity to anti-growth signals, limitless 
replicative potential, sustained angiogenesis, tissue invasion and 
metastasis, and evasion of apoptosis (Hanahan and Weinberg, 2000).  
This idea suggests a model where carcinogenesis is a process in which a 
cell progresses from a state of normalcy to one of malignancy acquiring at 
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least six mutations or sufficient mutations that fall within all six of the 
required categories. 
 The vast majority of adult cells are in a state of quiescence (Gap 
phase 0 or G0) and require a stimulus to exit this phase and enter the cell 
cycle.  The growth signals that cause this shift in the cell’s behavior are 
provided through the microenvironment; however, some oncogenes have 
acquired the ability to function as continuous growth stimuli.  An example 
is the Ras proto-oncogene that is activated through binding of a ligand, 
such as growth factors, to tyrosine kinase receptors  (Hanahan and 
Weinberg, 2000).  By activating Ras, one of the pathways activated is the 
Raf/MEK/ERK MAP kinase pathway, which promotes cell survival by 
providing a mitogenic growth stimulus.  It is estimated to be mutated and 
constitutively active in 25% of all cancers (Downward, 2006); furthermore, 
it is often used as a mechanism of transformation in research settings and 
has been one of the most studied receptor tyrosine kinase pathways 
relative to cancer.   Cancer cells not only induce neighboring cells to 
produce growth factors, but also often produce the growth factors to which 
they themselves respond generating an aberrant autocrine-signaling loop 
(Hanahan and Weinberg, 2000).  Having self-sufficiency in growth signals 
is one of the six capabilities defined above as being required for 
tumorigenesis.   
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Another capability of tumorigenesis is becoming insensitive to anti-
growth signals (Hanahan and Weinberg, 2000).  These signals are often 
conveyed to remove a cell that is actively participating in the cell cycle to a 
state of rest or to move the cell into a permanent differentiated state 
(Weinberg, 1995).  An example of an anti-growth signaling pathway is the 
TGFß pathway that maintains the tumor suppressor protein 
retinoblastoma (pRb) in a hypophosphorylated state, which then functions 
to halt progression of the cell cycle through the restriction point within gap 
phase 1 (G1).  This pathway is disrupted in many different types of human 
cancers, which, in turn, allows the phosphorylation of pRb and 
subsequently the cell to progress through the restriction point within G1 
(Weinberg, 1995).   
The ability to go through an infinite number of DNA replication 
cycles is another acquired trait of tumor cells (Hanahan and Weinberg, 
2000).  A typical cell has a finite number of divisions it can undergo 
because of the loss of terminal sequences at the end of chromosomes, 
which is known as the end-replication problem that occurs during DNA 
synthesis.  However, cancer cells are able to continuously replicate their 
DNA without entering into a state of cellular senescence or a state of crisis 
as a consequence (Hayflick, 1997; Shay and Bacchetti, 1997).  This ability 
largely depends on the enzyme telomerase that maintains telomere length 
at the end of chromosomes by adding six nucleotide bases to the newly 
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replicated strand of DNA (Bryan and Cech, 1999).  It has been estimated 
that 85-90% of all malignancies up-regulate the expression of telomerase. 
It has also been suggested that cells that do not up-regulate telomerase 
maintain their telomere length through an alternate form of maintenance 
known as alternative lengthening of telomeres (ALT)  (Shay and Bacchetti, 
1997; Bryan and Cech, 1999).   
Angiogenesis is not an innate ability of proliferating cells; in fact, the 
lack of a blood supply is actually a way of interfering with a proliferating 
mass of cells (Hanahan and Weinberg, 2000).  The cells within the center 
of a tumor mass will often die and subsequently initiate an inflammatory 
response due to the lack of a blood supply at the heart of the tumor.  
Tumor cells must acquire the ability to generate a source for oxygen and 
nutrients through angiogenesis (Bouck et al., 1996; Hanahan and 
Folkman, 1996; Folkman, 1997).  An initiating step during angiogenesis is 
the production of vascular endothelial growth factor (VEGF), which then 
binds to its cognate tyrosine kinase receptor present on endothelial cells 
(Veikkola and Alitalo, 1999).  Many cancers have up-regulated the 
expression of VEGF and/or down-regulated known inhibitors of VEGF 
such as thrombospondin-1, thereby facilitating and promoting 
angiogenesis (Volpert et al., 1997; Hanahan and Weinberg, 2000). 
Metastases account for 90% of human cancer cell deaths (Sporn, 
1996).  Advanced primary tumor masses can acquire the ability to 
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metastasize to close and/or distant secondary sites.  This process 
requires the ability of the tumor cells to release themselves from the site of 
origin to target tissues by down-regulating or mutating cell-cell interacting 
proteins such as cell adhesion molecules (CAMs) and/or cadherins, which 
are often altered in metastatic cells (Hanahan and Weinberg, 2000).  An 
example is E-cadherin, which is expressed ubiquitously on epithelial cells; 
however, epithelial-derived metastatic cancers have often down-regulated 
E-cadherin (Christofori and Semb, 1999).  This down-regulation prevents 
the anti-growth signal that is usually communicated between two cells 
through E-cadherin bridges thereby facilitating the release of the cells from 
the site of origin to target sites (Christofori and Semb, 1999).   
 Finally, the expansion of cancer cells is not only determined by the 
rate of proliferation but also the rate of cell death.  Resistance to apoptosis 
is thought to be a hallmark of most, if not all, types of cancer (Hanahan 
and Weinberg, 2000). This type of cell death can be triggered by 
intracellular and extracellular stimuli.  For example, apoptosis is stimulated 
extracellularly by death receptor ligands and/or the lack of survival signals, 
for example, hormones.  It is also stimulated intracellularly in response to 
DNA damage, oncogene activation, or hypoxia (Evan and Littlewood, 
1998). Apoptosis was first associated with cancer in 1972 through 
experiments using hormone withdrawal to stimulate death in hormone-
dependent tumors (Kerr et al., 1972).  
 6  
 An example of an anti-apoptotic mutation observed in more than 
50% of cancers is a mutation in the protein 53 gene (p53).  This protein 
functions as a tumor suppressor by halting the cell cycle in response to 
DNA damage, or triggers apoptosis if the damage is beyond repair (Harris, 
1996b; Harris, 1996a).  By mutating p53, the cell acquires two survival 
advantages with the first being progression through the cell cycle, 
irrespective of the amount of DNA damage.  The second survival 
advantage is avoidance of apoptotic cell death.  p53 is a unique tumor 
suppressor in that mutation of only one allele will render the cell mutant 
just as if it were a homozygous mutation.  Therefore, this tumor 
suppressor does not behave as suggested by Knudson’s two-hit 
hypothesis, which suggests that both tumor suppressor gene copies must 
be mutated for the cell to exhibit a loss-of-function phenotype (Knudson, 
1971).  p53 functions as a tetramer meaning that only 1 of 16 functional 
protein complexes would be produced in the heterozygous mutant.  
Furthermore, because of the dual function of this protein, mutations within 
this gene generate more than one survival and/or resistance effect.  
 
1.2 Overview of Chemotherapeutic Agents and Cell Death  
 
 Chemotherapy was introduced for the treatment of cancer over fifty 
years ago with the nitrogen mustard DNA alkylating agent 
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mechlorethamine (Bonte et al., 1956; Johnstone et al., 2002).  There are 
currently several different classes of chemotherapeutic agents, many of 
which kill tumor cells by inducing apoptosis as the therapeutic end-point, 
although they have distinct drug targets (Lowe and Lin, 2000).  Resistance 
to therapy, due to down-regulation of key components of the pro-apoptotic 
machinery or up-regulation of key anti-apoptotic proteins, is thought to be 
quite common.  Furthermore, resistance due to aberrant regulation of the 
apoptotic pathway is also thought to be a major component of multi-drug 
resistant cancers, although this argument is still under debate and other 
mechanisms are clearly involved, for example, upregulation of the efflux 
drug transporter P-glycoprotein (Brown and Wouters, 1999; Johnstone et 
al., 2002). 
 There are several classes of anticancer agents including: DNA 
damaging agents, antitubulin agents, kinase inhibitors, hormone inhibitors, 
antibody based therapies, and vascular targeting agents (Thurston 2007). 
This is not an exhaustive list, and new strategies are being developed, 
such as heat-induced cell death (Pissuwan et al., 2006) and the targeting 
of heat shock protein 90 (Hsp90) (Whitesell et al., 1994; Schulte et al., 
1995).  Nonetheless, the largest groups are those that bind and/or 
damage DNA either directly or indirectly (Thurston 2007).  
Chemotherapeutic agents are also often given in combination to achieve 
additive or synergistic effects, to enhance efficacy, and /or to decrease the 
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toxic adverse effects of the different drugs by lowering the administered 
dose compared to the dose when given independently.  It is currently 
estimated that 50% of combination chemotherapy regimens contain at 
least one type of DNA-damaging agent within the drug class of 
topoisomerase II inhibitors (Hande, 1998; Martincic and Hande, 2005).  
Because the majority of anti-cancer agents are not selective for neoplastic 
cells, there are short-term and long-term toxic adverse effects associated 
with the majority of these drugs due to the damaging and killing of cells 
that are not pathological.  
 
1.3 Overview of Topoisomerase II Inhibitors and Cell Death 
 
 Topoisomerase II is an enzyme that functions to decatenate DNA 
by cleaving both strands of DNA, pulling one strand through the other, and 
resealing the cleaved strands (Wang, 2002).  This process is energy-
dependent and requires the presence of the divalent cation Mg2+. There 
are two isoforms of this enzyme, α and β, and both function during DNA 
replication, chromatid condensation, and transcription to unravel 
supercoiled DNA.  Research is ongoing to determine if the functions are 
entirely redundant, although the phenotype of the topoisomerase II β 
knockout mice suggests these enzymes have distinct functions, at least in 
part (Yang et al., 2000). 
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 As mentioned above, one class of DNA-damaging agents are the 
topoisomerase II inhibitors.  This class of anticancer drugs contains both 
epipodophyllotoxins such as etoposide and anthracyclines such as 
doxorubicin with the therapeutic end-point of each being cell death.  
Although both types of drugs induce apoptosis, they each do so by similar, 
as well as distinct, mechanisms of action.  While epipodophyllotoxins are 
considered to be cell cycle-specific (late S/G2), anthracyclines are thought 
to not target the cell-cycle during a specific phase, although there is 
evidence to suggest they are selective for cells in the S/G2 phase of the 
cell cycle (Chu and Sartorelli 2007; AccessMedicine).  Furthermore, 
epipodophyllotoxins are thought to be specific for the topoisomerase II α 
isoform, whereas it is not known whether the anthracyclines discriminate 
between the two isoforms. 
Epipodophyllotoxins are semisynthetic derivatives of podophyllotoxin 
which is extracted from Podophyllum peltatum (mayapple root).  It is 
currently thought that podophyllotoxins directly bind to the active site of 
topoisomerase II and prevent the re-ligation of the cleaved strands of DNA 
(Nitiss, 2009) (Figure 1).  This causes an accumulation of DNA double-
strand breaks that then cause the cell to undergo mitochondria-mediated 
apoptosis.  Etoposide is an example of an epipodophyllotoxin that is 
currently used clinically to treat various cancers, including leukemia, 
lymphoma, lung cancer, and breast cancer.  Resistance to etoposide is  
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known to occur through an increased expression of the efflux transporter 
P-glycoprotein, a decrease in expression of topoisomerase II α, or through 
mutation of the catalytically active site (Nitiss and Beck, 1996).  The short-
term adverse effects of these drugs  include bone marrow suppression, 











Figure 1: Topoisomerase II-epipodophyllotoxin drug complex. 
Etoposide is used as an example of an epipodophyllotoxin that binds to 
the catalytically active site of topoisomerase II and prevents the 
religation of topoisomerase II-cleaved double stranded DNA; therefore, 
this drug induces double stranded DNA breaks. 
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classes of chemotherapeutic agents that target rapidly dividing cells within 
the body, whereas the most serious long-term adverse effect is 
development of secondary leukemias involving mixed lineage leukemia 
(MLL) chromosomal translocations (Felix et al., 2006). 
 
1.4 Overview of Hsp90 as an Anti-cancer Drug Target 
 
 The heat shock proteins (Hsps) were first discovered by Ritossa in 
1962 due to their induction in response to elevated temperatures (For 
Review: (Ritossa, 1996)).  It is now known that the majority of proteins 
within this family are present constitutively within the cell where they 
function to chaperone other proteins in their proper folding and localization 
within the cell.  In addition, they also prevent protein aggregation and 
mediate proteolytic turnover.  Heat shock proteins have been conserved 
throughout evolution ranging from bacteria to humans where the family 
members fall into five main classes depending on their molecular weight 
(i.e. Hsp27, Hsp60, Hsp70, Hsp90 and Hsp100) (Kregel, 2002).  Heat 
shock proteins are transriptionally up-regulated in response to proteotoxic 
and stressful environments (e.g. heat, toxins, and hypoxia), where it is 
widely believed that this is a compensatory mechanism implemented to 
maintain protein homeostasis and is termed the “heat shock response” 
(Whitesell and Lindquist, 2005).   
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 Although the heat shock family of proteins function as molecular 
chaperones to assist in protein folding, it has been suggested that they 
bind different clients at different times depending on the phase of protein 
maturation (Whitesell and Lindquist, 2005).  In addition, chaperones often 
function in protein complexes that include other heat shock proteins, 
adaptors, and co-chaperones.  The composition of these protein 
complexes is thought to depend on the specific client involved as well as 
its level of maturation (Whitesell and Lindquist, 2005).  An example is the 
estrogen receptor which initially is chaperoned by a complex containing 
Hsp70 and Hsp40; however as the receptor matures it will be passed to a 
complex containing Hsp70 and Hsp90 and the final mature protein will be 
associated with a complex where the only heat shock protein within the 
complex is Hsp90 (For Review: (Whitesell and Lindquist, 2005)).  This 
model suggests that the chaperoning properties of Hsp90 are needed late 
in the process of protein maturation and may offer stability for mature but 
labile client proteins (Whitesell and Lindquist, 2005). 
 Many cancers including solid tumors and hematological 
malignancies have been reported to have elevated levels of several heat 
shock proteins, where over-expression of Hsp27, Hsp70, and Hsp90 have 
been correlated with a poor therapeutic outcome(Morimoto and Santoro, 
1998; Bagatell and Whitesell, 2004) .  In response to a stressful stimulus, 
the transcriptional up-regulation of heat shock proteins is regulated by the 
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transcription factor HSF1 (heat shock factor-1) in healthy cells; however, it 
is currently not known if the mechanism of up-regulation is the same in 
cancer cells (Bagatell and Whitesell, 2004).  It seems reasonable to 
suspect that activation of HSF-1 resulting in the cytoprotective heat shock 
response would occur in cancer cells due to the harsh conditions of their 
microenvironment which often include hypoxia, acidosis, and nutrient 
deprivation (Bagatell and Whitesell, 2004).  HSF-1 is maintained in an 
inactive state through its binding to Hsp90, but it is thought that as 
misfolded proteins increase during a stress response, they compete with 
HSF-1 for Hsp90 which eventually causes the release of HSF-1 from the 
Hsp90 protein complex which, in turn,  facilitates its activation (Zou et al., 
1998). 
  Hsp90 represents a family of ATPase-containing molecular 
chaperones that comprise 1-2% of total cellular protein, although this can 
increase to as much as 6% under conditions of cellular stress.  There are 
four isoforms of Hsp90 including Hsp90α, Hsp90β, Grp94 (glucose 
regulating protein 94), and TRAP-1 (tumor necrosis factor receptor-
associated protein-1).  The functional difference between these isoforms 
has yet to be determined; however, there are differences in their 
localization and expression.  Hsp90α and Hsp90β are both located within 
the cytoplasm of the cell; however, it is thought that the α isoform is 
inducible, whereas the β isoform is present constitutively (Hahn, 2009).  
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Grp94 and TRAP-1 are localized to the endoplasmic reticulum and the 
mitochondira, respectively (Hahn, 2009).   
 Hsp90 is known to have between 100-200 client proteins and is 
often present at elevated levels in cancer cells where it is thought to 
stabilize oncogenic proteins involved in all six hallmarks of cancer (Figure 
Hsp 90 client proteins 
























Figure 2: Example of Hsp90 client proteins involved in the six 
hallmarks of cancer.  Bcr-Abl, translocation gene product resulting 
from the fusion of a portion of the Breakpoint Cluster Region gene 
fused with the Abl1 gene; Apaf-1, apoptotic protease activating factor-
1; MMP-2, matrix metalloproteinase-2; VEGF-R, vascular endothelial 
growth factor receptor. 
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2).  It has been reported that Hsp90 is often seen as a homo-dimer in 
healthy cells whereas it is often seen in a multimeric protein complex in 
cancer cells.  In addition, Hsp90 has also has been shown to have an 
increased amount of ATPase activity in cancer cells compared to healthy 
cells (Kamal et al., 2003). 
 Significantly, whereas many Hsp90 client proteins are being 
pursued individually as targets for anti-cancer drug development, inhibition 
of Hsp90 in cancer cells would be expected to prevent the maturation and 
stabilization of numerous Hsp90 client proteins, leading to their ultimate 
degradation within the ubiquitin-proteasome pathway (Whitesell et al., 
1994; Schulte et al., 1995). In this regard, Hsp90 has emerged as a target 
for cancer chemotherapeutic drug design because inhibition of its 
chaperoning function simultaneously leads to the destabilization and 
degradation of multiple oncogenic proteins.  
The earliest Hsp90 inhibitors were the natural products 
geldanamycin (GA), an analogue of GA, i.e.,17-AAG (17-
allylaminogeldanamycin), and radicicol (Whitesell et al., 1994; Sharma et 
al., 1998). These compounds were shown to inhibit Hsp90 by binding to its 
N-terminal ATP-binding site, which, in turn, induces destabilization of 
Hsp90-dependent client proteins (Roe et al. 1999). In the case of GA and 
17-AAG, these compounds were shown to exert antineoplastic effects in 
numerous preclinical experimental models. However, the likelihood of 
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these compounds making it into the clinic seems limited, in part, because 
of concerns about their adverse hepatotoxic effects (Egorin et al., 1998) 
and poor solubility (Chiosis et al., 2003). A more significant limitation is 
that the cytotoxic potential of these agents is limited because they 
frequently induce a strong stress response leading to increased de novo 
expression of the antiapoptotic proteins Hsp70 and Hsp90 (Whitesell et 


























Figure 3: Novobiocin and KU135 chemical structures.  KU135 is one 
of the novobiocin-derived analogues that inhibit Hsp90. 
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More recently, it has been shown that the antibiotic novobiocin can 
inhibit Hsp90 chaperone function of client proteins by binding to a 
previously unrecognized C-terminal ATP-binding domain in Hsp90 (Marcu 
et al., 2000a; Marcu et al., 2000b).  However, the binding affinity of 
novobiocin for the C-terminal ATP-binding site was shown to be poor, 
manifesting an IC50 of ~ 700 μM (Marcu et al., 2000a).  Currently, more 
than 300 analogues of novobiocin, designated “KU” compounds, have 
been developed in the medicinal chemistry laboratory of Brian Blagg on 
the KU-Lawrence campus, many of which exhibit significantly increased 
potency (Yu et al., 2005; Burlison et al., 2008a). Among these compounds 
is the novobiocin analogue KU135, which we have found binds to Hsp90 
and is a potent inducer of apoptosis in human leukemia cells (Figure 3). 
 
 
1.5 Overview of Heat-Induced Apoptosis 
 
There has recently been an increasing interest in the potential use 
of heat-induced apoptosis as novel treatment of neoplasms; furthermore, it 
has also gained interest as a way of inducing apoptosis by damaging the 
mitochondria directly which would be useful as mutations within the 
apoptotic pathway are usually upstream of the mitochondria (Johnstone et 
al., 2002; Milleron and Bratton, 2007a).  As mentioned in the previous 
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section, sub-lethal doses of heat exposure induce adaptive responses 
such as the expression of heat shock proteins (Hsp27, 70, and 90), which 
protects cells from subsequent stress, such as higher temperatures and 
chemotherapeutic agents (Jolly and Morimoto, 2000).  However, when 
cells are exposed initially to a lethal temperature, these adaptive 
responses do not prevent cell death.  It is currently thought that 
temperatures above 42°C induce apoptosis; however, as the temperature 
increases, it has been reported that the amount of apoptosis decreases 
with an increase in necrosis (Milleron and Bratton, 2007a).    
Currently, there is research being conducted on the therapeutic 
potential of heat shock using nanoparticles targeted to cancer cells, which 
are then heated to induce cell death (Huang et al., ; Pissuwan et al., 
2006).  Heat-induced cell death is also being explored as a putative 
component of adjuvant therapy (Kouloulias et al., 2005).  Although heat 
shock is known to induce apoptosis, the mechanism is poorly understood 
and currently controversial. 
 
1.6 Overview of Apoptosis and Key Protein Families 
 
Apoptosis or programmed cell death is a process ultimately leading 
to a cell’s demise in a tightly regulated and precise fashion.  It is distinct 
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from the necrotic form of cell death in several ways.  Key features of a cell 
undergoing apoptosis include cellular shrinkage, chromatid condensation, 
 
Table 1: Comparison of Apoptosis vs. Necrosis  
Apoptosis Necrosis 
Physiological/ Pathological Accidental 
Tightly Regulated Unregulated or Poorly Regulated
Membranes Intact Late Membrane Integrity Lost Early 
No Leakage of Cell Content Leakage of Cell Content 
Oligonucleosomal DNA- 
Fragmentation 
Random DNA Degradation 
Cell Shrinkage Cytoplasmic Swelling 
No Mitochondrial Swelling Mitochondrial Swelling 
ATP-dependent ATP Not Required 
No Inflammatory Response Inflammatory Response  
 
and the formation of apoptotic bodies (Kerr et al., 1972; Wyllie et al., 
1980).  These apoptotic bodies are engulfed by phagocytes to avoid the 
initiation of an inflammatory response (Danial and Korsmeyer, 2004).  
Typical features of necrosis, on the other hand, are cellular swelling and 
rupture, random DNA degradation, and generation of an inflammatory 
response (Table 1).  Apoptosis plays a necessary role during development 
 20  
and in maintaining tissue homeostasis (Danial and Korsmeyer, 2004).  
Several diseases can arise when this process is aberrant resulting in too 
much cell accumulation or cell attrition.  For example, cancers arise when 
cells accumulate rather than undergo apoptosis, and Parkinson’s disease 
has been associated with increased or accelerated cell death (Thompson, 
1995). 
Nobel Laureate H. Robert Horvitz is credited with identifying the 
regulatory genes responsible for the process of apoptosis in 
Caenorhabditis elegans (C. elegans) and helping to identify mammalian 
homologues of those genes (Figure 4) (Metzstein et al., 1998).  His work 
was largely based on the 131 cells that are pre-determined to die during 
normal development of C. elegans as determined by mapping the fate of 
all 1090 cells in the worm (Metzstein et al., 1998).  The genetic basis of 
apoptosis is now considered well-defined and consists of highly conserved 
core proteins.  In general, there are three primary protein categories that 
function to govern apoptosis: regulator, adaptor, and effector proteins.  As 
illustrated at the bottom of Figure 4, humans have also evolved an 
additional level of complexity with respect to apoptosis signaling 
pathways.  Specifically, human cells can be triggered to undergo a 
receptor-mediated form of apoptosis.  In addition, there is an important 
difference between C. elegans and humans.  Whereas Ced-9 can inhibit 
death by binding to and inhibiting Ced-4, the mammalian homologue of  
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Figure 3: Conservation of Core Cell Death Genes Between C. elegans 
and Humans.  C. elegans have one apoptotic pathway where Egl-1 inhibits 
Ced-9 which, in turn, alleviates the inhibition of Ced-9 on Ced-4, thereby 
facilitating Ced-4 activation.  Ced-4 then activates Ced-3 which results in 
death.  Two important differences have evolved in humans with the first 
being that the human homologue of Ced-9, Bcl-2, does not directly bind 
and inhibit Apaf-1.  Bcl-2 exerts its inhibition at the level of mitochondria by 
preventing the release of cytochrome c which is necessary for the 
activation of Apaf-1. The other important difference is that humans have 
evolved an additional pathway leading to cell death known as the receptor 
mediated pathway which is executed differently depending on whether a 
cell is characterized as either type I or type II (also see Figure 8).   Ced, 
cell death abnormal; Egl, egg laying defective; BH3, Bcl-2 homology 
domain 3; Bcl-2, B-cell lymphoma 2; Apaf-1, Apoptotic protease activating 
factor 1; FADD, fas associated death domain. 
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Ced-9, Bcl-2, does not bind to, and directly inhibit, Apaf-1(Apoptotic 
protease activating factor-1), but rather exerts its inhibitory effect by 
localizing to the outer mitochondrial membrane where it presumably 
prevents the release of cytochrome c (Figure 4) (Danial and Korsmeyer, 
2004).  Cytochrome c is required for activation of Apaf-1 in mammalian 
systems (Li et al., 1997) . 
 
1.6.1 Caspases  
 
 Caspases (cysteine proteases that cleave their substrates after 
aspartate residues) are the biochemical foundation of apoptosis and are 
responsible for the execution of cell death.  These enzymes are present 
constitutively in the cell as proforms and are activated in response to pro-
apoptotic stress.  Caspases are classified as either initiator caspases 
(e.g., caspase-8, -9, -10, possibly -2) or effector caspases (e.g., caspase-
6, -7, -3) according to their timing of activation within the caspase 
cascade, substrate specificity, and/or unique structural features (Fuentes-
Prior and Salvesen, 2004). The cysteine within the conserved penta-
peptide consensus sequence QACxG is considered to be the active site of 
caspases, and as mentioned above, active caspases cleave substrates 
following an aspartate amino acid residue (Cohen, 1997).  Initiator 
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caspases are activated early during apoptosis, whereas effector caspases 
are activated later by active initiator caspases (Nunez et al., 1998) (Figure 
5).    
Caspases have three distinct protein domains including a 
prodomain, a large subunit (~20 kDa), and a small subunit (~10 kDa) – 
with an aspartate residue being present at the interface of the different 
domains (Nunez et al., 1998).  The key structural feature unique to initiator 
caspases is the long prodomain that interacts with an adaptor molecule 
(e.g., Apaf-1, FADD, and possibly RIP-associated ICH-1/CED-3 
homologous protein with a death domain (RAIDD)).  This interaction 
facilitates their activation by bringing initiator procaspases of a single type 
into close proximity which facilitates their activation through dimerization 
and/or a conformational change, auto-activation, and subsequent 
proteolytic cleavage.  Active initiator caspases cleave downstream effector 
procaspases, which then dimerize to form an active effector caspase.  
Effector caspases destroy the cell by cleaving over 1000 known 
substrates and are responsible for the typical biochemical and 
morphological features observed during apoptosis, for example, chromatin 
condensation and apoptotic body formation.   
Currently, controversy surrounds the precise mechanism(s) 
required for initiator caspase activation.  There are two paradigms, namely 
the induced proximity and induced conformation models, attempting to  
























Figure 5:  Caspase classification and activation.  Caspases are  
cysteine proteases that cleave target substrates following an aspartate  
amino acid residue.  Procaspases have three domains with an aspartate  
amino acid and a non-specific amino acid (X) present at the interface of  
the different subunits.  The pentapeptide sequence, QACxG, within the  
large subunit, contains the active site where x represents any amino acid. 
Initiator caspases are activated through dimerization and/or a  
conformational change, whereas effector caspases are activated through 
cleavage by an active initiator caspase, which cleaves the effecotor  
caspases between their different domains.  Activated effector caspases 
cleave over 1000 known substrates which results in cellular death.  Casp, 
caspase; mCasp-12, mouse caspase-12; Asp, Aspartate; Q, glutamine; A,  
alanine; C, cysteine; x, non-specific; G, glycine.  
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describe the process of initiator caspase activation where it is possible 
that both perspectives are correct and not mutually exclusive.  The 
induced proximity model suggests that the adaptor molecules required for 
initiator caspase activation function to bring these caspases into close 
proximity to one another which results in their homo-dimerization and 
subsequent activation.  In this model the activating event is dimerization 
(Boatright and Salvesen, 2003).  The issue surrounding this perspective is 
that although engineered homo-dimerized caspase-9 does exhibit 
increased activity compared to monomeric caspase-9, the activity is much 
less than the activity of caspase-9 when it is activated within the 
apoptosome complex (Chao et al., 2005).  An alternative model is known 
as the induced conformation model and suggests that caspase-9 
undergoes a conformational change upon binding to the apoptosome 
which results in its activation (Bao and Shi, 2007).  It is worth mentioning 
that the experimental methods used to describe these models primarily 
focused on caspase-9, and it seems plausible that different initiator 
caspases utilize different mechanisms for their activation.   
 
1.6.2 Bcl-2 family of proteins 
 
The Bcl-2 family of proteins serve as key regulators of caspase 
activation.  In particular, the Bcl-2 family of proteins contains both pro- and  
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Figure 6. Well-characterized Bcl-2-family proteins and how they 
regulate mitochondrial outer membrane permeabilization. 
A, Well-characterized Bcl-2 faimly members include both pro- and anti-
apoptotic family members.  Anti-apoptotic family members contain four 
Bcl-2 homology (BH) domains, whereas pro-apoptotic members contain 
BH domains 1-3 or only the BH3 domain.  B, Activation of a pro-apoptotic 
BH123 protein occurs by displacing it from an anti-apoptotic family 
member (BH1-4 protein).  This displacement is mediated by a BH3-only 
family member.  C, Activation of a pro-apoptotic BH123 family member is 
mediated by an “activator” BH3-only family member.  The “activator” 
protein is maintained in an inactive state by an anti-apoptotic Bcl-2 family 
member (BH1-4 protein).  An “inactivator” BH3-only family member 
displaces the “activator” BH3-only family member from the anti-apoptotic 
Bcl-2 family member (BH1-4 protein).  This displacement allows the 
“activator” protein to activate the BH123 famly member.
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anti-apoptotic members that are thought to regulate apoptosis at the level 
of mitochondria by either promoting or inhibiting the release of cytochrome 
c and other intermembrane space proteins into the cytosol (Breckenridge 
and Xue, 2004).  The release of cytochrome c into the cytosol is significant 
insofar as it activates Apaf-1, which, in turn, activates procaspase-9 to 
initiate a caspase cascade (Li et al., 1997). 
In 1986, Bcl-2 was first identified as an oncogene in a B-cell 
lymphoma resistant cancer where this protein was overexpressed and 
contributed to drug resistance (Cleary et al., 1986).  Following the 
identification of Bcl-2, other family members have been identified and 
include both pro- and anti-apoptotic proteins.  The anti-apoptotic proteins 
contain four Bcl-2 homology domains (BH1-4), while the pro-apoptotic 
family members are further characterized as containing “BH123” domains 
(e.g. Bak and Bax) or “BH3-only” domains (e.g. Bim, Puma, and Bid) 
(Figure 6A).  The anti-apoptotic family members exert their protective 
effects in a similar fashion; however, the pro-apoptotic family members 
have different pro-death mechanisms (Breckenridge and Xue, 2004).  
Anti-apoptotic Bcl-2 family members are thought to exert their 
inhibitory effects primarily by localizing to the outer mitochondrial 
membrane (OMM), where they inhibit the release of cytochrome c by one 
of several proposed mechanisms.  One model involves the direct binding 
of an anti-apoptotic Bcl-2 protein to a BH123 protein to prevent its 
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activation (Figure 6B), while a second model suggests they bind to BH3-
only proteins and inhibit the ability of these proteins to activate a BH123 
protein.  The latter model supports a scheme in which specific BH3-only 
family members are classified as either inactivators (e.g. Bad and Noxa) 
or activator proteins (e.g. Bid, Bim, and Puma).  In this scheme, Bcl-2/xL 
normally bind and sequester the activators.  In response to an apoptotic 
stimulus, this inhibition is relieved by inactivator proteins, which displace 
the activators bound to Bcl-2/xL.  This displacement then allows the 
activators to activate the BH123 family members to induce MOMP 
(mitochondrial outer membrane permeabilization) (Figure 6C) (Kim et al., 
2006a). 
In response to intracellular damage, the pro-apoptotic Bcl-2 family 
members are thought to “sense” the damage and relay the signal to 
activate the mitochondrial apoptotic pathway, resulting in extrusion of 
intermembrane space proteins into the cytosol.   It is widely believed that 
the BH123 proteins homo-oligomerize forming  pores that  span the outer 
mitochondrial membrane in response to a pro-apoptotic signal, often 
involving the prior activation of a BH3-only protein.  The BH123 proteins, 
Bak and Bax, double knockout (DKO) phenotype is highly resistant to 
most, if not all, cytotoxic stressors including DNA-damaging agents, 
endoplasmic reticulum (ER) stressors, and hormone withdrawal-induced 
cell death (Wei et al., 2001).  Because they show this DKO phenotype but 
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have no observed phenotype when knocked out individually, it is accepted 
throughout the literature that these proteins are redundant in function with 
the primary function being pore formation spanning the OMM. 
Pore formation is necessary to facilitate MOMP in that it allows the 
release of cytochrome c and other intermembrane space proteins into the 
cytosol.  Cytochrome c will then interact with and activate Apaf-1 causing 
activation of the intrinsic caspase cascade, commencing with procaspase-
9.  The release of cytochrome c is considered to be the “point of no return” 
for the cell by some investigators because it is thought that all 
mitochondria release all of their cytochrome c within a very short period of 
time following MOMP (Goldstein et al., 2005).  However, there is also 
evidence to suggest that this is not the case, but rather that the amount of 
cytochrome c initially released is only a “trickle” and increases because of 
a feed-forward mechanism.  The first view favors a linear progression of 
apoptosis, while the second view favors a higher degree of complexity to 
the process.  The two perspectives also differ in the dependence of 
caspase activation for cytochrome c release; the former is caspase-
independent, while the latter appears to depend on caspase activation 
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1.6.3 Additional Modulators of Caspase Activation 
 
 Inhibitors of apoptosis (IAPs) make up an eight-membered family of 
proteins which include: c-IAP-1, c-IAP-2, XIAP, NAIP, Bruce, Survivin, ML-
IAP, and ILP2 (Eckelman et al., 2006).  The hallmark feature of all 
members within this family is that they contain at least one baculoviral IAP 
repeat (BIR) domain.  In addition, some also contain a really interesting 
new gene (RING) domain which is thought to be an E3 ubiquitin ligase 
domain (Eckelman et al., 2006).  Although they were initially discovered 
based on their ability to inhibit apoptosis in insect cells, it is now known 
that they play a functional role in a variety of cellular processes including 
cell cycle, cell signaling, and apoptosis(Clem et al., 1991; Schimmer, 
2004; Srinivasula and Ashwell, 2008) . 
 Of the eight IAP proteins, X-linked inhibitor of apoptosis (XIAP) has 
been the best characterized related to its inhibitory effects on caspase 
activation.  It is unique in that it is the only known IAP able to inhibit active 
caspases directly through binding via its BIR domains (Eckelman et al., 
2006).  XIAP binds caspase-9 through an interaction with the BIR3 
domain, whereas caspases-3 and -7 are inhibited through an interaction 
with the BIR2 domain (Figure 7).  Although it has been shown that other 
IAP family members are able to bind to caspases (e.g., c-IAP1 and c-
IAP2), the inhibitory effects of this binding have yet to be determined; 
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however, there is ongoing research focused on the possibility of caspase 
inhibition mediated by the RING domain resulting in ubiquitination and 
degradation (Choi et al., 2009).    
 Some resident proteins of the mitochondrial intermembrane space 
are released into the cytosol following MOMP where they function to 
facilitate caspase activation.  As mentioned, the role of cytochrome c in 
the cytosol is required for apoptosome formation and activation of 
caspase-9.  It is worth noting that the function of cytochrome c during 
apoptosis is unrelated to its role during oxidative phosphorylation, where it 
shuttles electrons between complex III and IV of the electron transport 
Figure 7: XIAP (X-linked inhibitor of apoptosis) protein and its 
inhibition on caspase-3,-7, and -9.  XIAP has three baculoviral inhibitor 
of apoptosis repeat (BIR) domains. The BIR2 domain is required for 
inhibition of activated caspase-3 and caspase-7. The BIR3 domain is 
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chain.  It has been shown experimentally in vitro and in vivo that it is 
possible to disrupt the pro-apoptotic function of cytochrome c, while 
maintaining its function during cellular respiration (Hao et al., 2005; 
Vempati et al., 2007) . 
 In addition to cytochrome c, there are two additional proteins that 
are released following MOMP that can facilitate caspase activation, 
reportedly by antagonizing XIAP.  Although both of these proteins function 
as XIAP antagonists, they do so by distinct mechanisms.  The first is 
second mitochondrial activator of caspases/direct IAP-binding protein with 
low pI (SMAC/DIABLO)(Du et al., 2000; Verhagen et al., 2000).  The 
second is High temperature requirement A2 (Htr2 /Omi) (Vande Walle et 
al., 2008).  Both proteins are synthesized in the nucleus with a 
mitochondrial localization signal on their amino terminus, which is 
removed upon successful translocation to the intermembrane space of the 
mitochondria.  The removal of the localization signal exposes a 
tetrapeptide sequence that is required for binding to XIAP (Srinivasula and 
Ashwell, 2008).  SMAC binds both BIR2 and BIR3 domains of XIAP, 
where it is thought to relieve the caspase inhibitory properties of XIAP 
(Shiozaki and Shi, 2004) .  Omi/HtrA2 is a serine protease that not only 
binds to the BIR3 domain of XIAP but irreversibly degrades the protein 
through its proteolytic activity (Yang et al., 2003). 
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1.7 Overview of Apoptosis: The Intrinsic and Extrinsic Pathways 
 
Apoptosis can be induced through either the extrinsic (death receptor-
mediated) or intrinsic (mitochondria-mediated) pathway (Figure 8) (Green, 
2000).  Current cytotoxic therapeutic approaches seem to utilize primarily 
the intrinsic pathway by causing intracellular damage (Johnstone et al., 
2002).  The extrinsic pathway is activated extracellularly upon binding of a 
death ligand to its cognate receptor, for example, Fas ligand binding to the 
Fas receptor, whereas the intrinsic pathway is activated intracellularly in 
response to internal stress, such as DNA damage (Green, 2000).  
However, activation of the extrinsic pathway will, in turn, activate the 
intrinsic pathway in some cell types. These unique cell types are termed 
“type II cells” and include hepatocytes  (Yin et al., 1999; Samraj et al., 
2006).   
As mentioned above, the extrinsic pathway is activated upon binding 
of a ligand to its cognate receptor.  The activated receptor will then cluster 
and recruit a corresponding adaptor molecule.  For example, the binding 
of Fas ligand to the Fas receptor results in trimerization of the receptor 
and recruitment of the adaptor protein FADD (Fas-Associated Death 
Domain).  FADD, in turn, recruits initiator procaspase-8 molecules to the 
cytoplasmic side of the receptor (Rensing-Ehl et al., 1995).  These protein-
protein interactions are facilitated through complementary protein- 









































Extrinsic Pathway Intrinsic Pathway
FAS Ligand
Figure 8: Overview of the extrinsic and intrinsic apoptosis pathways.  
The extrinsic pathway is activated upon ligand binding of a death 
receptor, such as Fas ligand binding to Fas. In this case, apoptosis 
occurs either by caspase-8-mediated direct activation of caspase-3 (type I 
cell) or by caspase-8-mediated cleavage of Bid to tBid, which then 
engages mitochondria (type II cell).  The intrinsic pathway is activated by 
an internal stress leading to cytochrome c release, which then interacts 
with Apaf-1 and facilitates the activation of caspase-9. Active caspase-9 
then activates caspase-3 resulting in the activation of other effector 
caspases and cell death. Bid, BH3 interacting domain; tBid, truncated Bid; 
Bak, Bcl-2 antagonist/killer 1; Bax, Bcl-2-associated X protein; Bcl-2, B-
cell lymphoma 2; Bcl-xL, B-cell lymphoma x-long. 
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interacting domains, such as the death domain (DD) shared by the Fas 
receptor and FADD, and the death effector domain (DED) shared by 
FADD  and procaspase-8.  The Fas-FADD-procaspase-8 protein complex 
is known as the death-inducing signaling complex (DISC), which promotes 
the activation of procaspase-8 by bringing two caspase-8 molecules into 
close proximity allowing their dimerization and/or conformational change, 
auto-activation, and subsequent proteolytic cleavage (Bao and Shi, 2007).  
In a type I cell, active initiator caspase-8 will directly cleave and activate 
effector procaspase-3, which will then cleave and activate other effector 
caspases, as well as target intracellular protein substrates resulting in 
dismantling of the cell. 
In a type II cell, activated caspase-8 does not directly cleave and 
activate caspase-3.  Instead, it is thought that the amount of activated 
caspase-8 in a type II cell is insufficient to cleave and activate enough 
caspase-3 to execute cell death (Schmitz et al., 1999).  Active caspase-8 
does, however, cleave the BH3-only Bcl-2 family member Bid to truncated 
Bid (tBid) (Li et al., 1998).  The cleavage of Bid to tBid leads to the 
engagement of the mitochondria-mediated pathway, presumably through 
tBid-mediated activation of the BH123 proteins Bak and/or Bax, which 
then homo-oligomerize to induce MOMP (Kim et al., 2006a).  The ensuing 
release of cytochrome c and other pro-apoptotic proteins leads to the 
activation of caspase-9 and caspase-3.   
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The type I and type II model of receptor-mediated cell death was 
originally described in 1998 when Jurkat T-lymphocytes were shown to be 
type II cells due to the fact that Bcl-2 or Bcl-XL overexpression effectively 
inhibited Fas-induced apoptosis (Scaffidi et al., 1998).  Controversy has 
surrounded the exact role that MOMP plays in mediating type II cell death.  
It has been reported that engagement of mitochondria is necessary for 
cytochrome c release and apoptosome formation; however, it has also 
been suggested that MOMP is necessary to neutralize XIAP-mediated 
inhibition of caspase-3 presumably through the release of SMAC (Sun et 
al., 2002; Wilkinson et al., 2004; Samraj et al., 2006).  Our laboratory has 
recently shown that Jurkat T-lymphocytes lacking the ability to form an 
apoptosome and therefore unable to activate caspase-9, depend on 
MOMP upon activation of the receptor-mediated pathway; however, it is 
SMAC that is needed to facilitate caspase activation and cell death rather 
than activation of caspase-9.  In other words, these cells are not 
dependent on activation of the intrinsic pathway per se, but rely on the 
presence of SMAC presumably to relieve XIAP-mediated inhibition of 
caspase-3 (Shawgo et al., 2009).  
As mentioned above, the mitochondria-mediated pathway is activated 
in response to intracellular stress; however, the precise mechanism of 
how the damage is integrated to produce a death signal is unclear.  Upon 
its release from the mitochondria, cytochrome c will bind to Apaf-1, which 
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serves as the adaptor protein for procaspase-9 (Li et al., 1997).  The 
binding of cytochrome c to Apaf-1 causes Apaf-1 to undergo a 
conformational change that unmasks its caspase recruitment domain 
(CARD).  The CARD of procaspase-9 will then bind the CARD of Apaf-1 
causing the dimerization and/or conformational change, auto-activation, 
and subsequent cleavage of initiator procaspase-9.  This protein complex, 
consisting of Apaf-1, caspase-9, cytochrome c, and dATP/ATP, is termed 
the apoptosome and serves as the initiating platform for procaspase-9 
(Bao and Shi, 2007).  Activated caspase-9 will then activate downstream 
effector procaspases through cleavage.  As mentioned above, the effector 
caspases will then dismantle the cell through the cleavage of target 
protein substrates. 
 
1.8 Overview of the “BH3-Domain” Only Protein Bid 
 
 Bid is a pro-apoptotic member of the Bcl-2 family of proteins 
containing only the BH3 domain.  The BH3 domain is required for the pro-
apoptotic effect(s) of this and other proapoptotic members of this protein 
family.  Full-length Bid is a 22-kDa protein that contains ~195 amino acids.  
During apoptosis, Bid often undergoes proteolysis to tBid.  Caspase-8-
mediated cleavage of Bid occurs after aspartate residue 60 where it is the  
C-terminal cleavage fragment that promotes apoptosis (Figure 9).  It has 
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been suggested that tBid may insert into the OMM because it contains 
typical structural features associated with transmembrane proteins.  One 
possibility is that the pro-apoptotic function of Bid is not limited to its 
activation of the BH123 proteins but that it also has pro-apoptotic function 
through protein-membrane lipid interactions.  In this scenario, tBid 
interacts with cardiolipin at mitochondrial contact sites causing cristae 
reorganization, which also promotes cytochrome c release (Yin, 2006).  
Bid is a unique BH3-only protein in that it requires post-translational 
modification for activation, most notably involving caspase-8-mediated 
cleavage to tBid (Wang et al., 1996; Li et al., 1998; Luo et al., 1998).  Bid 
normally resides in the cytosol and possibly the nucleus (Zinkel et al., 
2005).  Upon being cleaved, tBid is myristolyated at its N-terminus, 
translocates to the OMM, and/or activates a BH123 protein.  The best 





Figure 9: Full Length Bid (BH3-Interacting Domain Death Agonist) 
Protein.  Apartate amino acid residue 60 (D60) represents the 
caspase-8 cleavage site.  Upon cleavage, the C-terminal portion of the  
protein is the “active” form know as truncated Bid (tBid). 
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mitochondrial apoptotic pathway in certain cell types, such as 
hepatocytes, upon activation of the extrinsic pathway (Yin et al., 1999).  
The role of Bid/tBid in response to other stressors that activate the intrinsic 
pathway remains poorly understood and controversial.  More specifically, 
there has been controversy surrounding the role of Bid/tBid in response to 
DNA damage- and heat-induced apoptosis.   
 
 
1.9 Concluding Remarks 
 
 The majority of chemotherapeutic agents lack the specificity to 
directly target neoplastic cells, but often target cells actively participating in 
the cell cycle or those undergoing cell division.  Cytotoxic 
chemotherapeutics more often than not are thought to induce cell death 
through the initiation of mitochondria-mediated apoptosis.  Over the past 
decade, a better understanding of the molecular pathway(s) and the key 
players leading to the activation and execution of apoptosis has evolved.  
However, the precise details of how these pathways are regulated in 
response to anti-cancer therapies remain only partially understood.  New 
information regarding the details of these pathways would be expected to 
contribute to the development of more specific drug design and 
therapeutic approaches.   
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 Given the modest curative rates for cancer and given the 
considerable toxic adverse effects of many chemotherapeutic agents, a 
more detailed understanding of the mechanism of action of many 
anticancer therapeutics is warranted.  In general, cytotoxic anticancer 
drugs kill cells by causing the cell to undergo mitochondria-mediated or 
intrinsic apoptosis (Lowe and Lin, 2000).  Furthermore, defects in the 
apoptotic machinery, which contribute to tumorigenesis and therapeutic 
resistance, are considered to be one of the six hallmarks of cancer 
(Hanahan and Weinberg, 2000).  Although cytotoxic anticancer drugs are 
known to engage the intrinsic pathway of apoptosis, the precise 
mechanistic details remain elusive and, in some instances, controversial.  
It is also the case that the precise molecular requirements necessary for 
the induction of apoptosis in response to a given cytotoxic agent may be, 
at least in part, unique to that stressor.  For my dissertation research, I 
have investigated the underlying mechanisms responsible for 
mitochondria-mediated apoptosis induced by a DNA topoisomerase II 
inhibitor, a novel heat shock protein 90 (Hsp90) inhibitor, and elevated 
temperature.  The results of my studies are expected to contribute new 
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information toward an understanding of mitochondria-mediated apoptosis 
induced by cytotoxic stress.   
 Topoisomerase II inhibitors (e.g. etoposide) are DNA-damaging 
anti-cancer drugs that are often administered to fight a plethora of human 
malignancies.  Although these drugs are known to induce mitochondria-
mediated apoptosis, the exact details of how this process occurs are only 
partially understood.  Over the last several years, there has been an 
interest to develop new drugs that disrupt the function of Hsp90 by 
targeting the N-terminal ATP-binding site of the protein.  Two such agents, 
17-allylamino-demethoxygeldanamycin  (17-AAG) and17-
dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), have 
entered phase II clinical trials.  However, the potential clinical utility of 
these drugs as anticancer agents has been dampened significantly due to 
concerns about their adverse effects and tendency to induce new 
expression of cytoprotective Hsp90 and Hsp70 proteins (Whitesell et al., 
2003; Schmitt et al., 2007; Workman and Powers, 2007).  Finally, there is 
therapeutic interest in using methods to deliver heat to tumor masses to 
induce cell death. Although this option is becoming more of a realistic 
approach for cancer therapy, the mechanisms responsible for heat-
induced apoptosis remain virtually unknown; furthermore, controversy 
surrounds the limited amount of mechanistic details that have been 
proposed for this form of cell death (Milleron and Bratton, 2006). 
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2.2 Overall Hypothesis 
 
 The primary objective of my dissertation is to determine how 
cytotoxic stress leads to the initiation and execution of cell death 
pathways, more specifically, the mitochondria-mediated apoptotic cell 
death pathway.  The primary focus is to better understand the underlying 
molecular mechanistic details of apoptosis induced by DNA damage, 
inhibition of Hsp90, and heat shock.  The central hypothesis is that the 
molecular requirements necessary for irreversible engagement of the 
mitochondria-mediated apoptotic pathway vary depending upon the nature 
of the stimulus.  This central hypothesis will be tested by pursuing three 
Specific Aims.  Following the completion of these studies, an enhanced 
understanding of the molecular mechanisms linking stress-induced 
apoptosis to the activation, regulation, and execution of the mitochondria-
mediated pathway in cancer cells is expected. 
 
2.3 Specific Aims 
 
2.3.1 Specific Aim #1: Investigate the initiation and execution of 
mitochondria-mediated apoptosis in response to  
DNA damage induced by topoisomerase II inhibition. 
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 Specific Aim 1a.  Determine the molecular requirements necessary 
for mitochondrial outer membrane permeabilization (MOMP) in 
response to the DNA-damaging agent etoposide. 
 Specific Aim 1b.  Investigate the role of the BH3-only Bcl-2 family 
member, Bid, in response to the DNA-damaging agent etoposide. 
 
2.3.2 Specific Aim #2: To investigate the initiation and execution of 
mitochondria-mediated apoptosis in response to a novel novobiocin-
derived C-terminal Hsp90 inhibitor, designated KU135. 
 Specific Aim 2a.  Compare the antiproliferative effects of KU135 to 
the N-terminal Hsp90 inhibitor, 17-AAG. 
 Specific Aim 2b.  Determine if KU135 can directly bind to Hsp90, 
more specifically, the C-terminus portion of Hsp90. 
 Specific Aim 2c.  Evaluate and characterize the ability of KU135 to 
induce mitochondria-mediated apoptosis. 
 
2.3.3 Specific Aim #3: Investigate the initiation and execution of 
apoptosis in response to heat stress at 44°C. 
 Specific Aim 3a.  Identify and characterize the initiator caspase 
responsible for the onset of heat-induced apoptosis.  
 Specific Aim 3b.  Evaluate the role of MOMP in heat-induced 
apoptosis. 
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 Specific Aim 3c.  Investigate the role of the BH-3 only Bcl-2 family 
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Chapter 3: Materials and Methods 
 
3.1 Cell Culture 
 
 Wild-type (clones E6.1 and A3), caspase-8-deficient (clone I 9.2), 
and FADD-deficient (clone I 2.1) Jurkat T-lymphocytes (ATCC, Manasses, 
VA) were cultured in RPMI 1640 complete medium (Invitrogen, Carlsbad, 
CA) supplemented with 10% (v/v) heat inactivated fetal bovine serum 
(FBS) (HyClone, Logan, UT), 2% (w/v) glutamine (Invitrogen), 100 U/mL 
penicillin (Invitrogen) and 100 μg/mL streptomycin (Invitrogen) at 37°C in a 
humidified 5% CO2 incubator.  Cells were maintained at their optimal 
growth density of 105 - 106 cells/mL for a maximum time period of 3 
months.  For transfected Jurkat cells (pSFFV-Bcl-2, pSFFV-Bcl-xL, 
pSFFV-neo, pSUPER-Apaf-1, pSUPER-Bid, pSUPER-Caspase-2, 
pSUPER-RAIDD, pSUPER-neo, pcDNA3-XIAP, pcDNA3-XIAP-
BIR1/BIR2, or pcDNA3-neo), 1 mg/mL Geneticin (Invitrogen) was 
substituted for penicillin and streptomycin.  All cells were re-plated in fresh 
complete nonselective medium prior to all experiments.  Cells (5 x 106) 
were retained in liquid nitrogen for long-term storage in 1 mL of 
cryostorage medium (5% DMSO and RPMI 1640 with appropriate 
antibiotics).  Prior to submersion in liquid nitrogen, cells were placed at  
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-80°C in a Mr. Frosty (4 h – 1 week).  Cryopreserved cells were thawed at 
37°C and diluted with 10 mL of appropriate growth medium. Cells were 
then incubated at room temperature (22°C) for 5 min before centrifugation 
at 300 x g for 5 min. Cell pellets were resuspended in 10 mL of 
appropriate medium and allowed to recover for 1 week before experiments 
were performed.  Cells were treated with etoposide (2.4 nM – 47 µM) 
(Sigma), anti-Fas antibody (100 ng/mL) (clone CH-11, MBL International, 
Woburn, MA), KU135 (2.5 nM – 50 µM), 17-AAG (0.5 nM – 10 µM) 
(InvivoGen, San Diego, CA), DMSO (≤ 0.5% final concentration), or heat 
(44°C for 1 h).  The caspase inhibitor quinoline-Val-Asp-CH2-
difluorophenoxy (qVD-OPh) (MP Biomedicals, Solon, OH) was used at a 
final concentration of 20 µM. 
 
3.2 Measurement of Caspase Activity 
 
 Cells (5 x 105) were pelleted and washed once with ice-cold 
phosphate-buffered saline (PBS).  Cells were resuspended in 25 µL of 
PBS, added to a microtiter plate, and combined with DEVD-
aminomethylcoumarin (AMC) (Peptide Institute, Osaka, Japan) dissolved 
in a standard reaction buffer (100 mM Hepes, pH 7.25, 10% sucrose, 
10 mM dithiothreitol, 0.1% CHAPS).  Cleavage of DEVD-AMC was 
monitored by AMC production in a FLx800 Multi-detection Microplate 
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Reader (BioTek Instruments, Winooski, Vermont) using 355 nm excitation 
and 460 nm emission wavelengths. 
 
3.3 RNAi (RNA interference) 
 
 Initially, transient transfections were performed to validate the 
ability of an individual siRNA (short interfering RNA) oligonucleotide to 
knockdown the target gene of interest. The target siRNA molecules were 
21 nucleotides in length. For transient transfections, 1.5 x 106 cells were 
pelleted and resuspended in 75 μL of electroporation buffer (Ambion, 
Austin, TX). 1.5 μg of the target siRNA was added to cells.  Next, the 
solution mixture was added to a 0.1-cm cuvette and electroporated using 
a Bio-Rad Gene Pulser Xcell system at 200V.  The cells were then 
incubated for 48 h in complete growth medium at 37°C followed by 
processing for Western blot analysis. The appropriate primary antibody 
was then used to determine the protein expression level of the gene of 
interest. 
 The vector-based pSUPER (pSuper.neo) RNAi system 
(Oligoengine, Seattle, WA) was used to stably suppress the protein 
expression of the gene of interest by generating stable gene knockdown 
cell lines. The gene-specific targeting insert specifies a 19-nucleotide 
sequence downstream of the transcription start site followed by a 9 
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nucleotide non-complementary spacer sequence, followed by the reverse 
complement of the same 19-nucleotide sequence that is at the beginning 
of the target.  The sequence was ligated into BglII and XhoI sites of the 
pSUPER vector, which was then transformed into TOP10 competent 
Escherichia coli cells (Invitrogen, Carlsbad, CA) using the heat-pulse 
method.  Several clones were screened for the correct insert size by 
restriction enzyme digest and agarose gel eletrophoresis to separate the 




  Jurkat T-lymphocytes (107 cells) were washed with PBS and 
resuspended in 800 µL of RPMI.  Cells were then transfected with 20 μg 
of plasmid DNA (pSFFV-Bcl-2, pSFFV-Bcl-xL, pSFFV-neo, pSUPER-
Apaf-1, pSUPER-Bid, pSUPER-Caspase-2, pSUPER-RAIDD, pSUPER-
neo, pcDNA3-XIAP, pcDNA3-XIAP-BIR1/BIR2, or pcDNA3-neo) by 
electroporation using a Bio-Rad Gene Pulser Xcell system (0.4-cm 
cuvette, 300V, and 950 μF). Cells were then allowed to recover in 
complete medium for 48 h at 37°C in a humidified CO2 incubator.  
Selection of transfected cells was done in the presence of 1 mg/mL 
Geneticin for one month followed by serial dilutions to obtain single-cell 
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clones with silenced or overexpressed genes.  The extent of protein 
overexpression or knockdown was determined by Western blot analysis. 
 
3.5 Flow Cytometry Measurements for Cell Death, Mitochondrial 
Membrane Potential (ΔΨ), Bak Activation, and Cell Cycle Analysis 
 
 
 Phosphatidylserine (PS) exposure on the outer leaflet of the plasma 
membrane was detected by staining with Annexin V-FITC (BD 
PharMingen), whereas disruption of the plasma membrane was detected 
by staining DNA with the non-cell permeable dye propidium iodide (PI). In 
brief, 106 cells were pelleted by centrifugation at 300 x g for 5 min 
following treatment.  Cells were then washed with PBS and centrifuged at 
300 x g for 5 min.  Pellets were resuspended in 500 μL of binding buffer 
(10 mM Hepes, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) containing 1.5 μg 
annexin V-FITC and 5 μL PI.  Flow cytometric analysis was then 
performed using the BD LSRII and BD FACS Diva v6.1.2 software. 
 Dissipation of the ΔΨ was detected using the stain DiIC1(5) 
(Invitrogen), which is a cell-permeable dye that accumulates in 
mitochondria with active membrane potentials.  The intensity of the 
fluorescence decreases as ΔΨ diminishes.  Briefly, cells (106) were 
pelleted by centrifugation at 300 x g for 5 min at the end of the experiment. 
Cells were then washed once in PBS, and resuspended in 1 mL of warm 
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PBS.  Next, 5 μL of DiIC1(5) (10 μM) was added to the cells and incubated 
in a humidified 5% CO2 incubator at 37°C for 15 min.  Cells were then 
pelleted by centrifugation at 300 x g for 5 min and resuspended in 500 μL 
of cold PBS.  Flow cytometric analysis was then performed using the BD 
LSRII and BD FACS Diva v6.1.2 software.  
 For detection of activated Bak by flow cytometry, cells (2.5 x 106) 
were washed in PBS, fixed in 400 μL of 0.25% paraformaldehyde in PBS 
for 5 min, then washed with 1% fetal bovine serum in PBS.  Following 
centrifugation, the cells were resuspended in 50 μL of staining buffer (1% 
fetal bovine serum and 100 μg/mL digitonin in PBS) containing a 
conformation-specific mouse monoclonal antibody against the active 
conformation of Bak (1:30; AM03, Calbiochem) for 30 min at room 
temperature (22°C).  Cells were then washed and resuspended in 50 μL of 
staining buffer containing 0.25 μg of Alexa Fluor 488-labeled chicken anti-
mouse antibody for 30 min in the dark. Cells were washed and 
resuspended in PBS.  Flow cytometric analysis was then performed using 
the BD LSRII and histogram overlays were performed using FlowJo 
software (Tree Star, Ashland, OR). 
 For cell cycle analysis, 106 cells were pelleted following treatment 
and washed with cold PBS.  Cells were fixed in 1 mL of ice-cold 70% 
ethanol and incubated at room temperature (22°C) for 30 min.  Next, the 
fixed cells were pelleted, resupended in 500 μL of PI/RNase Staining 
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Buffer (BD PharMingen), incubated at room temperature (22°C), and 
analyzed by flow cytometry using the BD LSRII and BD FACS Diva v6.1.2 
software.   
 




 Cells (5 x 106) were centrifuged at 300 x g for 5 min.  Pelleted cells 
were resuspended and lysed in 200 μL of ice-cold lysis buffer (10 mM 
50 Tris/HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2, 1 mM EDTA, 0.1% 
Nonidet P-40) supplemented with a mixture of protease inhibitors 
(Complete Mini EDTA-Free, Roche Applied Science).  Protein 
concentrations were determined using the bicinchoninic acid assay 
(Pierce).  BSA standards (0 μg, 1 μg, 2 μg, 4 μg, 8 μg, 16 μg, 32 μg, 64 
μg) were used to determine sample protein concentrations. The protein 
was then mixed with Laemmli’s buffer at a final concentration of 1X (50mM 
Tris HCl pH 6.8, 2% SDS, 6% glycerol, 1% β-mercaptoethanol, 0.004 % 
bromophenol blue) before being incubated for 5 min at 100°C.  Protein (30 
– 40 μg) was loaded on a polyacrylamide gel (8-15%).  Polyacrylamide 
gels were allowed to run for ~ 45 min at 195 V in a Mini-PROTEAN® 3 
Cell (BioRad, Hercules, CA) in electrode buffer (25 mM Tris, 192 mM 
glycine, 1% SDS).  The proteins were then transferred to a nitrocellulose 
membrane in a BioRad transfer apparatus for 1 h at 100 V using the 
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Trans-Blot® Electrophoretic Transfer Cell (BioRad) with transfer buffer (25 
mM Tris, 192 mM glycine, 20% v/v methanol, pH 8.3).  Nitrocellulose 
membranes were incubated in 5% non-fat dry milk in PBS for 1 h at 22°C 
with gentle shaking.  Nitrocellulose membranes were then washed in PBS 
before incubation with primary antibody overnight.  The primary antibodies 
were diluted in 1% BSA in PBS.  Nitrocellulose membranes were 
incubated with primary antibody overnight at 4°C with gentle shaking.  
Antibodies and dilutions used were mouse 1:1,000 rabbit anti-Akt (pan) 
(clone C67E7, Cell Signaling Technology, Danvers, MA), 1:500 anti-Apaf-
1 (clone 94408, R&D Systems, Minneapolis, MN), 1:1,000 rabbit anti-Bax 
(Cell Signaling Technology, Danvers, MA), 1:1,000 rabbit anti-Bak NT 
(Millipore), 1:500 mouse anti-Bcl-2 (DakoCytomation, Glostrup, Denmark), 
1:1,000 rabbit anti-Bcl-xL (clone 54H6, Cell Signaling), 1:5,000 mouse 
anti-β-actin (clone AC-15, Sigma), 1:1,000 rabbit anti-Bid (Cell Signaling), 
1: 1,000 mouse anti-caspase-2 (clone 35, BD Pharmingen, San Jose, 
CA), 1:1,000 rabbit anti-caspase-3 (clone 8G10, Cell Signaling), 1:1,000 
rabbit anti-caspase-6 (Cell Signaling), 1:1,000 rabbit anti-caspase-7 (Cell 
Signaling), 1:1,000 mouse anti-caspase-8 (clone 1C12, Cell Signaling), 
1:1,000 rabbit anti-caspase-9 (Cell Signaling), 1:1,000 mouse anti-cdc2 
p34 (sc-54, Santa Cruz Biotechnology),1:1,000 mouse anti-cytochrome c 
(clone 7H8.2C12, Pharmingen), 1:5,000 rabbit anti-glyceraldehyde-3-
phosphate dehydrogenase (Trevigen, Gaithersburg, MD), 1: 2,000 rat anti-
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GRP94 (clone 9G10, Assay Designs, Ann Arbor, MI), 1:1,000 rabbit anti-
Hif-1α (Novus Biologicals, Littleton, CO), 1:1,000 mouse anti-Hsp70 
(Hsp72) (clone C92F3A-5, Assay Designs), 1:250 rat anti-Hsp90α (clone 
9D2, Assay Designs), 1:2,000 mouse anti-Hsp90β (clone K3705, Assay 
Designs), 1:500 mouse anti-Myc (clone 9E10, Santa Cruz Biotechnology), 
1:1,000 rabbit anti-phospho-Akt (Ser473) (clone 193H12, Cell Signaling), 
1:1,000 mouse anti-Smac/DIABLO (Cell Signaling), 1:2,000 mouse anti-
TRAP (Affinity BioReagents, Rockford, IL), and 1:1,000 mouse anti-XIAP 
(clone 28, BD Transduction Laboratories).  Nitrocellulose membranes 
were washed with 1X PBS for 10 min, 1X PBST for 10 min, and 1X PBS 
for 10 min at room temperature (22°C) with gentle shaking to remove 
excess primary antibody.  Membranes were then incubated with 
horseradish peroxidase-conjugated secondary antibody for 1 h at room 
temperature (22°C) with gentle shaking.  Secondary antibodies were 
diluted at 1:10,000 in 2.5% non-fat dry milk in PBS. Secondary antibodies 
used include goat anti-mouse IgG, (Thermo Scientific, Pierce 
Biotechnology), goat anti-rabbit IgG (Thermo Scientific, Pierce 
Biotechnology), and goat anti-rat (Pierce Biotechnology).  The 
nitrocellulose membranes were then washed with 1X PBS for 10 min, 1X 
PBST for 10 min, and 1X PBS for 10 min at room temperature (22°C) with 
gentle shaking.  The membrane was then blotted to remove excess buffer 
and incubated with 2 mL each of ECL Detection Reagent 1 and ECL 
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Detection Reagent 2 (Amersham, Buckinghamshire, UK) for 1 min before 
developing using classic autoradiography film BX (MidSci, St. Louis, 
Missouri). 
 
3.7 Subcellular Fractionation 
 
Subcellular fractionation was used to detect the release of cytochrome c 
from the intermembrane space of the mitochondria into the cytosol. 
Cells (2.5 x 106) were centrifuged at 300 x g for 5 min at room temperature 
(22°C) and washed in cold PBS. Cells were then centrifuged at 300 x g for 
5 min at room temperature (22°C).  Cells were resuspended in 125 μL of 
buffer (140 mM mannitol, 46 mM sucrose, 50 mM KCl, 1 mM KH2PO4, 5 
mM MgCl2, 1 mM EGTA, 5 mM Tris, pH 7.4) supplemented with a mixture 
of protease inhibitors (Complete Mini EDTA-Free), and permeabilized with 
7.5 μg of digitonin (Sigma) on ice for 10 min with occasional vortexing.  
Plasma membrane permeabilization was monitored by trypan blue 
staining.  Cell suspensions were centrifuged at 12,000 x g for 10 min at 
4°C to separate the cytosol (supernatant) from the mitochondria (pellet).  
Supernatant and pellet fractions were subjected to Western blot analysis. 
 
3.8 Determination of Bak Oligomerization 
 
 
Bak oligomerization can be visualized by Western Blot analysis after 
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incubation with a cross-linking agent (Wei et al., 2000). For detection of 
Bak oligomerization, cells (2.5 x 106) were harvested after treatment by 
centrifugation at 300 x g for 5 min at room temperature (22°C). Cells were 
washed in cold PBS and centrifuged for 5 min at 300 x g at room 
temperature (22°C). Cells were then resuspended in 200 μL of 100 mM 
EDTA/PBS and incubated with the cross-linking agent 
bismaleimidohexane (BMH) at a final concentration of 1 mM.  After the 
addition of BMH, tubes were mixed by inverting 2-3X followed by a 30 min 
incubation at room temperature (22°C) while rocking.  The reaction was 
quenched by the addition of 100 mM DTT followed by a 15 min incubation 
at room temperature (22°C) while rocking. The cell suspension was then 
centrifuged at 500 x g for 5 min and processed for Western blot analysis.  
 
3.9 Digitonin-Permeabilized Cells 
 
 Jurkat cells (2.5 x 106) were washed in PBS, resuspended in 125 
μL of buffer (140 mM mannitol, 46 mM sucrose, 50 mM KCl, 1 mM 
KH2PO4, 5 mM MgCl2, 5 mM succinate, 1 mM EGTA, 5 mM Tris, pH 7.4) 
supplemented with a mixture of protease inhibitors (Complete Mini EDTA-
Free).  Recombinant purified protein, truncated Bid or full-length Bid (R & 
D systems, Minneapolis, MN), was added at a final concentration ranging 
from 5 nM to 250 nM.  The cells were then permeabilized with 7.5 μg of 
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digitonin (Sigma) and incubated at room temperature (22ºC) for 15 min 
followed by centrifugation at 12,000 x g for 10 min at 4°C. Supernatant 
and pellet fractions were subjected to Western blot analysis. 
 
3.10 Cell proliferation assay  
 
 Cellular metabolic activity/viability was assessed using the CellTiter 
96 AQueous One Solution Cell Proliferation Assay (Promega, Madison, 
WI) according to the manufacturer’s instructions.  This approach uses the 
tetrazolium compound 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) 
that is bioreduced by metabolically active/viable cells into a colored 
formazan product that is soluble in tissue culture medium.  In brief, 3 x 104 
cells/well were cultured in 96-well plates in 100 μL of complete growth 
medium for 24 or 48 h.  At the end of incubation, 20 µL of MTS solution 
was added to each well and incubated for 1-4 h at 37°C.  The amount of 
soluble formazan from cellular reduction of MTS was assessed by 
measurement of absorbance at 490 nm VICTOR3V Multilabel Reader 
(PerkinElmer).  Data were analyzed using non-linear regression and 
sigmoidal dose-response curves (GraphPad Prism) from which IC50 values 
were calculated. 
*These experiments were done by Shawna B. Matthews 
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3.11 Novobiocin affinity column chromatography 
 
 Novobiocin-sepharose was prepared as described previously 
(Marcu et al., 2000b).  In brief, three grams of epoxy-activated sepharose 
6B (Sigma) were washed and swollen in 100 mL of distilled water for 1 h 
at room temperature (25°C).  The resin was washed further with coupling 
buffer (300 mM sodium carbonate, pH 9.5).  The gel was mixed with 400 
mg of novobiocin (sodium salt, Sigma) in 10 mL of coupling buffer and 
incubated at 37°С with gentle rotation for 20 h.  Excess ligand was 
washed away with coupling buffer, and the remaining epoxy-active groups 
were blocked with 1 M ethanolamine in coupling buffer for 12 h at 30°С 
with gentle shaking.  The gel was washed sequentially with coupling 
buffer, 500 mM NaCl in coupling buffer, distilled water, 500 mM NaCl in 
100 mM sodium acetate (pH 4.0), and again in distilled water.  The resin 
was subsequently equilibrated in 25 mM Hepes (pH 8.0) containing 1 mM 
EDTA, 10% ethylene glycol, and 200 mM KCl and stored in the dark at 
4°С.  
 Rabbit reticulocyte lysate was incubated in the presence of an ATP-
regenerating system (10 mM creatine phosphate and 20 units/mL creatine 
phosphokinase) for 5 min at 37°C, after which, the reticulocyte lysate was 
applied to the novobiocin column that had been pre-equilibrated with 10 
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mM Tris-HCl (pH 7.4) buffer.  The novobiocin column was then washed 
with 20 volumes of 10 mM Tris-HCl (pH 7.4) buffer containing 150 mM 
NaCl.  Subsequently, bound proteins were eluted with increasing 
concentrations of KU135 or 10 mM novobiocin.  All experiments were 
carried out under dark conditions at 4°C.  The eluents were separated via 
SDS-PAGE and analyzed with Hsp90 antibodies. 
*These experiments were done in the laboratory of Brian Blagg. 
 
3.12 Proteolytic fingerprinting of Hsp90.  
 
Proteolytic fingerprinting was performed using a modified method 
described previously (Yun et al., 2004).  In brief, 50% (v/v) rabbit 
reticulocyte lysate, an ATP-regenerating system (10 mM creatine 
phosphate and 20 units/mL creatine phosphokinase), and 75 mM KCl 
were incubated in the presence of drug or vehicle for 5 min at 37 °С.  
Following the incubation period, the reaction mixtures were chilled on ice 
and digested with 125 μg/mL TPCK-treated trypsin (Worthington 
Biomedical, Lakewood, NJ) for 6 min (Hartson et al., 1999).  Reactions 
were terminated by immediate boiling in Laemmli loading buffer.  
Subsequently, the samples were separated by SDS-PAGE and Western 
blotted using antibodies specific to the N-terminus of Hsp90 (PA3-013, 
 60  
Affinity BioReagents) or the C-terminus of Hsp90 (clone AC88, Assay 
Designs). 
*These experiments were done in the laboratory of Brian Blagg. 
 
3.13 Surface plasmon resonance (SPR) analysis of KU135 binding to 
Hsp90 
 
 Insect Sf9 cells overexpressing Hsp90β were cultured and 
harvested by the Baculovirus/Monoclonal Antibody Core Facility at Baylor 
College of Medicine.  Hsp90β was extracted and purified (>98% pure) as 
described previously (Grenert et al., 1997; Owen et al., 2002) but without 
the initial DEAE-cellulose chromatography step.  The surface of a SSOO 
COOH1 SPR sensor chip mounted in a SensiQ SPR instrument (ICX 
Nomadics) was activated by treatment with N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride and N-hydroxysuccinimide for preferential 
cross-linking of the protein’s N-terminus to the surface.  For Hsp90 
immobilization, 250 μL of Hsp90 (7 mg/ml) in 20 mM sodium bicarbonate 
buffer (pH 8) containing 150 mM NaCl was injected at a flow rate of 10 
μL/min, giving 2800 response units of protein stably immobilized to the 
surface of the flow cell, representing ~0.08 picomoles of Hsp90.  
Unreactive groups were then quenched with 1 M ethanolamine (pH 8), 
and the surface washed with buffer containing 10 mM Pipes (pH 7.4), 300 
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mM NaCl, 2% DMSO and 0.01% Igepal CA-630 followed by equilibration 
in assay buffer.  KU135 or novobiocin was diluted in assay buffer 
containing 10 mM Pipes, pH 7.4, 300 mM NaCl, 2% DMSO and 0.00075% 
Igepal CA-630 and injected over the surface of the derivatized chip at a 
flow rate of 25 μL/min at 25 °C at the indicated concentrations.  All 
measurements were done in triplicate.  SPR binding curves were analyzed 
using QDAT software (ICX Nomadics). To calculate the Kd, binding 
constants were fitted using the equations:  Req = KA (A) Rmax / (KA(A) +1) 
and re-graphed using Origin software for Scatchard analysis and to 
demonstrate saturation of binding. Novobiocin’s binding isotherm was 
globally fit for total and nonspecific binding using the equation Y= 
(Bmax(X))/(KD +X)) +NS(X) to fit total binding and the equation Y=NX(X) to 
fit nonspecific binding. 
*These experiments were done in the laboratory of Robert L. Matts. 
 
3.14 b-VAD-fmk affinity labeling of initiator caspases 
 
 
 Cells (2.5 X 106)/mL were incubated with 120 µM of the biotinylated 
pan-caspase inhbitor biotin-Val-Ala-Asp(OMe)-CH2F (b-VAD-fmk) (Kamiya 
Biomedical Company, Seattle, Washington) for 3 hours.  The cells were 
then incubated at 44°C for 1 h followed by a 6 h recovery period at 37°C .  
Following the six-hour recovery time period post-heat shock, cells were 
washed with PBS and lysed with 500 µL of lysis buffer (50mM Tris/HCl pH 
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7.4, 150 mM NaCl, 1% NP-40, 1 mM DTT) supplemented with a mixture of 
protease inhibitors (Complete Mini EDTA-Free, Roche Applied Science).  
The lysate was then incubated on ice for 30 min, followed by 
centrifugation at 12,000 x g for 10 min at 4°C.  The supernatants were 
then incubated with streptavidin-sepharose beads (GE Healthcare, 
Piscataway, NJ) that had been pre-equilibrated with lysis buffer followed 
by gentle rocking overnight.  The beads were then washed four times with 
wash buffer (50mM Tris/HCl pH 7.4, 150 mM NaCl, 0.5% NP-40, 1 mM 
and subsequently incubated with 2X Laemmli buffer and boiled followed 
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Chapter 4: Cleavage of Bid by Executioner Caspases 
Mediates Feed Forward Amplification of Mitochondrial 
Outer Membrane Permeabilization During Genotoxic 





 The extent to which the BH3-only protein Bid is important for 
intrinsic (mitochondria-mediated) apoptotic cell death induced by 
genotoxic stress remains controversial.  In the present study, we examine 
this issue using a panel of gene-manipulated Bax-deficient Jurkat T-
lymphocytes.  Cells stably depleted of Bid were far less sensitive than 
control-transfected cells to etoposide-induced apoptosis.  In particular, 
drug-induced Bak activation, cytochrome c release, loss of mitochondrial 
membrane potential, and caspase activation were all decreased in cells 
lacking Bid.  Reconstitution experiments using recombinant proteins and 
permeabilized Bid-deficient cells demonstrated that truncated Bid (tBid), 
but not full-length Bid, potently induced Bak activation and the release of 
cytochrome c.  Further, caspase-8-deficient Jurkat cells efficiently cleaved 
Bid and were sensitive to drug-induced apoptosis.  By comparison, Apaf-
1-deficient cells, as well as cells overexpressing full-length XIAP or the 
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BIR1/BIR2 domains of XIAP, failed to cleave Bid in response to genotoxic 
stress.  These data suggest that tBid plays an important regulatory role in 
the execution of DNA damage-induced cytochrome c release and 
apoptosis.  However, the fact that cleavage of Bid to tBid is mediated by 
executioner caspases suggests that a self-amplifying feed forward loop 
involving caspases, Bid, and mitochondria may help determine irreversible 




 Apoptosis is an active form of cell death that plays an essential role 
during normal embryonic development and in the maintenance of tissue 
homeostasis in the adult organism (Danial and Korsmeyer, 2004).  
Consequently, dysregulation of apoptosis has been implicated as a 
contributing factor to the onset of different pathological conditions, 
including cancer.  In addition, it is now generally accepted that many 
genotoxic anticancer drugs are effective against tumor cells for their ability 
to induce mitochondria-mediated apoptosis  (Lowe and Lin, 2000).  
Similarly, mutations or the altered expression of pro- and anti-apoptotic 
proteins can contribute to the development of drug resistance. 
Execution of apoptosis is mediated by a family of cysteine-
dependent aspartate-specific proteases (caspases).  During true 
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mitochondria-mediated apoptosis, members of the Bcl-2 family of proteins 
are the primary regulators of caspase activation for their role in controlling 
mitochondrial outer membrane permeabilization (MOMP) (Adams and 
Cory, 1998).  The process of MOMP results in the release of cytochrome 
c, second mitochondria-derived activator of caspase (Smac, also known 
as DIABLO), and Omi (also known as HtrA2) into the cytosol where they 
converge to promote the activation of caspase-9 within the apoptotic 
protease-activating factor-1 (Apaf-1) apoptosome complex.  The Bcl-2 
family contains proteins with opposing functions, and it is generally 
thought that the induction of MOMP requires the activation of either Bak or 
Bax triggered by a Bcl-2 homology 3 (BH3)-only protein (Chipuk et al., 
2006; Ow et al., 2008; Youle and Strasser, 2008).  Indeed, evidence in the 
literature indicates that cells lacking either Bak or Bax exhibit only subtle 
defects in MOMP, whereas doubly-deficient cells are often found to be 
highly resistant to mitochondria-mediated apoptosis (Lindsten et al., 2000; 
Wei et al., 2001).     
At present, there are two models for the activation of Bax or Bak by 
BH3-only proteins.  One model argues that BH3-only proteins function as 
either “sensitizer” (e.g. Bad and Noxa)  or “activator” proteins (e.g. 
truncated Bid (tBid), Bim, and perhaps Puma) (Kim et al., 2006b).  In this 
scenario, a sensitizer protein is needed to displace an activator protein 
from a prosurvival protein (e.g. Bcl-2, Bcl-xL, or Mcl-1) in order to activate 
 66  
Bak or Bax.  The second model argues that BH3-only proteins bind and 
inhibit the function of prosurvival Bcl-2 proteins, which normally bind to 
and inhibit Bak and Bax (Chen et al., 2005; Willis et al., 2007).  Of the 
seven or so known BH3-only proteins (Youle and Strasser, 2008),  Bid is 
unique in that it requires post-translational modification for activation, most 
notably involving caspase-8-mediated cleavage to tBid (Wang et al., 1996; 
Li et al., 1998; Luo et al., 1998).  Bid normally resides in the cytosol and 
possibly the nucleus (Zinkel et al., 2005).  Upon being cleaved, the C-
terminal fragment (tBid) is myristoylated at its newly exposed N-terminus, 
translocates to the outer mitochondrial membrane (OMM), and/or 
activates Bak or Bax protein (Zha et al., 2000).  Recently, it was shown 
that the N-terminal cleavage fragment of Bid is quickly ubiquitinated for 
degradation and that this degradation is necessary for the pro-apoptotic 
function of tBid (Tait et al., 2007).  The same study also concluded that, 
although full-length Bid is capable of translocating to the OMM, it is not 
able to induce MOMP on its own (Tait et al., 2007).  A well-characterized 
example of tBid involvement during apoptosis is in the engagement of the 
mitochondrial apoptotic pathway in so-called type II cells upon activation 
of the extrinsic pathway (Yin et al., 1999).     
 Here, we have investigated whether Bid plays a functional role in 
the induction of MOMP during apoptosis in response to the genotoxic 
anticancer drug etoposide.  To that end, we used Bax-deficient Jurkat 
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cells that are stably depleted of Bid and evaluated the extent to which 
these cells underwent drug-induced MOMP.  In addition, Jurkat clones in 
which the intrinsic pathway had been inhibited due to the stable 
knockdown of Apaf-1 or the overexpression of full-length XIAP or the 
baculoviral IAP repeat 1 and 2 (BIR1/BIR2) of XIAP were used to gain 
insight into the molecular requirements necessary for cleavage of Bid to 
tBid during drug-induced apoptosis.  Strikingly, the data showed that 
etoposide-induced apoptosis was decreased in Bid-deficient Jurkat cells.  
In particular, cells lacking Bid expression exhibited decreased Bak 
activation, cytochrome c release, loss of mitochondrial membrane 
potential (Δψ), and caspase activation.  Further, incubation of 
permeabilized Bid-deficient cells with recombinant tBid, but not full-length 
Bid, induced Bak dimerization and cytochrome c release.  Significantly, we 
also found that cleavage of Bid to tBid occurred strictly downstream of 
Apaf-1 by a mechanism that required active executioner caspases.    
 
4.3 Results and Discussion 
 
4.3.1 Bid Is Cleaved in Response to the DNA-damaging 
Chemotherapeutic Agent Etoposide 
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Although it has been reported that overexpression of full-length Bid 
causes cell death (Wang et al., 1996) and that full-length Bid can 
translocate to the OMM in response to an apoptotic stimulus (Tafani et al., 
2002; Sarig et al., 2003; Valentijn and Gilmore, 2004), it is generally 
accepted that tBid is far more potent than full-length Bid at activating Bak 
or Bax to induce MOMP (Li et al., 1998; Luo et al., 1998; Yin et al., 1999).   
The mechanism responsible for cleavage of Bid to tBid is at least partially 
understood.  Caspase-8-mediated proteolysis of Bid to tBid during 
receptor-mediated cell killing in type II cells is probably the best 
characterized example of Bid’s involvement during apoptotic cell death (Li 
et al., 1998; Luo et al., 1998).  It is also known that cathepsins, calpains, 
and Granzyme B can cleave Bid, although in most instances the cleavage 
sites are different from those targeted by caspase-8 (Yin, 2006).  It has 
also been suggested that caspase-3, and possibly caspase-2, can cleave 
Bid in vitro, although other evidence indicates that Bid is a relatively poor 
substrate for caspase-2 (Guo et al., 2002; Bonzon et al., 2006).  
Irrespective of the mechanism responsible for the cleavage of Bid, it is the 
C-terminal fragment that promotes apoptosis.  Further, caspase-8-
mediated cleavage of Bid to tBid exposes a glycine residue at the newly 
formed N-terminus that, in turn, undergoes myristoylation to facilitate 
translocation of tBid to mitochondria where it promotes MOMP induction 
(Zha et al., 2000). 
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 Although tBid is a potent inducer of Bak/Bax-controlled MOMP 
during receptor-mediated cell killing, whether tBid is an important 
upstream regulator of MOMP during true intrinsic apoptotic cell death is 
controversial (Kamer et al., 2005; Zinkel et al., 2005; Kaufmann et al., 
2007; Zinkel et al., 2007).  Thus, we set out to determine the extent to 
which Bid or tBid is functionally important for MOMP induction and 
apoptosis in response to DNA damage.  As illustrated in Fig. 10A, 
Western blot analysis of Jurkat whole-cell lysates obtained at 6 h following 
incubation with etoposide (10 µM) revealed that Bid had been cleaved to 
tBid.  Drug-induced cleavage of Bid to tBid was accompanied by an 
increase in the percentage of cells undergoing apoptosis (28%) as 
determined by annexin V-FITC and propidium iodide co-staining (Fig. 
10B).  Further, in agreement with our previous findings, incubation of cells 
with 10 µM etoposide for 6 h resulted in the proteolytic cleavage of 
caspase-9, -3, and -7, and a concomitant increase in caspase (DEVDase) 
activity (Fig. 10C and D).    
 
4.3.2 Stable Knockdown of Bid Desensitizes Jurkat Cells to Genotoxic 
Drug-induced Apoptosis 
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Figure 10.  Etoposide-induced Bid cleavage and apoptosis in wild-
type Jurkat T cells.  A, wild-type cells (106/mL) were cultured with DMSO 
or 10 µM etoposide for 6 h, harvested, and lysed for Western blotting.  B-
D, duplicate aliquots of cells in A were harvested and processed for cell 
death determination by flow cytometric analysis of annexin V-FITC and 
propidium iodide staining (B), Western blotting of caspases (C), or 
caspase (DEVDase) activity measurements (D). In B, quadrants are 
defined as live (lower left), early apoptotic (lower right), late apoptotic 
(upper right), and necrotic (upper left).  Numbers refer to the percentage of 


























Fig. 1. Etoposide-induced Bid cleavage and apoptosis in wild-type Jurkat T cells.  
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Having shown that tBid is generated in wild-type Jurkat cells 
undergoing DNA damage-induced apoptosis, we next used a vector-
based system that directs the synthesis of short hairpin RNA (shRNA) to  
produce stable silencing of Bid.  We hypothesized that such cells would 
shed light on whether Bid was important for genotoxic stress-induced 
apoptosis or if cleavage of Bid to tBid (Fig. 10A) was largely a bystander 
event in this setting with little biological significance. 
Two single-cell Bid-deficient Jurkat clones (#7 and #13) were used 
for these studies, and the extent to which Bid was suppressed was 
confirmed by Western blot analysis (Fig. 11A).  As mentioned previously, 
the requirement for Bid cleavage to tBid upon activation of the extrinsic 
pathway in type II cells has been well characterized and is widely 
accepted (Li et al., 1998; Luo et al., 1998; Scaffidi et al., 1998).  Because 
Jurkat cells are considered to be of type II origin, we first tested the 
sensitivity of these cells to apoptosis induced by agonistic anti-Fas 
antibody (100 ng/mL).  As anticipated, Bid-deficient cells were highly 
resistant to anti-Fas-induced apoptosis with clone #13 exhibiting the 
greatest degree of resistance as assessed by annexin V-FITC and 
propidium iodide co-staining (Fig. 11B) and proteolytic processing of 
caspases (Fig. 11C, lanes 6 and 9 versus 3).  Next, having demonstrated 
that Bid was strictly required for receptor-mediated apoptosis in Jurkat 
cells, we incubated the cells for 6 h in the presence of etoposide (10 μM) 
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Figure 11. Bid-deficient Jurkat cells are less susceptible to 
etoposide-induced apoptosis.  A, vector control or two single-cell Bid-
deficient Jurkat clones (#7 and #13) were harvested and lysed for Western 
blotting.  Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was 
used as a loading control.  B, cells (106/mL) were cultured in the presence 
or absence of DMSO, 10 μM etoposide, or 100 ng/mL agonistic anti-Fas 
antibody for 6 h, harvested, and processed for cell death determination by 
flow cytometric analysis of annexin V-FITC and propidium iodide staining.  
Quadrants are defined as live (lower left), early apoptotic (lower right), late 
apoptotic (upper right), and necrotic (upper left).  Numbers refer to the 
percentage of cells in each quadrant.  C, duplicate aliquots of cells in B 
were harvested and lysed for Western blotting.  shRNA, short hairpin 
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and evaluated the different clones for their sensitivity to apoptosis 
induction.  The results indicated that both Bid-deficient clones were less 
sensitive than control-transfected cells to etoposide-induced apoptosis 
with the degree of resistance paralleling the extent to which Bid 
expression had been suppressed (Fig. 11B).  In agreement with these 
findings, Western blot analysis of cell lysates obtained at 6 h post-
etoposide treatment showed that proteolytic processing of caspase-9, -3, 
and -7 was decreased in Bid-deficient cells (Fig. 11C, lanes 5 and 8 
versus 2).  Overall, these data suggest that Bid plays an important 
function during genotoxic drug-induced apoptosis in Jurkat cells. 
 
4.3.3 DNA Damage-induced Mitochondrial Events Are Attenuated in Bid-
deficient Jurkat Cells 
 
Studies from numerous laboratories have shown that MOMP is 
tightly regulated by pro- and anti-apoptotic proteins of the Bcl-2 family 
(Youle and Strasser, 2008).  In particular, MOMP is widely accepted to 
require the activation of a multidomain protein, notably Bak or Bax.  The 
presence and activation of either Bak or Bax is thought to be sufficient to 
induce MOMP.  In fact, because the deletion of either gene alone 
produces only subtle defects in apoptosis, whereas doubly-deficient cells 
exhibit severe apoptosis deficiencies (Lindsten et al., 2000), Bak and Bax 
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are generally thought to be redundant in function.  The activation of Bak 
and Bax coincides with their homo-oligomerization and in most instances 
is thought to depend on the presence and prior activation of a BH3-only 
Bcl-2 family member.  However, the mechanism by which BH3-only 
proteins activate Bak or Bax is controversial (Chipuk and Green, 2008).  
As mentioned previously, one model suggests that BH3-only proteins 
activate Bak and Bax directly, whereas the second model indicates BH3-
only proteins activate Bak and Bax indirectly by neutralizing the anti-
apoptotic function of pro-survival Bcl-2 family proteins.       
 Because we had observed that etoposide-induced apoptosis was 
decreased in Bid-deficient Jurkat cells, we next evaluated mitochondrial 
events that characteristically define MOMP, such as the dimerization and 
activation of Bak or Bax, the release of intermembrane space proteins, 
and the loss of ΔΨ.  In a recent paper, we showed that Jurkat (E6.1) cells 
express Bak, but not Bax, protein (Shawgo et al., 2008a).  Those findings 
were confirmed in Fig. 12A, and we also determined that silencing Bid had 
no effect on the expression level of Bak protein (lane 4 versus 3 and 2).  
Therefore, we next examined the extent to which Bak had undergone 
oligomerization in response to etoposide, using the cross-linking agent 
bismaleimidohexane.  As illustrated in Fig. 12B, cross-linked complexes 
consistent with Bak dimers were detected in control-transfected cells 
following treatment with 10 μM etoposide, whereas the extent of drug-  
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Figure 12. Inhibition of etoposide-induced mitochondrial apoptotic 
changes in cells lacking Bid.  A, whole-cell lysates of Jurkat (E6.1) and 
MCF-7 (positive control for Bax expression) cells were subjected to SDS-
PAGE and Western blotted.  B and C, cells (106/mL) were cultured with 
DMSO or 10 µM etoposide for 6 h and processed for determination of Bak 
oligomerization by Western blotting (B) or Bak activation by flow 
cytometric analysis (C).  Numbers in C refer to the percentage increase in 
Bak-associated fluorescence between DMSO- and etoposide-treated 
samples.  D, duplicate aliquots of cells in B and C were harvested and 
processed for subcellular fractionation.  Supernatant (s) and pellet (p) 
fractions were analyzed by Western blotting.  E, duplicate aliquots of cells 
in B and C were harvested and processed for mitochondrial membrane 
potential (ΔΨ) determination by flow cytometry.  Reduced DiIC1(5) 
fluorescence is indicative of a loss of ΔΨ, and numbers refer to the 
percentage of cells that underwent a dissipation of ΔΨ.  shRNA, short 
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induced dimerization was markedly decreased in the Bid-deficient cells as 
illustrated in lane 4 of Fig. 12B.  These findings were in line with results 
obtained using an active conformation-specific monoclonal Bak antibody 
and flow cytometric analysis where activation causes a shift to the right of 
the resulting histogram (Fig. 12C). 
Next, consistent with the inhibition of Bak activation in cells lacking 
Bid, the release of cytochrome c in response to etoposide was also 
markedly inhibited (Fig. 12D).  Finally, as illustrated in Fig. 12E, the loss of 
ΔΨ in response to etoposide was also decreased in the Bid-deficient cell 
line (Fig. 12E).  Combined, these data strongly suggest that Bid functions 
to promote Bak-controlled MOMP during DNA damage-induced apoptosis 
in Jurkat cells. 
 
4.3.4 Cleaved Bid (tBid) Mediates MOMP and Is Generated Independently 
of Caspase-8 in Response to DNA damage 
 
 A previous study reported that the expression of sublethal levels of 
wild-type or uncleavable Bid in bid-/- mouse embryonic fibroblasts resulted 
in a similar sensitization of cells to DNA damage-induced apoptosis that 
was accompanied by an enhanced localization of Bid to mitochondria and 
release of cytochrome c (Sarig et al., 2003).  In this regard, because we 
had demonstrated that cells lacking Bid were resistant to drug-induced 
 80  
apoptosis, we next sought to determine if the phenotype we observed was 
due to the absence of full-length Bid or tBid.  To address this issue, we 
made several attempts to rescue the phenotype of our Bid-deficient cells  
by reintroducing wild-type human Bid and mutants of Bid that were 
uncleavable or unable to be myristoylated.  Although it had been reported 
previously that overexpression of Bid is lethal to Jurkat cells (Wang et al., 
1996), we reasoned that reintroduction of wild-type or mutant Bid into cells 
that were deficient in this protein would yield viable cell clones.  
Surprisingly, however, all attempts to express wild-type or mutant Bid into 
Bid-silenced cells were unsuccessful because we found that cells simply 
could not be transfected with any form of Bid and remain viable.  Since our 
efforts to rescue the phenotype in whole cells failed, we next performed 
experiments in which we tried to reconstitute the phenotype using 
permeabilized cells.  Specifically, recombinant full-length and caspase-8-
cleaved Bid were used to treat permeabilized Bid-deficient Jurkat cells to 
evaluate more precisely whether Bid, tBid, or both could promote the 
engagement of the mitochondrial pathway.  As shown in Fig. 13A, when 
Bid-deficient Jurkat cells were permeabilized with digitonin and incubated 
with 5, 10, 25, 50, 100, or 250 nM recombinant tBid for 15 min at 22 ºC, 
cytochrome c was released into the cytosol.  By comparison, full-length 
Bid failed to stimulate the release of any cytochrome c, even at the highest 
concentration of 250 nM.  Consistent with the cytochrome c release data,  
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Figure 13.  tBid, but not Bid, mediates MOMPand is generated 
independently of caspase-8 in response to etoposide.  A, Bid-deficient 
(clone #13) Jurkat cells (2.5 x 106) were permeabilized with 7.5 μg of 
digitonin and incubated with recombinant tBid (top panels) or Bid (bottom 
panels) protein (5-250 nM) at 22 ºC for 15 min.  Subsequently, 
supernatant (s) and pellet (p) fractions were obtained, subjected to SDS-
PAGE, and Western blotted.  B, digitonin-permeabilized Bid-deficient cells 
as in A were incubated in the presence or absence of either 25 nM tBid or 
Bid and processed for determination of Bak oligomerization by Western 
blotting.  C, wild-type cells (106/mL) were pre-incubated in the presence or 
absence of 20 μM qVD-OPh for 1 h and subsequently incubated in the 
presence or absence of DMSO or 10 μM etoposide for an additional 6 h at 
which time cells were harvested and processed for Western blot analysis.  
D, whole-cell lysates of wild-type (A3) and caspase-8-deficient (I 9.2) 
Jurkat cells were subjected to SDS-PAGE and Western blotted.  E and F, 
cells (106/mL) were incubated in the absence or presence of DMSO, 10 
μM etoposide, or 100 ng/mL agonistic anti-Fas antibody for 6 h, harvested, 
and lysed for Western blotting (E) or processed for cell death 
determination by flow cytometric analysis of annexin V-FITC and 
propidium iodide staining (F).  Quadrants in F are defined as live (lower 
left), early apoptotic (lower right), late apoptotic (upper right), and necrotic 
(upper left).  Numbers refer to the percentage of cells in each quadrant.  
 82  
shRNA, short hairpin RNA; Cyt c, cytochrome c; Conc, concentration; 
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only tBid (25 nM) induced the oligomerization of Bak when added to 
digitonin-permeabilized Bid-deficient cells (Fig. 13B).  These findings 
indicate that tBid, and not full-length Bid, is most probably responsible for  
drug-induced activation of Bak and the induction of MOMP in response to 
genotoxic stress.  
As mentioned previously, it is widely accepted that caspase-8-
mediated cleavage of Bid is required for execution of extrinsic apoptotic 
cell death in type II cells.  It has also been suggested that other caspases 
may have the ability to cleave Bid, such as caspase-2 (Guo et al., 2002; 
Bonzon et al., 2006) and caspase-3 (Bossy-Wetzel and Green, 1999; Slee 
et al., 2000).  Additional lines of evidence have shown that non-caspase 
proteases, such as calpains (Chen et al., 2001; Mandic et al., 2002) and 
cathepsins (Stoka et al., 2001; Droga-Mazovec et al., 2008), are also 
capable of cleaving full-length Bid.  Further, a different study reported that 
tBid is important during DNA damage-induced apoptosis and that the 
cleavage of Bid to tBid in this context was not caspase-dependent.  
Instead, cleavage was suggested to occur by an unidentified aspartate 
protease (Werner et al., 2004).  The same study concluded that the 
importance of tBid for genotoxic stress-induced apoptosis was that it 
functioned to promote MOMP upstream of caspase activation.   
To determine if the cleavage of Bid to tBid was a caspase-mediated 
event in our experimental system, we incubated wild-type Jurkat cells with 
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the caspase inhibitor quinoline-Val-Asp-CH2-difluorophenoxy (qVD-OPh, 
20 µM) for 1 h prior to the addition of etoposide (10 μM).  As illustrated in 
Fig. 13C, pretreatment of cells with qVD-OPh completely prevented drug-
induced generation of tBid.  Next, because of early reports indicating that 
caspase-8 is important during DNA damage-induced apoptosis (Friesen et 
al., 1996; Kasibhatla et al., 1998; Petak et al., 2000) and because 
caspase-8 is the best characterized protease responsible for the cleavage 
of Bid, we used caspase-8-deficient Jurkat cells (Fig. 13D) to determine 
whether caspase-8 is necessary for mitochondria-mediated apoptosis 
and/or Bid cleavage.  As expected, these cells were highly resistant to 
receptor-mediated apoptosis induced by anti-Fas (Fig. 13F).  By 
comparison, caspase-8-deficient cells underwent etoposide-induced 
apoptosis to the same extent as A3 control cells (Fig. 13F), suggesting 
that caspase-8 is dispensable for etoposide-induced apoptosis.  Further, 
cleavage of Bid to tBid was prevented in caspase-8 null cells incubated in 
the presence of anti-Fas, whereas Bid was cleaved to a similar extent in 
caspase-8-deficient and A3 control cells treated with etoposide (Fig. 13E).  
Combined, these data suggest that caspase-8 is dispensable for 
etoposide-induced cleavage of Bid to tBid.   
 
4.3.5 Executioner Caspases Mediate Bid Cleavage During Etoposide-
induced Apoptosis 
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To extend these findings and to determine whether drug-induced 
Bid cleavage was mediated by a caspase other than caspase-8, we first 
used Apaf-1-deficient Jurkat cells described previously that are totally 
resistant to etoposide-induced apoptosis (Franklin and Robertson, 2007).  
As illustrated in Fig. 14A, cleavage of Bid to tBid did not occur in Apaf-1-
deficient cells incubated in the presence of 10 μM etoposide for 6 h.  
Because Bid cleavage appeared to require apoptosome-dependent 
caspase activation, we were next interested to determine the extent to 
which this was mediated by an initiator or executioner caspase protease.  
To distinguish between these two possibilities, we used Jurkat cells 
described recently that overexpress either full-length XIAP or the 
BIR1/BIR2 domains of XIAP (Shawgo et al., 2008a).  Full-length XIAP 
inhibits apoptosis by preventing caspase-9, -3, and -7 activity, whereas 
the BIR1/BIR2 domains of XIAP can inhibit caspase-3 and -7, but not 
caspase-9 (Shiozaki et al., 2003; Scott et al., 2005).  During either 
mitochondria-mediated apoptosis or receptor-mediated apoptosis in type II 
cells, the prosurvival activity of XIAP is neutralized by Smac and Omi, 
which are released into the cytosol from the intermembrane space of 
mitochondria as a consequence of MOMP.  In agreement with our 
previous findings (Shawgo et al., 2008a), Jurkat cells that overexpressed 
either full-length XIAP or the BIR1/BIR2 domains of XIAP were impaired in 
their ability to activate caspases and undergo apoptosis, exhibiting 7%  
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Figure 14.  Cleavage of Bid in response to etoposide is mediated by 
executioner caspases.  A, wild-type, control-transfected, and Apaf-1-
deficient Jurkat cells (106/mL) were incubated in the presence or absence 
of DMSO or 10 μM etoposide for 6 h, harvested, and lysed for Western 
blotting.  B, control-transfected, XIAP-overexpressing, and Myc-
BIR1/BIR2-expressing Jurkat cells (106/mL) were incubated in the 
presence or absence of DMSO or 10 μM etoposide for 6 h, harvested, and 
lysed for Western blotting.  C, duplicate aliquots of cells in B were 
processed for determination of Bak activation by flow cytometric analysis.  
Numbers in C refer to the percentage increase in Bak-associated 
fluorescence between DMSO- and etoposide-treated samples. shRNA, 



























































































 89  
and 12% apoptotic cells, respectively, in response to etoposide (data not 
shown).  Western blot analysis of duplicate cell aliquots revealed that  
control-transfected, but not XIAP- or BIR1/BIR2-transfected, cells had 
cleaved Bid in response to etoposide treatment (Fig. 14B).  Importantly, 
the absence of etoposide-induced Bid cleavage in cells overexpressing 
either XIAP or the BIR1/BIR2 domains of XIAP was accompanied by a 
marked decrease in Bak activation in these cells incubated under the 
same conditions (Fig. 14C).  Taken together, these data suggest that 
etoposide-induced cleavage of Bid to tBid and tBid-mediated activation of 
Bak occur by a mechanism that requires the prior activation of executioner 
caspases.  
 
4.4 Concluding Remarks 
 
 A key step during true intrinsic apoptosis is the induction of MOMP 
mediated by an active multidomain pro-apoptotic protein Bak or Bax 
(Chipuk and Green, 2008).  In fact, it is generally accepted that the 
presence and activation of either Bak or Bax is strictly required for MOMP.  
BH3-only proteins are most often responsible for the activation of Bak and 
Bax, which involves their homo-oligomerization and insertion into the 
OMM to form pores through which intermembrane space proteins, such as 
cytochrome c and Smac, are released into the cytosol to activate 
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caspases.  As mentioned previously, the best characterized example of a 
BH3-only protein being responsible for the activation of a multidomain 
protein is during receptor-mediated apoptosis in type II cells where tBid 
activates Bak/Bax to induce MOMP.  A similar emergent role for a BH3-
only protein in the activation of Bak or Bax during true intrinsic apoptotic 
cell death is currently lacking. 
Some evidence in the literature indicates that the activation of Bak 
or Bax following DNA damage can be mediated by p53-dependent 
upregulation of the BH3-only protein Puma (Jeffers et al., 2003; Villunger 
et al., 2003).  However, Jurkat cells, which are highly susceptible to DNA 
damage-induced apoptosis, possess mutant p53 (Cheng and Haas, 
1990).  In addition, cycling T lymphoma cells and mitogenically activated T 
lymphocytes from p53-/- mice were shown to be sensitive to genotoxic 
stress-induced apoptosis (Strasser et al., 1994).   In this regard, p53-
induced upregulation of Puma is unlikely to be the sole mediator of 
Bak/Bax-dependent apoptosis in response to DNA damage.  In fact, 
accumulating evidence in the literature suggests that the activation of Bak 
or Bax during true intrinsic apoptosis requires the presence of either Bid or 
Bim, irrespective of p53 status (Letai, 2008).   
Recent studies investigating a potential role for Bid during DNA 
damage-induced apoptosis have produced conflicting results (Kamer et 
al., 2005; Zinkel et al., 2005; Kaufmann et al., 2007).  On one hand, 
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embryonic fibroblasts and myeloid progenitor cells from Bid-deficient mice 
were shown to be less susceptible to etoposide-induced apoptosis (Kamer 
et al., 2005; Zinkel et al., 2005), whereas another study reported that Bid 
plays no role in DNA damage-induced apoptosis (Kaufmann et al., 2007).  
The fact that each of these studies used cells that were cultivated from 
bid-/- mice on a C57BL/6 background makes it difficult to reconcile the 
different findings in the absence of additional experimentation.     
As mentioned previously, a separate study using Jurkat T cells 
suggested that tBid was required for apoptosis signaling during DNA 
damage-induced apoptosis (Werner et al., 2004).  The authors also 
concluded that Bid cleavage occurred independently of caspase activity.  
Rather, it was speculated that an unidentified aspartate protease was 
responsible for the cleavage of Bid to tBid, which, in turn, was critical for 
MOMP and the activation of all caspases.   
 Our findings using a panel of gene-manipulated Jurkat cells also 
support a role for cleavage of Bid to tBid in eliciting cytochrome c release 
and apoptosis in response to etoposide.  However, unlike Werner et al. 
(38), our data suggest that most, if not all, Bid cleavage occurs 
downstream of MOMP by a mechanism that depends on active 
executioner caspases (Fig. 15).  In this regard, our current data support 
and extend a model of the intrinsic pathway in which downstream 
caspases and mitochondria forge a circuit of positive amplification to  
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Figure. 15.  Hypothetical scheme of etoposide-induced apoptosis.  
Genotoxic stress in response to etoposide induces initial MOMP by 
generating a still poorly defined death signal that activates Bax/Bak.  As a 
consequence of early MOMP, intermembrane space proteins, including 
cytochrome c and Smac, are released into the cytosol.  The initial release 
of these proteins into the cytosol per se is not an irreversible commitment 
point to apoptotic cell death.  Instead, the point of commitment occurs 
when the accumulation of Smac is sufficient to inhibit XIAP-mediated 
inhibition of caspase-9, -3, and -7 and/or the accumulation of cytochrome 
c surpasses a threshold needed for the conversion of sufficient numbers 
of monomeric Apaf-1 molecules to heptameric apoptosome signaling 
platforms necessary for initial caspase-9 activation.  The ensuing 
caspase-9 activity would need to be sufficiently strong to activate enough 
executioner caspase-3 or -7 molecules to kill a cell outright and/or to elicit 
feed forward amplification of MOMP by cleaving Bid to tBid. BH3, Bcl-2 
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ensure irreversible commitment to apoptosis.  Indeed, it is tempting to 
speculate that some cell types may be spared death if feed forward 
amplification of early mitochondrial apoptotic events is inhibited.  
We envision a scenario where genotoxic stress triggers initial MOMP and 
the release of intermembrane space proteins by activating Bak or Bax by 
an as yet poorly understood mechanism that may or may not involve a 
BH3-only protein (Fig. 15).  The initial induction of MOMP would not 
necessarily mark the “point of no return” for an injured cell unless, or until, 
the release of intermembrane space proteins, including cytochrome c, 
exceeded a threshold necessary to trigger apoptosome formation resulting 
in caspase-9 activation and the subsequent activation of caspase-3/7.  In 
turn, active caspase-3 (or -7) would mediate feed forward amplification of 
initial MOMP by cleaving Bid to tBid to increase the activation of Bak or 
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Chapter 5: KU135, a Novel Novobiocin-derived C-terminal 
Inhibitor of Hsp90, Exerts Potent Antiproliferative Effects in 




 Heat shock protein 90 (Hsp90) assists in the proper folding of 
numerous mutated or overexpressed signal transduction proteins that are 
involved in cancer.  Consequently, there is considerable interest in 
developing chemotherapeutic drugs that specifically disrupt the function of 
Hsp90.  Here, we investigated the extent to which a novel novobiocin-
derived C-terminal Hsp90 inhibitor, designated KU135, induced 
antiproliferative effects in Jurkat T-lymphocytes.  The results indicated that 
KU135 bound directly to Hsp90, caused the degradation of known Hsp90 
client proteins, and induced more potent antiproliferative effects than the 
established N-terminal Hsp90 inhibitor 17-AAG.  Closer examination of the 
cellular response to KU135 and 17-AAG revealed that only 17-AAG 
induced a strong upregulation of Hsp70 and Hsp90.  Also, KU135 caused 
wild-type cells to undergo G2/M arrest, whereas cells treated with 17-AAG 
accumulated in G1.  Further, KU135, but not 17-AAG, was found to be a 
potent inducer of mitochondria-mediated apoptosis as evidenced, in part, 
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by the fact that cell death was inhibited to a similar extent by Bcl-2/Bcl-xL 
overexpression or the depletion of Apaf-1.  Combined, these data suggest 
that KU135 inhibits cell proliferation by regulating signaling pathways that 
are mechanistically different from those targeted by 17-AAG and as such 




Members of the heat shock protein (Hsp) 90  protein family are 
commonly overexpressed in cancer cells and play critical roles in 
promoting survival by chaperoning client proteins associated with all six of 
the acquired cancer capabilities (Hanahan and Weinberg, 2000; Isaacs et 
al., 2003; Blagg and Kerr, 2006).  A growing number of natural product, 
synthetic, and semi-synthetic Hsp90 inhibitors are being developed that 
largely target the N-terminal ATP-binding pocket and have been shown to 
cause potent antiproliferative effects (Roe et al., 1999; Whitesell and 
Lindquist, 2005; Avila et al., 2006a; Avila et al., 2006b).  However, the 
potential clinical utility of several of the N-terminal inhibitors as anticancer 
drugs has been dampened significantly due to concerns about their 
adverse hepatotoxic effects (Egorin et al., 1998) and tendency to induce 
expression of cytoprotective Hsp90 and Hsp70 proteins (Chiosis et al., 
2003; Whitesell et al., 2003; Powers and Workman, 2007; Schmitt et al., 
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2007).  More recently, the observation was made that Hsp90 contains a 
previously unrecognized C-terminal ATP-binding domain (Marcu et al., 
2000a; Marcu et al., 2000b), which has led several groups to pursue the 
development of specific C-terminal Hsp90 inhibitors as potential 
anticancer drug modalities (Burlison et al., 2006; Burlison et al., 2008b; 
Donnelly et al., 2008).  Both N-terminal and C-terminal Hsp90 inhibitors 
can exert an antiproliferative response, in some instances, by stimulating 
apoptosis (Isaacs et al., 2003; Georgakis and Younes, 2005; Whitesell 
and Lindquist, 2005), although the underlying mechanisms are not well 
understood. 
Apoptotic cell death is mediated by a family of cysteine proteases 
that cleave after aspartate residues (caspases).  In general, the activation 
of caspases can occur by two distinct signaling pathways.  Within the 
extrinsic (receptor-mediated) pathway, ligand (e.g., FasL and TNFα) 
binding to a corresponding death receptor (e.g., Fas and TNF-R1) leads to 
recruitment of FADD and procaspase-8 molecules to the cytosolic side of 
the cell membrane to form the death-inducing signaling complex (DISC) 
(Kischkel et al., 1995).  Activation of procaspase-8 occurs at the DISC, 
and active caspase-8, in turn, can activate caspase-3 directly or by first 
cleaving and activating the BH3-only protein Bid to truncated Bid (tBid), 
which, in turn, can engage the intrinsic or mitochondria-mediated apoptotic 
pathway (Li et al., 1998; Luo et al., 1998).  The intrinsic (mitochondria-
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mediated) pathway, however, is most often initiated by cytotoxic stress, 
including growth factor withdrawal, DNA damage, γ-radiation, and heat.  In 
response to these types of stimuli, mitochondrial outer membrane 
permeabilization (MOMP) generally occurs, resulting in the release of 
cytochrome c, Smac (also known as DIABLO), and Omi into the cytosol, 
where they work together to activate procaspase-9 within the apoptotic 
protease-activating factor-1 (Apaf-1) apoptosome complex (Li et al., 
1997).  Once activated, caspase-9 can cleave and thereby activate 
caspase-3, which, in turn, is responsible for proteolytic dismantling of the 
cell.      
The aim of the current study was to investigate the extent to which 
a novobiocin-derived C-terminal Hsp90 inhibitor, KU135, could induce an 
antiproliferative response and how such an effect compared to that 
exhibited by the established N-terminal inhibitor 17-allylamino-
demethoxygeldanamycin (17-AAG).  The results indicated that KU135 
binds directly to Hsp90 and exhibits more potent antiproliferative effects 
than 17-AAG.  Both 17-AAG and KU135 stimulated the degradation of 
known Hsp90 client proteins, whereas only 17-AAG triggered a 
pronounced increased expression of Hsp70 and Hsp90 proteins.  KU135 
was found to induce both G2/M cell cycle arrest and mitochondria-
mediated apoptosis, whereas 17-AAG predominantly induced G1 cell cycle 
arrest.   
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5.3 Results 
 
5.3.1 A novobiocin-derived C-terminal Hsp90 inhibitor, KU135, induces a 
potent antiproliferative response in Jurkat T-lymphocytes. 
 
 As mentioned previously, a new possibility for Hsp90 inhibition was 
raised when the antibiotic novobiocin was found to bind a previously 
unidentified C-terminal ATP-binding site (Fig. 16A), albeit with poor affinity 
(IC50, ~700 µM).  Through systematic investigations, new novobiocin 
analogues have been produced that exhibit significantly better efficacy.  
We began our studies by evaluating the extent to which wild-type Jurkat T-
lymphoblastoid leukemia cells (clone E6.1) were sensitive to the novel 
novobiocin analogue KU135 (Fig. 16B).  KU135 is part of a larger library of 
structurally related compounds that will be discussed in detail in a 
forthcoming manuscript under preparation by Blagg and coworkers 
(unpublished information).  The potency of KU135 was compared to that 
of novobiocin, 17-AAG, and the anticancer drug etoposide, which 
damages DNA by inhibiting topoisomerase II and is a well-established 
inducer of mitochondria-mediated apoptosis.  Wild-type Jurkat cells were 
incubated with increasing concentrations of KU135 (2.5 nM – 50 µM), 
novobiocin (25 nM – 500 µM), 17-AAG (0.5 nM – 10 µM), and etoposide 
(2.4 nM – 47 µM) or DMSO (0.5% final concentration) for 24 or 48 h and  
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Figure 16. KU135, a novel analogue of novobiocin, causes 
antiproliferation.  A, Hsp90 contains four functional domains and the 
numbering (1-732) reflects the approximate number of amino acids that 
comprise each region.  NCR refers to the negatively-charged region that 
links the N-terminal and middle domains.  The regions where nucleotides, 
small molecule inhibitors, and/or cisplatin bind Hsp90 are shown.  B, the 
structures of novobiocin and KU135.  C, cells (3 x 104/well) were cultured 
in a 96-well plate in the absence or presence of DMSO (), KU135 (2.5 
nM – 50 μM) (▲), 17-AAG (0.5 nM – 10 μM) (), etoposide (2.4 nM – 47 
μM) (), or novobiocin (25 nM – 500 μM) () for 24 or 48 h and 
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cell viability was determined by the MTS proliferation assay.  As illustrated 
in Fig. 16C, all four compounds (i.e., KU135, novobiocin, 17-AAG, and 
etoposide) inhibited cell proliferation in a concentration- and time-
dependent manner.  In particular, the IC50 values for KU135, etoposide, 
17-AAG, and novobiocin at 48 h post-treatment were found to be 416 nM, 
1.3 µM, 4 μM, and 252 µM, respectively.  Thus, while all four drug 
treatments inhibited Jurkat cell proliferation, KU135 was ~3, ~10, and 
~600 times more potent than etoposide, 17-AAG, and novobiocin, 
respectively. 
 
5.3.2 KU135 inhibits cell division and induces apoptotic cell death in wild-
type Jurkat cells. 
 
 Next, we were interested in determining whether the decrease in 
viability observed in response to KU135 administration using the MTS 
assay was due to an induction of apoptosis.  Indeed, as shown in Fig. 
16A, wild-type Jurkat cells underwent apoptosis in a concentration-
dependent manner when incubated with KU135 for 24 h.  In particular, we 
found that treatment with 1 µM and 2.5 µM KU135 induced 38% and 47% 
apoptosis, respectively (Fig. 17A).  The level of KU135-induced apoptosis 
did not increase further when cells were incubated with concentrations of 
KU135 greater than 2.5 µM (data not shown).  By comparison, and in  
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Figure 17. KU135 and 17-AAG exert different effects on apoptosis 
and cell cycle distribution.  A, cells (5 x 105/mL) were cultured with 
DMSO or the indicated concentrations of 17-AAG or KU135 for 24 h and 
processed for apoptotic cell death determination by flow cytometric 
analysis of annexin V-FITC staining in a buffer containing propidium 
iodide.  Increased annexin V-FITC fluorescence reflects 
phosphatidylserine externalization on the plasma membrane, and 
numbers refer to the percentage of cells undergoing apoptosis.  B, cells (5 
x 105/mL) were cultured with DMSO, 1 μM KU135, or 10 μM 17-AAG for 
24 h, fixed in 70% ethanol, and analyzed for cell cycle status using 
PI/RNase Staining Buffer and flow cytometry.  C, quantification of cell 
cycle distribution of viable/euploid cells as obtained in B.  D, quantification 
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agreement with previous findings (Rahmani et al., 2003), 17-AAG 
exhibited a much milder apoptotic effect in Jurkat cells, even at the highest 
concentration of 10 µM, where only 12% of cells had externalized PS.  
Combined, these data suggest that the more potent antiproliferative effect 
of KU135 as compared to 17-AAG (Fig. 17) is due, at least in part, to the 
ability of KU135 to induce apoptotic cell death. 
Because 17-AAG induced significantly less apoptosis than KU135, 
and yet was found to have an IC50 value relatively similar to that of 
etoposide (Fig. 16), we speculated that the antiproliferative activity of 17-
AAG might involve an effect on cell cycle status.  As illustrated in Fig. 17B 
and C, the distribution of non-apoptotic cells differed between KU135- and 
17-AAG-treated cells at 24 h.  Specifically, 66% and 26% of cells 
incubated with 17-AAG had accumulated in G1 and G2/M phases of the 
cell cycle, respectively.  This was compared to KU135-treated cells in 
which 20% and 53% of cells had accumulated in G1 and G2/M phases of 
the cell cycle, respectively (Fig. 17B and C).  In agreement with the low 
level of 17-AAG-induced apoptosis that was observed compared to KU135 
as assessed by annexin V positivity (Fig. 17A), cell cycle distribution 
analysis revealed a considerably smaller fraction of sub-G1 cells in 
response to 17-AAG than KU135 (Fig. 17B and D).  The fact that the 
percentage of KU135-treated cells containing hypodiploid DNA content 
was low as compared to the amount of apoptosis that was observed using 
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annexin V-FITC and propidium iodide staining as an endpoint can likely be 
explained by the fact that DNA fragmentation is a late apoptotic event 
relative to PS externalization.  Overall, these data indicate that the 
antiproliferative effect of KU135 is mechanistically different to that 
exhibited by 17-AAG.    
 
5.3.3 Binding of KU135 to Hsp90 and the effect of KU135 and 17-AAG on 
the levels of Hsp90 isoforms and associated client proteins. 
 
Next, using three complementary approaches, we tested the extent 
to which KU135 bound Hsp90.  Initially, we performed novobiocin-binding 
experiments in which rabbit reticulocyte lysate was loaded onto a 
novobiocin-sepharose column in order to bind endogenous Hsp90.  
Thereafter, the column was washed extensively with 10 mM Tris-HCl (pH 
7.4) buffer, containing 150 mM NaCl, and bound proteins were eluted with 
increasing concentrations of KU135 or 10 mM novobiocin.  As shown in 
Fig. 18A, Hsp90 was eluted from the column with KU135 in a 
concentration-dependent manner (lanes 3-7).  In contrast to novobiocin, 
which binds the C-terminus of Hsp90 (lane 2), the N-terminal Hsp90 
inhibitor geldanamycin was unable to elute Hsp90 from the novobiocin-
sepharose column (data not shown), which is consistent with previous 
studies by Neckers and coworkers (Marcu et al., 2000b).  Next, proteolytic  
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Figure 18.  KU135 binds Hsp90 and exhibits different effects than 17-
AAG on the expression levels of Hsp90 isoforms and known client 
proteins.  A, rabbit reticulocyte lysate (50 μl) was applied to a novobiocin-
sepharose column after ATP regeneration and eluted with the indicated 
concentrations of KU135 and Western blotted.  DMSO and 10 mM 
novobiocin were used as controls.  B, rabbit reticulocyte lysate (50 μl) was 
incubated at 30 °С for 10 min with DMSO, 20 mM geldanamycin, 
novobiocin and molybdate (lanes 1–4, respectively) or 0, 1, 5, 10 and 20 
mM KU135 (lanes 5–9).  Subsequently, the reactions were chilled on ice 
and incubated for 6 min with 125 μg/mL trypsin and Western blotted.  C – 
F, representative curves of surface plasmon resonance (SPR) analysis of 
KU135 binding to Hsp90β injected at the indicated concentrations (C),  
hyperbolic replot of the amount of KU135 bound versus concentration of 
KU135 (D), a scatchard plot of the binding of KU135 to Hsp90 (E), and 
hyperbolic replot of the amount of novobiocin bound versus concentration 
of novobiocin, corrected for nonspecific binding as described under 
“Materials and Methods” (F).  G and H, cells (5 x 105/mL) were cultured 
with DMSO, 1 μM KU135, or 10 μM 17-AAG for 24 h, harvested, and lysed 
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fingerprinting of Hsp90 in rabbit reticulocyte lysate was performed to  
determine whether binding of a C-terminal inhibitor, such as novobiocin, 
molybdate, and perhaps KU135, caused Hsp90 to adopt a conformation 
that differs from the tertiary structure it assumes upon binding of the N-
terminal inhibitor geldanamycin (Fig. 18B) (Yun et al., 2004).  Briefly, 
rabbit reticulocyte lysate was incubated at 37 °С for 5 min with DMSO, 20 
mM geldanamycin, novobiocin, or molybdate (lanes 1–4, respectively), or 
0, 1, 5, 10 and 20 mM KU135 (lanes 5–9), partially digested with trypsin, 
subjected to SDS-PAGE, and Western blotted with an Hsp90 antibody 
against the N-terminus of the protein.  As shown in Fig. 18B, reticulocyte 
lysate incubated with KU135 produced a similar proteolytic fingerprint 
pattern as previously reported for novobiocin and molybdate (Yun et al., 
2004).  In contrast, incubation of reticulocyte lysate with geldanamycin 
(lane 2) resulted in no proteolytic fingerprinting.  Combined, these data 
strongly suggest that KU135 binding of the C-terminus of Hsp90 in 
reticulocyte lysate exposes a cleavage site necessary for tryptic digestion 
and production of a 40-kDa N-terminal fragment of Hsp90.   
To further support that Hsp90 specifically binds KU135, the 
interaction of KU135 with immobilized Hsp90β was measured by surface 
plasmon resonance spectroscopy.  Fig. 18C shows representative curves 
for the binding of KU135 to Hsp90β.  As illustrated in Fig. 18D and E, the 
binding of KU135 to Hsp90 was saturable with a calculated Kd of 1-2 μM 
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and a stoichiometry of 1 mole per mole of Hsp90β monomer.  Thus, the 
high affinity binding of KU135 correlates directly with its potency in whole-
cell assays (Fig. 16 and 17).  By comparison, the Kd for novobiocin binding 
of Hsp90 was mathematically determined to be 3  1 mM, and the half-
maximal saturation concentration of novobiocin determined by 
extrapolation from the hyperbolic fitted curve was just below 1 mM (Fig. 
18F).  Taken together, these results demonstrate that Hsp90 exhibits a 
binding affinity for KU135 that is more than 500 times greater than its 
affinity for novobiocin.  Significantly, Hsp90 binding affinity for KU135 is 
comparable to that reported for geldanamycin and 17-AAG (Kd approx. 1 
μM) (Marcu et al., 2000b).   
Currently, approximately 100-200 Hsp90-dependent client proteins 
have been identified.  Many of these clients are oncogenic proteins (e.g., 
Akt, p-Akt, HIF-1α, cdc2, and Hsp70) that are involved in regulating signal 
transduction, cell growth, and apoptosis (Isaacs et al., 2003).  In many 
instances, the molecular profile of Hsp90 inhibition includes depletion of 
numerous client proteins and induction of Hsp70 and/or Hsp90 in a 
concentration- and/or time-dependent manner (Banerji et al., 2005a; 
Banerji et al., 2005b).  Because KU135 was found to be more potent than 
17-AAG at inhibiting cell proliferation, we sought to investigate the extent 
to which this might correspond to differences in the expression profiles of 
the four different Hsp90 proteins (i.e., Hsp90α, Hsp90β, Grp94, and 
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TRAP1), the depletion of associated client proteins, and/or the induction of 
Hsp70.   
As illustrated in Fig. 18G, Jurkat cells constitutively express 
Hsp90α, Hsp90β, Grp94, and TRAP-1, and incubation with 17-AAG, but 
not KU135, for 24 h led to a considerable increase in the expression levels 
of Hsp90α and Hsp90β.  In addition, both KU135 and 17-AAG caused 
significant alterations in the level of known Hsp90 client proteins (Fig. 
18H).  Specifically, treatment with 17-AAG or KU135 caused a time-
dependent decrease in the level of p-Akt.  We also found that incubation 
with KU135 or 17-AAG caused a decrease in the level of Hif-1α over 24 h, 
whereas only 17-AAG was found to affect the expression level of the cell 
cycle regulator cdc2.  Significantly, Fig. 18H also illustrates that Hsp70 
expression was induced to a far greater extent in cells treated with 17-
AAG than cells treated with KU135.  Collectively, these findings 
demonstrate that both 17-AAG and KU135 effectively inhibit the 
chaperoning function of Hsp90.  Furthermore, the fact that the expression 
of Hsp90α, Hsp90β, and Hsp70 were markedly increased only in response 
to 17-AAG might partially explain why KU135 was found to exert more 
potent cytotoxic effects than 17-AAG (Fig. 17). 
 
5.3.4 KU135-induced apoptosis occurs independently of the extrinsic 
pathway. 
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In light of the finding that KU135 was a potent inducer of apoptosis, 
we next investigated the extent to which this effect involved the extrinsic 
(receptor-mediated) pathway.  To test this possibility, we used a clone of 
Jurkat cells lacking caspase-8 (I 9.2).  The absence of this protein was 
confirmed previously by Western blot analysis, and this clone was found to 
be completely resistant to Fas-induced apoptosis (Shelton et al., 2009).  
As illustrated in Fig. 19A, cells lacking caspase-8 were as sensitive as 
control A3 cells to KU135-induced apoptosis at 24 h, as determined by 
annexin V-FITC and propidium iodide fluorescence.  In addition, Western 
blot analysis of cell lysates obtained at 24 h post-treatment revealed that 
KU135 (1 μM) caused robust processing of procaspase-9, -3, and -2 (Fig. 
19B).  Further, caspase-3-like (DEVDase) activity was stimulated to the 
same extent in caspase-8-null cells as control A3 cells when incubated in 
the presence of KU135 for 24 h (data not shown).  Although caspase-9 
underwent proteolytic cleavage in response to 17-AAG (Fig. 19B, lanes 3 
and 6), only the p37 inactive form of this caspase was observed 
(Srinivasula et al., 1998; Denault et al., 2007).  Combined, these findings 
confirm that 17-AAG is a relatively poor inducer of apoptosis (cf. Fig. 17) 
and demonstrate that KU135-induced apoptosis occurs independently of 
the extrinsic (receptor-mediated) pathway. 
 
5.3.5 KU135-induced apoptosis relies heavily on the intrinsic pathway. 
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Figure 19.  KU135-induced apoptosis occurs independently of the 
receptor-mediated apoptotic pathway.  A, cells (5 x 105/mL) were 
cultured in the presence or absence of DMSO, 1 μM KU135, or 10 μM 17-
AAG, harvested, and processed for cell death determination by flow 
cytometric analysis of annexin V-FITC and propidium iodide staining.  
Quadrants are defined as live (lower left), early apoptotic (lower right), late 
apoptotic (upper right), and necrotic (upper left).  Numbers refer to the 
percentage of cells in each quadrant.  B, duplicate aliquots of cells in A 
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We next investigated whether the intrinsic (mitochondria-mediated) 
pathway was responsible for KU135-induced cell killing.  For these 
experiments, we took advantage of Apaf-1-deficient Jurkat cells (Franklin 
and Robertson, 2007), as well as cells in which we had overexpressed 
Bcl-2 or Bcl-xL (Shawgo et al., 2008b).  Apaf-1 is strictly required for 
apoptosome-mediated activation of initiator caspase-9 within the intrinsic 
pathway, whereas Bcl-2 and Bcl-xL are well characterized anti-apoptotic 
proteins whose overexpression is known to inhibit intrinsic apoptosis by 
preventing MOMP and the release of intermembrane space pro-apoptotic 
proteins (e.g., cytochrome c and Smac) into the cytosol.   
As illustrated in Fig. 20A, cells lacking Apaf-1 or overexpressing 
Bcl-2/Bcl-xL were resistant to KU135-induced apoptosis, having 
undergone only 3-6% apoptosis after incubation with KU135 (1 µM) for 24 
h, whereas control-transfected cells had undergone 40% apoptosis at the 
same time-point.  In agreement with these findings, Western blot analysis 
of cell lysates obtained at 24 h post-KU135 treatment revealed that 
extensive proteolytic processing of procaspase-9, -3, and -2 occurred in 
wild-type and control-transfected cells (Fig. 20B).  Whereas proteolytic 
processing of these three caspases did not occur in Bcl-2- or Bcl-xL-
overexpressing cells, some processing was observed in Apaf-1-deficient 
cells (Fig. 20B), despite their being resistant to KU135-induced apoptosis.  
However, the cleavage of caspase-9 in response to KU135 in the wild- 
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Figure 20.  KU135-induced apoptosis relies on the mitochondria-
mediated apoptotic pathway.  A, cells (5 x 105/mL) were cultured in the 
presence or absence of DMSO or 1 μM KU135 for 24 h, harvested, and 
processed for cell death determination by flow cytometric analysis of 
annexin V-FITC and propidium iodide staining.  Quadrants are defined as 
live (lower left), early apoptotic (lower right), late apoptotic (upper right), 
and necrotic (upper left).  Numbers refer to the percentage of cells in each 
quadrant.  B, duplicate aliquots of cells in A were harvested and lysed for 
Western blotting.  C, cells (5 x 105/mL) were cultured in the presence or 
absence of DMSO or 1 μM KU135 for 24 h, harvested, and processed for 
determination of Bak oligomerization by Western blotting.  D and E, 
duplicate aliquots of cells in C were processed for subcellular fractionation 
into supernatant (s) and pellet (p) fractions (D) or for mitochondrial 
membrane potential (ΔΨ) determination by flow cytometry (E).  Reduced 
DiIC1(5) fluorescence is indicative of a loss of ΔΨ, and numbers refer to 
the percentage of cells that underwent a dissipation of ΔΨ.  BMH, 
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type and control-transfected cells produced two fragments (p37/p35), 
whereas only one caspase-9 cleavage fragment (p37) was detected in the 
Apaf-1-deficient cells (Fig. 20B).  This finding and the observation made 
with 17-AAG (Fig. 19B) are significant because apoptosome-dependent 
activation of caspase-9 yields the p35 fragment, whereas the p37 form of 
caspase-9 is generally thought to be produced by caspase-3-mediated 
cleavage and to be catalytically inactive (Srinivasula et al., 1998; Denault 
et al., 2007).  However, only a trace amount of active caspase-3 was 
detected in both instances (Fig. 20B and 19B), suggesting that the 
generation of the p37 fragment of caspase-9 may be caspase-3-
independent.  Finally, caspase-2 also underwent some proteolytic 
cleavage in KU135-treated Apaf-1-deficient cells (Fig. 20B).  However, 
whether proteolysis of caspase-2 in this context reflects its activation or 
whether caspase-2 is being cleaved as an “innocent bystander” remains to 
be determined.  Notwithstanding, these data demonstrate that the 
antiproliferative effect of KU135 involves an ability to induce intrinsic 
(mitochondria-mediated) apoptosis. 
We next evaluated the extent to which mitochondrial endpoints 
typically associated with MOMP, including Bak/Bax activation, the release 
of mitochondrial intermembrane space proteins (e.g., cytochrome c), and 
the loss of mitochondrial membrane potential (ΔΨ), were inhibited in 
KU135-resistant cells.  As illustrated in Fig. 20C, wild-type, control-
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transfected, and Apaf-1-deficient cells treated with 1 μM KU135 for 24 h 
activated Bak (Jurkat E6.1 cells do not express Bax) as evidenced by the 
presence of Bak dimers in these cells using the cross-linking agent 
bismaleidmidohexane.  In agreement with these data, KU135 induced 
cytochrome c release in wild-type, control-transfected, and Apaf-1-
deficient cells (Fig. 20D).  Both Bak oligomerization and cytochrome c 
release were completely inhibited in Bcl-2- or Bcl-xL-overexpressing cells 
incubated under the same conditions (Fig. 20C and D).  Finally, we 
evaluated the different clones for KU135-induced changes in ΔΨ at 24 h 
(Fig. 20E).  Wild-type and control-transfected cells incubated in the 
presence of 1 μM KU135 showed that 35% of cells had lost ΔΨ, whereas 
cells overexpressing Bcl-2 or Bcl-xL had retained ΔΨ.  By comparison, 
Apaf-1-deficient cells, which were found to be resistant to KU135, despite 
activating Bak, releasing cytochrome c, and cleaving certain caspases, 
largely retained ΔΨ (Fig. 20E).  Overall, these findings offer support of a 





Hsp90 represents a family of ATPase-containing molecular 
chaperones that comprise as much as 1-2% of total cellular protein under 
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unstressed conditions.  In response to various stressors, this amount can 
increase to 4-6% (Whitesell and Lindquist, 2005).  Hsp90 is often present 
at elevated levels in cancer cells and functions to stabilize oncogenic 
proteins involved in signal transduction, growth, and apoptosis regulation 
(Isaacs et al., 2003).  A possible explanation for Hsp90 overexpression in 
cancer cells is that malignant cells are in a persistent state of proteotoxic 
stress due, in part, to acidosis and/or the accumulation of mutated 
signaling molecules that would otherwise result in cell lethality.  In this 
way, the presence of Hsp90 (as well as other heat shock proteins) is 
thought to compensate for the hostility of many cancer cell 
microenvironments (Whitesell and Lindquist, 2005; Solit and Rosen, 
2006).  As mentioned previously, there are currently between one and two 
hundred reported cytosolic and nuclear client proteins for Hsp90, including 
protein kinases (e.g., Akt and Her2), transcription factors (e.g., mutant p53 
and HIF-1α), chimeric signaling proteins (e.g., Bcr-Abl), and several 
proteins involved in apoptosis (e.g., Bid, Apaf-1, and RIP) (for an updated 
list see http://www.picard.ch/downloads/downloads.htm).  Significantly, 
whereas many of the aforementioned Hsp90 client proteins are being 
pursued individually as targets for anti-cancer drug development, inhibition 
of Hsp90 would prevent the maturation and stabilization of numerous 
Hsp90 client proteins simultaneously, leading to their ultimate degradation 
within the ubiquitin-proteasome pathway (Whitesell et al., 1994; Schulte et 
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al., 1995).  In this regard, Hsp90 has emerged as an exciting novel target 
for cancer chemotherapeutic drug design because inhibition of its 
chaperoning function simultaneously leads to the destabilization and 
degradation of multiple oncogenic proteins.   
Although one of the earliest Hsp90 inhibitors, 17-AAG, which 
targets the N-terminal ATP-binding pocket of Hsp90, has entered clinical 
trials for refractory malignancies, it has shown little clinical effect as 
monotherapy (Goetz et al., 2005; Nowakowski et al., 2006).  Further, even 
though 17-AAG is less toxic than its parent compound geldanamycin, its 
widespread use is still hindered by concerns regarding its hepatotoxicity 
(Egorin et al., 1998; Solit et al., 2007).  A new approach to targeting 
Hsp90 began with the observation that the antibiotic novobiocin binds with 
low affinity to a C-terminal ATP-binding pocket (Marcu et al., 2000a; 
Marcu et al., 2000b).  More potent analogues of novobiocin have been 
developed, and we report here that one such lead candidate inhibitor, 
designated KU135, binds directly to Hsp90 and suppresses cell 
proliferation by engaging signaling pathways that are mechanistically 
different from those affected by 17-AAG. 
 Indeed, KU135 was found to exert more potent antiproliferative 
effects than 17-AAG.  Whereas 17-AAG predominantly induces cell cycle 
arrest, KU135 causes both cell cycle arrest and an induction of apoptosis.  
This is significant since an Hsp90 inhibitor exhibiting combined cytostatic 
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and cytotoxic effects would be expected to eradicate tumor cells and 
thereby lower tumor cell burden, while a purely cytostatic inhibitor would 
only inhibit tumor cell growth/division.  A possible explanation for why 17-
AAG is not able to induce a similar apoptotic response as KU135 is that 
differences may exist in the number and types of client proteins that are 
affected by an N-terminal (17-AAG) versus a C-terminal (KU135) Hsp90 
inhibitor.  Another possibility is that the relative absence of cytotoxic 
activity with 17-AAG is due to the robust upregulation of Hsp90α, Hsp90β, 
and Hsp70 that is observed compared to KU135.     
 Overall, the data presented here provide compelling evidence for 
the continued development of novobiocin-based C-terminal Hsp90 
inhibitors as promising alternatives to N-terminal inhibitors, such as 17-
AAG, for the treatment of human malignancies.  KU135 is one such lead 
candidate novobiocin-derived compound.  Experiments are currently 
ongoing in the laboratory to characterize the specific molecular ordering of 
the caspase activation cascade induced by KU135, as well as the 
molecular requirements necessary for MOMP to occur in response to this 
compound.      
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Chapter 6: Caspase-9 activation is Essential for Heat-




Exposure of cells to heat is known to induce apoptosis, although 
the underlying mechanisms remain poorly understood.  In the present 
study, we examined the molecular requirements necessary for heat-
induced apoptosis using a panel of genetically modified Jurkat T-
lymphocytes.  Wild-type Jurkat cells cultured at 44°C for 1 h underwent 
apoptosis as determined by caspase activation and phosphatidylserine 
externalization.  By comparison, cells stably overexpressing Bcl-2/Bcl-XL 
or stably depleted of Apaf-1 were completely resistant to heat-induced 
apoptosis, implicating the involvement of the mitochondria-mediated 
pathway in this form of cell death.  Pretreatment of wild-type cells with a 
biotinylated general caspase inhibitor (b-VAD-fmk) both inhibited heat-
induced apoptosis and trapped activated initiator caspase-2, 8,and 9.  In 
spite of this finding, however, cells deficient in either caspase-8 or the 
caspase-2 adaptor RAIDD were highly susceptible to heat-induced 
apoptosis.  Furthermore, b-VAD-fmk pretreatment failed to label any 
activated caspase in Apaf-1-deficient cells exposed to heat.  Additionally, 
cells stably lacking Apaf-1 or the BH3-only protein Bid displayed less heat-
induced Bak activation, cytochrome c release, and loss of ΔΨ, even 
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though cleavage of Bid to tBid occurred downstream of caspase-9 
activation.  Combined, these data suggest that caspase-9 is the critical 
apical caspase activated during heat-induced apoptosis and that tBid may 
function to promote cytochrome c release during this process as part of a 




 Exposure to elevated temperatures is known to induce an 
evolutionarily conserved adaptive response known as the heat shock 
response.  A key feature of this response includes transcriptional 
upregulation of several heat shock proteins (Hsp), which is thought to 
protect the organism from proteotoxic stress and lethality (Jolly and 
Morimoto, 2000).  In addition, induction of the heat shock response is 
known to offer protection against subsequent exposure to otherwise lethal 
cellular stressors, including chemotherapeutic agents (Parsell et al., 
1993).  Due to the harsh microenvironment of many tumors, induction of 
the heat shock response is often seen in tumorigenic cells where it is 
thought to play a key role in oncogenesis and therapeutic resistance (Jolly 
and Morimoto, 2000).  However, initial exposure to more severe or 
prolonged elevated temperatures, is known to bypass this protective heat 
shock response and induce an apoptotic cellular death (Milleron and 
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Bratton, 2007b).  The ability of hyperthermia to induce cell death has led 
to its successful use in the treatment of a variety of cancers (Wust et al., 
2002; Kouloulias et al., 2005), and interest has been gaining in developing 
ways to directly target tumorigenic cells with heat (Ito et al., 2006; 
Pissuwan et al., 2006). 
 There are two distinct apoptotic pathways, namely, the 
mitochondria-mediated (i.e. intrinsic) pathway and the receptor-mediated 
(i.e. extrinsic) pathway.  The extrinsic pathway is activated upon binding of 
death ligand to its cognate receptor (e.g. Fas binding to the Fas receptor), 
which causes the receptors to move within close proximity to one another 
and recruit an adaptor protein, such as FADD, followed by recruitment of 
an initiator procaspase, such as caspase-8 (Kischkel et al., 1995; 
Boatright and Salvesen, 2003).  This protein complex is termed the death-
inducing signaling-complex (DISC) and serves as the activating platform 
for initator caspases 8 and 10 during receptor-mediated apoptosis.  In so-
called type I cells, there is sufficient activation of caspase-8 at the DISC to 
directly cleave and activate effector caspase-3 resulting in execution of 
apoptosis.  However, in so-called type II cells, activated caspase-8 does 
not directly cleave and activate a sufficient amount of effector caspase-3 
to execute apoptosis.  In this cell type, activated caspase-8 cleaves the 
pro-apoptotic Bcl-2 family member, Bid, to truncated-Bid (tBid) which then 
engages the mitochondria-mediated pathway (Barnhart et al., 2003).   
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 Mitochondria-mediated apoptosis is activated following exposure to 
cytotoxic stressors, including DNA damage, growth factor withdrawal, and 
γ-radiation.  During intrinsic apoptosis, caspase activation is largely 
regulated by the Bcl-2 family of proteins.  The Bcl-2 family of proteins 
contains both pro- and anti-apoptotic members and largely function to 
either promote or inhibit mitochondrial outer membrane permeabilization 
(MOMP).  MOMP allows the release of cytochrome c from the 
intermembrane space of mitochondria into the cytosol where it is required 
for caspase activation (Jiang and Wang, 2004).  Cytosolic cytochrome c 
interacts with the adaptor protein, apoptotic protease activating factor-1 
(Apaf-1), which then recruits initiator caspase-9 to this protein complex, 
termed the apoptosome (Jiang and Wang, 2004).  This protein complex 
serves as the activating platform for initiator caspase-9.  Activated initiator 
caspase-9 cleaves and activates downstream effector casapses which 
then cleave various target substrates resulting in the biochemical and 
morphological characteristics associated with apoptotic cell death.   
 Although adaptive cellular responses to heat have been studied for 
decades, heat-induced apoptosis has been studied to a much lesser 
extent and conflicting results have emerged from these studies (Milleron 
and Bratton, 2006; Tu et al., 2006; Milleron and Bratton, 2007b).  In this 
regard, the aim of the current study was to help determine the molecular 
requirements necessary for heat-induced apoptosis.  Because several of 
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the more recent studies have used Jurkat T-lymphocytes as a model 
system to investigate apoptosis induced by elevated temperatures, we 
also used a large panel of genetically modified Jurkat cells in which key 
steps in the intrinsic or extrinsic pathway were inhibited.  In agreement 
with previous studies, our results indicated that heat-induced apoptosis 
relies heavily on the mitochondria-mediated apoptotic pathway.  
Significantly, although caspases 2, 8, and 9 were affinity labeled as apical 
proteases, subsequent experiments revealed that only activated caspase-
9 was strictly required for heat-induced apoptosis.  Bid was observed to 
play a role in this form of apoptosis, although its cleavage to tBid occurred 
downstream of Apaf-1.   
 
6.3 Results and Discussion 
 
6.3.1 Heat induces Jurkat cells to undergo apoptosis in a Bcl-2- and Bcl-
XL-inhibitable manner 
 
 Previous studies have suggested several different mechanisms for 
the initiation of heat-induced apoptosis that, in many cases, are difficult to 
reconcile.  For instance, it has been suggested that caspase-2 is the most 
apical caspase activated during heat-induced apoptosis (Tu et al., 2006; 
Bouchier-Hayes et al., 2009), and that caspase-2 functions by cleaving 
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Bid to tBid (Bonzon et al., 2006), which then induces MOMP.  However, a 
different study suggested that the apical caspase activated in response to 
heat is a z-VAD-inhibitable protease that functions, at least in part, by 
directly cleaving and activating caspase-3, implying that caspase-9 may 
not always be necessary (Milleron and Bratton, 2006; Milleron and 
Bratton, 2007b).  In addition, a very recent study found that Mcl-1 
degradation is important in response to heat where its ubiquitination 
disrupts the binding between Mcl-1 and Noxa which, in turn, facilitates Bax 
activation (Stankiewicz et al., 2009); however, this is in contrast to a 
different study indicating that Bax and/or Bak can be activated directly by 
heat (Pagliari et al., 2005).   
 Because of the conflicting and, in some cases, contradictory nature 
of the reported data, we set out to better characterize and resolve some of 
the confusion relating to the mechanistic details of heat-induced 
apoptosis.  As illustrated in Fig. 21A, exposure of wild-type Jurkat cells to1 
h of heat at 44°C, followed by a 6 h recovery time period at 37°C caused 
32% of the cells to undergo apoptosis as determined by annexin V-FITC 
and propidium iodide co-staining followed by flow cytometric analysis.  
Heat-induced apoptosis was accompanied by proteolytic cleavage of 
caspases 9, 3, and 2, as well as an increase in caspase-3-like (DEVDase) 
activity (Fig. 21, B and C).  In addition, incubation of the pan-caspase 
inhibitor, qVD-OPH (20 uM), for 1 h prior to heat exposure completely 
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prevented cell death (data not shown).  Next, the requirement of MOMP in 
response to heat-induced apoptosis was evaluated in clones of Jurkat 
cells described previously (Shawgo et al., 2008b) that do not undergo 
MOMP due to the overexpression of Bcl-2 or Bcl-XL..  As illustrated in Fig. 
21D, Jurkat cells overexpressing either Bcl-2 or Bcl-XL were completely 
resistant to heat-induced apoptosis.  Taken together, these data suggest 
that heat-induced cell death is a caspase-mediated apoptotic event that 
requires MOMP. 
 
6.3.2 Caspase-2, -8, and -9 are activated apically during heat-induced 
apoptosis 
 
 Execution of apoptosis requires the activation of the caspase 
cascade, where active initiator caspases cleave and thereby activate 
downstream effector caspases that, in turn, dismantle the cell.  Whereas 
proteolytic cleavage of an effector caspase is indicative of its activation, 
the same is not necessarily true with initiator caspases.  There are 
currently two prevailing models that describe initiator caspase activation.  
The induced proximity model suggests that the adaptor molecules 
required for initiator caspase activation function to bring caspases into 
close proximity leading to caspase homo-dimerization and subsequent 
activation (Boatright and Salvesen, 2003).  By comparison, the induced 
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Figure 21.  Heat induces Jurkat cells to undergo apoptosis in a Bcl-2- 
and Bcl-XL-inhibitable manner.  A, wild-type cells (10
6/mL) were heat 
shocked for 1 h at 44°C followed by a 6 h recovery period at 37°C, cells 
were then harvested, and processed for cell death determination by flow 
cytometric analysis of annexin V-FITC and PI staining.  Quadrants are 
defined as: live (lower left); early apoptotic (lower right); late apoptotic 
(upper right); and necrotic (upper left).  Numbers refer to the percentage of 
cells in each quadrant.  B-C, duplicate aliquots of cells were harvested 
and lysed for (B,) Western blotting of caspases (C), or caspase 
(DEVDase) activity measurements. D, control-transfected or  Bcl-xL- and 
Bcl-2-overexpressing, Jurkat cells (106/mL) were heat shocked for 1 h at 
44°C followed by a 6 h recovery period at 37°C, harvested, and processed 
for cell death determination by flow cytometric analysis of annexin V-FITC 
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conformation model suggests that initiator caspases undergo a 
conformational change upon binding to an adaptor protein resulting in 
activation (Bao and Shi, 2007).  Neither model suggests that cleavage is 
an activating event, although it was recently shown that dimerization and 
cleavage are necessary for caspase-8 activation (Oberst et al.).  
Because proteolytic cleavage of initiator caspases does not 
necessarily reflect their activation, and because so-called specific peptide 
substrates are not specific (McStay et al., 2008), it has been technically 
challenging to unambiguously identify the most apical caspase activated in 
response to a given insult.  A recent study, however, used an innovative 
approach to affinity label or “trap” initiator caspases as they become 
activated inside cells (Tu et al., 2006).  The method relies on a biotinylated 
form of the general caspase inhibitor z-VAD-fmk and immobilized 
streptavidin (Boatright et al., 2003).   
Using this approach to identify the most apical initiator caspase(s) 
activated in response to heat, we pretreated wild-type Jurkat cells with b-
VAD-fmk (120 µM) for 3 h at 37°C prior to a 1 h exposure to 44°C and a 6 
h recovery at 37°C.  As illustrated in Fig. 22A, b-VAD-fmk completely 
inhibited heat-induced apoptosis as determined by annexin V-FITC and 
propidium iodide co-staining.  Next, having demonstrated that b-VAD-fmk 
inhibited cell death, we lysed the cells and incubated them in the presence 
of immobilized streptavidin to pull down any activated caspases.  As  
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Figure 22.  Caspase-2, -8, and -9 are activated apically during heat-
induced apoptosis.  A, wild-type cells (106/mL) were preincubated in the 
presence or abasece of 120 µM b-VAD-fmk for 3 h then heat shocked for 
1 h at 44°C followed by a 6 h recovery period at 37°C.  Cells were then 
harvested, and processed for cell death determination by flow cytometric 
analysis of annexin V-FITC and PI staining.  Quadrants are defined as: 
live (lower left); early apoptotic (lower right); late apoptotic (upper right); 
and necrotic (upper left).  Numbers refer to the percentage of cells in each 
quadrant.  B, duplicate aliquots of cells were harvested, lysed, and 
incubated with strepavidin beads followed by washing and boiling of beads 
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illustrated in Fig. 22B, initiator caspases 2, 8, and 9 were affinity labeled, 
although the intensity of the bands detected were different with caspase-9 
showing the greatest intensity.  Taken together, these data indicate that b-
VAD-fmk both effectively inhibits apoptosis and labels initiator caspases 2, 
8, and 9 as the apical caspases activated in response to heat. 
 
6.3.3 RAIDD is dispensable during heat-induced apoptosis 
 
 Because we had observed, in agreement with a recent study (Tu et 
al., 2006), that caspase-2 was activated apically in response to heat, we 
next sought to determine the significance of its activation.  To do so, we 
used the pSUPER vector-based system that directs the synthesis of 
siRNAs and a recently validated target (Shi et al., 2009) to silence 
caspase-2.  Two single-cell caspase-2-deficient Jurkat clones (#8 and 
#14) were used for these studies, and the extent to which caspase-2 was 
suppressed was confirmed by Western blot (Fig. 23A).  To test the extent 
to which caspase-2 activation was important for heat-induced apoptosis, 
we incubated the individual clones for 1 h at 44°C and evaluated them for 
differences in annexin V-FITC fluorescence after a 6-h recovery at 37°C.   
Unexpectedly, despite a very similar level of caspase-2 knockdown 
between the two clones (#8 and #14), the percentage of cells undergoing 
heat-induced apoptosis was markedly dissimilar at 37% and 12%,  
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Figure 23.  RAIDD is dispensable during heat-induced apoptosis.  A, 
vector control or two single-cell Caspase-2-deficient Jurkat clones (#8 and 
#14) were harvested and lysed for Western blotting.  Actin was used as a 
loading control.  B, cells (106/mL) were cultured in the presence or 
absence of 1 h at 44°C followed by a 6 h recovery period,then harvested, 
and processed for cell death determination by flow cytometric analysis of 
annexin V-FITC and propidium iodide staining.  Quadrants are defined as 
live (lower left), early apoptotic (lower right), late apoptotic (upper right), 
and necrotic (upper left).  Numbers refer to the percentage of cells in each 
quadrant.  C,. vector control or two single-cell RAIDD-deficient Jurkat 
clones (2C3 and 1C7) were harvested and lysed for Western blotting.  
Actin was used as a loading control.  B, cells (106/mL) were cultured in the 
presence or absence of 1 h at 44°C followed by a 6 h recovery period, 
then harvested, and processed for cell death determination by flow 
cytometric analysis of annexin V-FITC and propidium iodide staining.  
Quadrants are defined as in B.  
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respectively (Fig. 23B).  The inconsistency in our findings with these cells 
is similar to a previous report in which the authors had used a different 
siRNA target to silence caspase-2 (Lassus et al., 2002).     
 Because our attempt to directly evaluate the requirement of 
caspase-2 in response to heat was inconclusive, we next used shRNA to 
generate RAIDD (RIP associated Ich-1/CED homologous protein with 
death domain)-deficient Jurkat cells.  We hypothesized that because 
RAIDD is the adaptor protein responsible for activation of caspase-2 
(Duan and Dixit, 1997; Tinel and Tschopp, 2004; Park et al., 2007), such 
cells would offer important insight into the requirement of caspase-2 in 
response to heat.  Additionally, a previous study reported that RAIDD is 
important for caspase-2 activation during heat-induced cell death (Tu et 
al., 2006).  To that end, two single-cell RAIDD-deficient Jurkat clones (2C3 
and 1C7) were generated and the extent to which RAIDD was suppressed 
was confirmed by Western blot analysis (Fig. 23C).  As illustrated in Fig. 
22D, both RAIDD-deficient cell lines were as sensitive to heat-induced 
apoptosis as control-transfected cells.  Combined, although b-VAD-fmk 
labeled active caspase-2 as an apical caspase following heat shock, our 
findings do not support an essential role for RAIDD-mediated activation of 
caspase-2 during heat-induced apoptosis.   
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6.3.4 Apaf-1 is required for heat-induced apoptosis, whereas caspase-8 is 
dispensable 
 
 In addition to caspase-2, caspase-8 and -9 were pulled down as 
apical caspases using the b-VAD-fmk approach (Fig. 22B).  Furthermore, 
it has been reported that caspase-8 plays a role in heat-induced apoptosis 
due to an increased expression of Fas ligand, which acts in a paracrine 
manner (Cippitelli et al., 2005; Tu et al., 2006).  To determine the 
significance of caspase-8 activation in our hands, caspase-8-deficient 
Jurkat cells that have been described previously and are completely 
resistant to Fas-induced apoptosis (Shelton et al., 2009) were evaluated 
for their sensitivity to heat-induced apoptosis.  As illustrated in Fig. 24A 
and B, the results indicated that caspase-8-deficient cells underwent heat-
induced apoptosis and processed caspases-9, -3, and -2 to the same 
extent as A3 control cells (Fig. 24A and B) suggesting caspase-8 is 
dispensable in this setting.  
 Having shown that neither caspase-2 nor caspase-8 was necessary 
for heat-induced apoptosis, we were interested to determine the extent to 
which caspase-9 was involved.  To do so, we used Apaf-1-deficient Jurkat 
cells that were shown previously to not activate caspase-9 (Shawgo et al., 
2009) and to be completely resistant to mitochondria-mediated apoptosis 
induced by etoposide (Franklin and Robertson, 2007).   This is significant  
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Figure 24.  Apaf-1 is required for heat-induced apoptosis, whereas 
caspase-8 is dispensable.  A, Caspse-8-deficient cells (106/mL) were 
heat-shocked for 1 h at 44°C followed by a 6 h recovery period at 37°C, 
cells were then harvested, and processed for cell death determination by 
flow cytometric analysis of annexin V-FITC and PI staining.  Quadrants 
are defined as: live (lower left); early apoptotic (lower right); late apoptotic 
(upper right); and necrotic (upper left).  Numbers refer to the percentage of 
cells in each quadrant.  B, duplicate aliquots of cells were harvested and 
lysed for Western blotting of caspases. C, Apaf-1-deficient cells (106/mL) 
were heat-shocked for 1 h at 44°C followed by a 6 h recovery period at 
37°C, cells were then harvested, and processed for cell death 
determination by flow cytometric analysis of annexin V-FITC and PI 
staining.  Quadrants are defined as: live (lower left); early apoptotic (lower 
right); late apoptotic (upper right); and necrotic (upper left).  Numbers refer 
to the percentage of cells in each quadrant.  D, duplicate aliquots of cells 
were harvested and lysed for Western blotting of caspases. 
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because Apaf-1 is strictly required for caspase-9 activation within the 
apoptosome complex (Malladi et al., 2009).  In stark contrast to caspase-
8-deficient cells, Apaf-1-deficient Jurkat cells were completely resistant to 
heat-induced apoptosis (Fig. 24C).  In agreement with these findings, 
Western blot analysis of cell lysates showed that proteolytic processing of 
caspase-2, -3, and-9 was inhibited in Apaf-1-deficient cells following heat 
exposure.  Taken together, these data suggest that caspase-8 is 
dispensable during heat-induced apoptosis, whereas caspase-9 is 
required for this form of cell death. 
 
6.3.5 b-VAD-fmk does not associate with any initiator caspase in Apaf-1-
deficient cells exposed to heat 
 
 Because up to this point caspase-9 appeared to be the only initiator 
caspase that was essential for heat-induced apoptosis, we sought to 
extend these findings by testing whether caspase-2 or -8 could be pulled 
down by b-VAD-fmk in the Apaf-1-deficient cells following heat exposure.  
As illustrated in Fig. 25A, b-VAD-fmk failed to label caspase-2, caspase-8, 
or caspase-9 in the Apaf-1 knockdown cells providing additional evidence 
that caspase-9 is the most apical caspase during heat-induced apoptosis.   
 As mentioned previously, stimulation of the Fas receptor with Fas 
ligand or agonistic anti-Fas antibody results in DISC formation and  
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Figure 25.  b-VAD-fmk does not associate with any initiator caspase 
in Apaf-1-deficient cells exposed to heat.  A, Apaf-1-deficient cells 
(106/mL) were preincubated in the presence or abasece of 120 µM b-VAD-
fmk for 3 h, then heat shocked for 1 h at 44°C followed by a 6 h recovery 
period at 37°C.  Cells were then harvested, lysed, and incubated with 
strepavidin beads followed by washing and boiling of beads with sample 
buffer followed by Western blot analysis.  B, Apaf-1-deficient cells 
(106/mL) were preincubated in the presence or abasece of 120 µM b-VAD-
fmk for 3 h, then incubated for 6 h with anti-Fas antibody (100ng/mL).  
Cells were then harvested, lysed, and incubated with strepavidin beads 
followed by washing and boiling of beads with sample buffer followed by 
Western blot analysis. 
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activation of caspase-8 (Boatright and Salvesen, 2003).  To ensure that 
the b-VAD-fmk labeling method was effectively working in the Apaf-1-
deficient cells, we pretreated the cells with b-VAD-fmk for 3 h and then 
incubated in the presence of anti-Fas agonistic antibody (100 ng/mL) for 6 
h.  Consistent with our previous results, Apaf-1-deficient Jurkat cells were 
partially sensitive to apoptosis induced by anti-Fas (Shawgo et al., 2009).  
Further, as expected, caspase-8 was the only initiator caspase that was 
labeled by b-VAD-fmk (Fig. 25B).  Overall, these data strongly suggest 
that caspase-9 is the only required apically-activated caspase during heat-
induced apoptosis. 
 
6.3.6 Heat-induced mitochondrial events are attenuated in both Bid-
deficient and Apaf-1-deficient Jurkat cells 
 
 Several studies have concluded that MOMP is tightly regulated by 
pro- and anti-apoptotic members of the Bcl-2 family of proteins (Youle and 
Strasser, 2008).  It is widely accepted that Bax and/or Bak are required to 
facilitate MOMP (Lindsten et al., 2000), where their activation results in 
homo-oligomerization and pore formation spanning the outer 
mitochondrial membrane.  It is through this pore that cytochrome c and 
other pro-apoptotic proteins are released from the intermembrane space 
of the mitochondria into the cytosol.  Although it is widely accepted that 
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the activation of Bak and Bax depends on the prior activation of a BH3-
only Bcl-2 family member, the precise mechanism of Bax and Bak 
activation during mitochondria-mediated apoptosis remains poorly 
understood (Chipuk and Green, 2008). 
 Because it has been reported that caspase-2-mediated Bid 
cleavage to tBid is required for MOMP during heat-induced apoptosis, Bid-
deficient Jurkat cells, which were described previously and shown to be 
completely resistant to apoptosis receptor-mediated apoptosis (Shelton et 
al., 2009), were evaluated for their ability to undergo heat-induced 
apoptosis.  As illustrated in Fig. 26A, flow cytometric analysis of Bid-
deficient cells showed that these cells were partially resistant to heat-
induced apoptosis with 25% of the population undergoing apoptosis as 
compared to 47% in the control-transfected cells suggesting a role for Bid 
in this process. 
 Given that Bid-deficient Jurkat cells were partially resistant and 
Apaf-1-deficient Jurkat cells were completely resistant to heat-induced 
apoptosis, mitochondrial events that characteristically define MOMP such 
as Bak and/or Bax activation, release of intermembrane space proteins, 
and loss of ΔΨ were evaluated.  Previously, we have reported that Jurkat 
(E6.1) cells express Bak, but do not express Bax (Shawgo et al., 2008b; 
Shelton et al., 2009).  Therefore, Bak activation was evaluated using an 
active conformation-specific monoclonal Bak antibody and flow cytometric  
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Figure 26.  Heat-induced mitochondrial events are attenuated in both 
Bid-deficient and Apaf-1-deficient Jurkat cells. A, vector control or Bid-
deficient Jurkat cells (106/mL) were heat-shocked for 1 h at 44°C followed 
by a 6 h recovery time period, then harvested, and processed for cell 
death determination by flow cytometric analysis of annexin V-FITC and 
propidium iodide staining.  Quadrants are defined as live (lower left), early 
apoptotic (lower right), late apoptotic (upper right), and necrotic (upper 
left).  Numbers refer to the percentage of cells in each quadrant.  B, cells 
(106/mL) were heat-shocked for 1 h at 44°C followed by  6 h of recovery, 
and processed for determination of Bak activation by flow cytometric 
analysis.  Numbers in B refer to the percentage increase in Bak-
associated fluorescence between untreated and heat-shocked samples.  
C, duplicate aliquots of cells in B were harvested and processed for 
subcellular fractionation.  Supernatant (s) and pellet (p) fractions were 
analyzed by Western blotting.  D, duplicate aliquots of cells in B  were 
harvested and processed for mitochondrial membrane potential (ΔΨ) 
determination by flow cytometry.  Reduced DiIC1(5) fluorescence is 
indicative of a loss of ΔΨ, and numbers refer to the percentage of cells 
that underwent a dissipation of ΔΨ.  
















































































































 149  
analysis where activation causes a shift to the right of the resulting 
histogram.  As illustrated in Fig. 26B, Bak activation was markedly 
decreased in both the Apaf-1-deficient and Bid-deficient cell lines.   
 Next, consistent with the inhibition of Bak activation in cells lacking 
either Bid or Apaf-1, the release of cytochrome c in response to heat-
shock was also markedly decreased (Fig. 26C).  Finally, as illustrated in 
Fig. 26D, the loss of ΔΨ was also decreased in the Apaf-1-deficient and 
Bid-deficient cell lines.  Combined, these data suggest that Bid functions 
to promote Bak-mediated MOMP and that MOMP largely depends on 
events downstream of Apaf-1 during heat-induced apoptosis. 
 
6.3.7 Cleavage of Bid is a caspase-mediated event that occurs 
downstream of Apaf-1 
 
 Previously, we reported that effector caspases cleaved Bid to tBid 
during etoposide-induced apoptosis, and tBid functioned as part of a feed 
forward amplification loop to induce Bak oligomerization and cytochrome c 
release (Shelton et al., 2009).  In light of those observations, we next set 
out to determine if cleavage of Bid was a caspase-mediated event in 
response to heat.  To do so, wild-type Jurkat cells were incubated with 
qVD-OPH (20 uM) for 1 h prior to heat exposure at 44°C for 1 h followed 
by a 6-h recovery at 37°C.  As illustrated in Fig. 27A, the inclusion of qVD- 
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Figure 27.  Cleavage of Bid is a caspase-mediated event that occurs 
downstream of Apaf-1.  A, wild-type cells (106/mL) were pre-incubated in 
the presence or absence of 20 μM qVD-OPh for 1 h and subsequently 
incubated at 44°C for 1 h followed by a 6 h recovery period at which time 
cells were harvested and processed for Western blot analysis.  B, control-
transfected, and Apaf-1-deficient Jurkat cells (106/mL) were heat-shocked 
for 1 h followed by a recovery of 6 h, harvested, and lysed for Western 
blotting.  
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OPH completely inhibited the heat-induced generation of tBid.  To extend 
these findings and to determine if Bid was cleaved upstream or 
downstream of apoptosome formation, we evaluated the extent of Bid 
cleavage in the Apaf-1-deficient cell line in response to heat.  As illustrated 
in Fig. 27B, cleavage of Bid to tBid did not occur in the Apaf-1-deficient 
cell line when exposed to 44°C for 1 h followed by a recovery at 37°C  for 
6 h.  These data suggest that the cleavage of Bid to tBid is a caspase-
mediated event that occurs downstream of apoptosome-dependent 
caspase activation during heat-induced apoptosis.  
 
6.4 Concluding remarks 
 
 Previous studies characterizing heat-induced apoptosis have 
suggested several different possible mechanisms generating conflicting 
results (Pagliari et al., 2005; Bonzon et al., 2006; Milleron and Bratton, 
2006; Tu et al., 2006).  Caspase-2 was identified as the apical caspase in 
response to heat through the innovative b-VAD-fmk affinity labeling 
approach (Tu et al., 2006).   Intriguingly, caspase-2 was labeled even in 
Bcl-2 and Bcl-xL-overexpressing cells leading the authors to conclude that 
it must be activated upstream of MOMP.  In addition, heat-induced 
apoptosis was markedly reduced but not eliminated in caspase-2-deficient 
splenocytes and MEFs.  Further, b-VAD-fmk failed to label caspase-2 in 
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RAIDD-deficient splenocytes and these cells were partially resistant to 
heat-shock leading to the conclusion that RAIDD was important for 
caspase-2 activation (Tu et al., 2006).  However, a different study that was 
published around the same time reported that caspase-2-deficient MEFs 
were sensitive to heat-induced apoptosis and suggested that an unknown 
protease able to activate caspase-3 was the apical caspase (Milleron and 
Bratton, 2006).  Although the authors also reported that Apaf-1 and 
caspase-9 were both dispensable for heat-induced apoptosis, the case 
was made that MOMP may still be necessary to antagonize IAPs via 
Smac release (Milleron and Bratton, 2006).   
 Although it is known that MOMP is required during intrinsic 
apoptosis and that prior activation of Bak or Bax is necessary to facilitate 
permeabilization of the outer mitochondrial membrane, the mechanistic 
details of Bak and Bax activation are only partially understood (Chipuk and 
Green, 2008).  During extrinsic apoptosis in type II cells, caspase-8-
mediated cleavage of the BH3-only protein Bid to its active form, tBid, is 
required for the activation of Bax and Bak (Li et al., 1998; Luo et al., 
1998).  A similar emergent role for any one of the BH3-only family 
members during true intrinsic apoptotic signaling has not been 
established.   Nevertheless, the prevailing view is that BH3-only proteins 
are responsible for Bax and Bak activation during mitochondria-mediate 
apoptosis.  A possible exception to the rule is during heat-induced 
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apoptosis where it was reported that Bax and Bak can be activated by 
heat in vitro (Pagliari et al., 2005).  However, because of the fact that Bcl-
XL could inhibit heat-induced Bax activation, the point was made that 
activation of Bax and Bak in intact cells may still require a BH3-only 
protein to antagonize the anti-apoptotic Bcl-2 family members (Pagliari et 
al., 2005) . 
 As mentioned previously, it has also been reported that caspase-2-
mediated Bid cleavage is required for MOMP during heat-induced 
apoptosis (Bonzon et al., 2006).  This study also reported that Bid-
deficient MEFs were largely resistant to heat-induced apoptosis.  Although 
there was a percentage of the population of cells that remained sensitive, 
this population was also sensitive in the presence of qVD-OPh, leading 
the authors to conclude that the population of sensitive cells died by a 
caspase-independent cell death (Bonzon et al., 2006).   
 A more recent study has suggested a model where the depletion of 
Mcl-1 is important for Bax activation in response to heat (Stankiewicz et 
al., 2009).  The authors suggest that the BH3-only protein, Noxa, plays an 
important role in regulating the expression levels of Mcl-1 where heat-
shock results in displacement of Noxa from Mcl-1 which then allows the 
ubiquitin ligase, Mule, to bind Mcl-1 leading to its proteosomal 
degradation.  In addition, they found that Hsp70 overexpression prevented 
Mcl-1 degradation and Bax activation (Stankiewicz et al., 2009). 
 155  
 Our findings using a large panel of gene-manipulated Jurkat cells 
suggest that caspase-9 is activated apically during heat-induced 
apoptosis.  The activation of caspase-9 is strictly dependent on formation 
of the apoptosome, which requires cytochrome c.  Significantly, however, 
there is very little cytochrome c released upstream of apoptosome 
formation.  In fact, our data showed that the majority of MOMP occurred 
downstream of initial caspase-9 activation and was mediated largely by 
tBid.  Although these data support a role for Bid during heat-induced 
apoptosis, most, if not all, cleavage of Bid occurred downstream of 
MOMP.  Combined, these data support an emerging model of 
mitochondria-mediated apoptosis where the activation of caspases 
downstream of caspase-9 is necessary to feed forward and amplify the 
initial apoptotic signal to ensure cell demise.  In such a scenario, the 
earliest release of cytochrome c into the cytosol would remain sublethal 
unless or until it accumulated to an extent that is sufficient to promote 
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Chapter 7: Conclusions and Future Directions 
 
7.1 General Discussion 
 
 
The implication that apoptosis plays an important role in human 
disease has driven the desire to better understand and characterize the 
apoptotic pathway in hopes that cell survival and cell death can be 
manipulated for therapeutic purposes.  It is now known that deregulated 
apoptosis is a contributing factor in several diseases characterized by 
either excessive or insufficient apoptosis (Thompson, 1995).   Parkinson’s 
disease is an example of a disease associated with excessive apoptosis, 
whereas the lack of apoptosis is considered to be a hallmark of cancer 
(Thompson, 1995; Hanahan and Weinberg, 2000).  In addition, the 
therapeutic end-point of most cytotoxic anti-cancer drugs is to induce 
apoptosis, more specifically, mitocondria-mediated apoptosis (Lowe and 
Lin, 2000). 
Initial observations of what we now know to be apoptotic cell death 
date back to the late 1800s (Lockshin and Zakeri, 2001), but the field 
progressed slowly until the mid-1980s after which time apoptosis-focused 
research expanded rapidly (Hacker and Vaux, 1997).  It was during the 
late 1980s through the 1990s that the key regulators and mediators of 
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apoptosis were identified and characterized in humans (Hacker and Vaux, 
1997) .  An apoptotic signaling model emerged from insights gained during 
this time period, and this model is considered to be the conventional 
paradigm today. 
The current perspective of mitochondria-mediated apoptosis 
assumes a linear apoptotic signaling cascade where an initial cytotoxic 
stress results in the permeabilization of the outer mitochondrial membrane 
followed by caspase activation and cell death (Goldstein et al., 2000; 
Goldstein et al., 2005).  However, there is some evidence that is at odds 
with a strictly linear view of the pathway (Hao et al., 2005; Lakhani et al., 
2006; Shawgo et al., 2008b; Shelton et al., 2009).  At issue is that the 
conventional linear paradigm has argued that cytochrome c release is a 
caspase-independent event, and that MOMP leading to cytochrome c 
release is an all-or-none event that marks the “point of no return” 
(Goldstein et al., 2000; Goldstein et al., 2005).  There have been some 
studies, however, that have shown there are differences in engagement 
and execution of the mitochondria-mediated apoptotic pathway in 
response to different stressors.  However, several of these studies have 
produced conflicting results and thus led to considerable confusion within 
the field.  One example is caspase-2-mediated apoptosis where several 
studies have reported novel functions for caspse-2 upstream of MOMP in 
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response to different stimuli (Bouchier-Hayes), although none of these 
studies has fostered an emergent understanding of caspase-2’s function. 
It seems reasonable to suspect that different cytotoxic agents 
induce apoptosis through similar as well as distinct mechanisms.  The 
results of the studies in my dissertation contribute to the understanding of 
apoptotic cell death pathways in response to three different cytotoxic 
therapeutic strategies including a topoisomerase II inhibitor, an Hsp90 
inhibitor, and elevated temperature.   
 
7.2 Overall Conclusions 
 
 
7.2.1 The role of Bid in DNA-damage induced apoptosis 
 
 
 The best characterized setting of Bid’s involvement in apoptotic cell 
death is during receptor-mediated apoptosis in so-called type II cells, 
where it functions to activate Bak and/or Bax leading to MOMP (Li et al., 
1998; Luo et al., 1998).  By comparison, there have also been reports in 
the literature that have produced conflicting results regarding the role of 
Bid during DNA-damage induced apoptosis (Werner et al., 2004; Zinkel et 
al., 2005; Kaufmann et al., 2007).  My data support a role for Bid in 
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mediating MOMP downstream of effector caspase activation during 
apoptosis induced by etoposide (Shelton et al., 2009). 
 As mentioned, the prevailing view of mitochondria-mediated 
apoptosis is a linear view beginning with the induction of MOMP.  The 
data generated under Specific Aim 1 support more complex signaling 
events leading to the irreversible commitment of a cell to die.  In response 
to the DNA-damaging drug, etoposide, my data suggest that MOMP and 
caspases forge an amplification loop to execute cell death in Jurkat T-
lymphocytes.  In this scenario, the initial amount of cytochrome c released 
may not always be sufficient to irreversibly activate caspases and execute 
cell death.  In other words, cytochrome c release does not occur in an all-
or-none fashion and is not the “point of no return.” 
 Instead, the initial amount of released cytochrome c remains 
sublethal until some poorly defined threshold is exceeded that caspase-9 
and subsequently caspase-3/7 are activated.  Active caspase-3/7, in turn, 
cleaves the BH3-only protein, Bid, to tBid, which functions to induce more 
MOMP to seal the cell’s fate.  The fact that tBid induces MOMP is in 
agreement with its known function; however, the fact that it appears to be 
important during DNA-damage induced apoptosis where its cleavage is 
mediated by caspases-3 and/or -7 was unexpected.  These data offer new 
insights into mechanism(s) responsible for DNA damage-induced 
apoptosis. 
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7.2.2 Targeting Hsp90 via its C-terminal domain 
 
 Hsp90 functions as a molecular chaperone where it is required for 
the conformational stability and function of numerous client proteins.  
Although Hsp90 is present constitutively, it is also induced in response to 
cellular stress.  Hsp90 expression is often elevated in human 
malignancies where it is thought to be a compensatory mechanism to the 
harsh microenvironment often found in tumors (Whitesell and Lindquist, 
2005).  There are currently over 200 known Hsp90 client proteins and 
many are known oncogenic proteins involved in all six hallmarks of cancer 
(Whitesell et al., 2003; Bagatell and Whitesell, 2004; Whitesell and 
Lindquist, 2005). 
 Hsp90 is currently being pursued as an anti-cancer drug target 
where its inhibition would presumably lead to the destabilization and 
degradation of numerous client proteins.  Whereas several Hsp90 client 
proteins are being pursued individually as drug targets, inhibition of Hsp90 
would attack cancer cells on multiple levels by simultaneously 
destabilizing several oncogenic client proteins.  N-terminal Hsp90 
inhibitors (e.g. 17-AAG) have been developed and entered clinical trials 
(Whitesell and Lindquist, 2005); however, their clinical use has been 
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limited due to adverse effects and the compensatory induction of 
cytoprotective Hsp90 and Hsp70 (Solit et al., 2003; Banerji et al., 2005b).  
 Data generated under Specific Aim 2 investigated a novel C-
terminal Hsp90 inhibitor, KU135, and compared the antiproliferative 
effects of this compound to the N-terminal inhibitor, 17-AAG.  KU135 was 
found to have more potent antiproliferative effects than 17-AAG.  In 
addition, 17-AAG was found to be primarily cytostatic, whereas KU135 
was both cytostatic and cytotoxic.  The cytotoxicity of KU135 was found to 
be due to induction of the mitochondria-mediated apoptotic pathway, 
where activation of caspase-9 was required for cell death but not MOMP.  
In other words, MOMP occurred upstream and independently of caspse-9 
activation.     
Although the first Hsp90 inhibitor entered clinical trials more than 10 
years ago, there are no drugs within this class approved for anti-cancer 
therapy (Solit and Chiosis, 2008).  My data show that KU135 and 17-AAG 
have different antiproliferative mechanisms, and that KU135 does not 
induce a robust cytoprotective response.  These data provide evidence 
and support for the continued development of C-terminal Hsp90 inhibitors 
where these compounds could be a viable alternative to the N-terminal 
Hsp90 inhibitors in the clinic. 
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7.2.3 Mechanisms of heat-induced apoptosis 
 
 Exposure of cells to stress is known to induce the heat shock 
response which includes the induction of heat shock proteins.  However, 
acute exposure to elevated temperatures can induce an apoptotic 
response (Milleron and Bratton, 2007b) .  Therapeutic approaches to 
directly target tumor cells with heat are currently underway (Huang et al., ; 
Ito et al., 2006; Pissuwan et al., 2006), but the mechanistic details 
surrounding heat-induced apoptosis remain poorly defined.  Currently, the 
existing literature on heat-induced apoptosis is somewhat controversial. 
 Of the few studies that have been performed investigating heat-
induced apoptosis, differences regarding the mechanistic details have 
been reported surrounding key points including the apically activated 
caspase and whether MOMP is necessary (Pagliari et al., 2005; Bonzon et 
al., 2006; Milleron and Bratton, 2006; Tu et al., 2006).  It has been 
reported that caspase-2 is the apically activated caspase and induces 
MOMP by cleaving Bid to tBid (Bonzon et al., 2006); however, it has also 
been reported that the apical caspase is an unidentified caspase that is 
capable of directly cleaving and activating caspase-3 (Milleron and 
Bratton, 2006).  Whereas one study suggested that tBid is needed to 
induce MOMP by activating Bak and/or Bax (Bonzon et al., 2006), another 
study has suggested that Bax and Bak are activated directly by heat 
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(Pagliari et al., 2005).  The data generated under Specific Aim 3 resolve 
some of these issues using Jurkat-T-lymphocytes, which were also used 
as a model system in most of the studies mentioned above. 
 The data generated in response to heat-induced apoptosis clearly 
show that this stressor activates the mitochondria-mediated pathway and 
that MOMP is required.  Caspase-9 was identified as the apical caspase, 
and Bid was found to play a role in heat-induced apoptosis by inducing 
MOMP.  As in specific aim 1, tBid was generated downstream of caspase-
9 activation leading to the conclusion that it facilitates an amplification of 
the initial apoptotic signal where the initial amount of cytochrome c that is 
released to activate caspase-9 is mediated by an unknown mechanism 
and may not commit the cell to death.  The data generated under this 
specific aim offer some resolution to the conflicting results in the literature 
and provide insight into the mechanistic details of heat-induced apoptosis.  
 
7.3 Concluding Remarks 
 
 Combined, the results presented in my dissertation support the idea 
that different cytotoxic stressors utilize similar as well as distinct 
mechanisms to induce mitochondria-mediated apoptosis.  The results of 
specific aims 1 and 3 support a scenario of an initial amount of MOMP that 
does not irreversibly commit a cell to die.  In this scenario, executioner 
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caspases and mitochondria are required to mediate amplification of the 
initial signal and irreversibly commit a cell to death.  On the other hand, 
the results of specific aim 2 support an initial signal that is sufficient to 
induce enough MOMP to irreversibly commit the cell to death by a 


















 165  
 
 
Chapter 8: Literature Cited 
 
Adams JM and Cory S (1998) The Bcl-2 protein family: arbiters of cell 
survival. Science 281:1322-1326. 
Avila C, Hadden MK, Ma Z, Kornilayev BA, Ye QZ and Blagg BS (2006a) 
High-throughput screening for Hsp90 ATPase inhibitors. Bioorg 
Med Chem Lett 16:3005-3008. 
Avila C, Kornilayev BA and Blagg BS (2006b) Development and 
optimization of a useful assay for determining Hsp90's inherent 
ATPase activity. Bioorg Med Chem 14:1134-1142. 
Bagatell R and Whitesell L (2004) Altered Hsp90 function in cancer: a 
unique therapeutic opportunity. Mol Cancer Ther 3:1021-1030. 
Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons 
L, Maloney A, Raynaud F, Campbell M, Walton M, Lakhani S, Kaye 
S, Workman P and Judson I (2005a) Phase I pharmacokinetic and 
pharmacodynamic study of 17-allylamino, 17-
demethoxygeldanamycin in patients with advanced malignancies. J 
Clin Oncol 23:4152-4161. 
Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, 
Judson I and Workman P (2005b) Pharmacokinetic-
pharmacodynamic relationships for the heat shock protein 90 
 166  
molecular chaperone inhibitor 17-allylamino, 17-
demethoxygeldanamycin in human ovarian cancer xenograft 
models. Clin Cancer Res 11:7023-7032. 
Bao Q and Shi Y (2007) Apoptosome: a platform for the activation of 
initiator caspases. Cell Death Differ 14:56-65. 
Barnhart BC, Alappat EC and Peter ME (2003) The CD95 type I/type II 
model. Semin Immunol 15:185-193. 
Blagg BS and Kerr TD (2006) Hsp90 inhibitors: small molecules that 
transform the Hsp90 protein folding machinery into a catalyst for 
protein degradation. Med Res Rev 26:310-338. 
Boatright KM, Renatus M, Scott FL, Sperandio S, Shin H, Pedersen IM, 
Ricci JE, Edris WA, Sutherlin DP, Green DR and Salvesen GS 
(2003) A unified model for apical caspase activation. Mol Cell 
11:529-541. 
Boatright KM and Salvesen GS (2003) Mechanisms of caspase activation. 
Curr Opin Cell Biol 15:725-731. 
Bonte FJ, Storaasli JP and Weisberger AS (1956) Comparative evaluation 
of radioactive colloidal gold and nitrogen mustard in the treatment 
of serous effusions of neoplastic origin. Radiology 67:63-66. 
Bonzon C, Bouchier-Hayes L, Pagliari LJ, Green DR and Newmeyer DD 
(2006) Caspase-2-induced apoptosis requires bid cleavage: a 
 167  
physiological role for bid in heat shock-induced death. Mol Biol Cell 
17:2150-2157. 
Bossy-Wetzel E and Green DR (1999) Caspases induce cytochrome c 
release from mitochondria by activating cytosolic factors. J Biol 
Chem 274:17484-17490. 
Bouchier-Hayes L The role of caspase-2 in stress-induced apoptosis. J 
Cell Mol Med. 
Bouchier-Hayes L, Oberst A, McStay GP, Connell S, Tait SW, Dillon CP, 
Flanagan JM, Beere HM and Green DR (2009) Characterization of 
cytoplasmic caspase-2 activation by induced proximity. Mol Cell 
35:830-840. 
Bouck N, Stellmach V and Hsu SC (1996) How tumors become 
angiogenic. Adv Cancer Res 69:135-174. 
Breckenridge DG and Xue D (2004) Regulation of mitochondrial 
membrane permeabilization by BCL-2 family proteins and 
caspases. Curr Opin Cell Biol 16:647-652. 
Brown JM and Wouters BG (1999) Apoptosis, p53, and tumor cell 
sensitivity to anticancer agents. Cancer Res 59:1391-1399. 
Bryan TM and Cech TR (1999) Telomerase and the maintenance of 
chromosome ends. Curr Opin Cell Biol 11:318-324. 
Burlison JA, Avila C, Vielhauer G, Lubbers DJ, Holzbeierlein J and Blagg 
BS (2008a) Development of novobiocin analogues that manifest 
 168  
anti-proliferative activity against several cancer cell lines. J Org 
Chem 73:2130-2137. 
Burlison JA, Avila C, Vielhauer G, Lubbers DJ, Holzbeierlein J and Blagg 
BS (2008b) Development of Novobiocin Analogues That Manifest 
Anti-proliferative Activity against Several Cancer Cell Lines. J Org 
Chem 73:2130-2137. 
Burlison JA, Neckers L, Smith AB, Maxwell A and Blagg BS (2006) 
Novobiocin: redesigning a DNA gyrase inhibitor for selective 
inhibition of hsp90. J Am Chem Soc 128:15529-15536. 
Chao Y, Shiozaki EN, Srinivasula SM, Rigotti DJ, Fairman R and Shi Y 
(2005) Engineering a dimeric caspase-9: a re-evaluation of the 
induced proximity model for caspase activation. PLoS Biol 3:e183. 
Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, 
Day CL, Adams JM and Huang DC (2005) Differential targeting of 
prosurvival Bcl-2 proteins by their BH3-only ligands allows 
complementary apoptotic function. Mol Cell 17:393-403. 
Chen M, He H, Zhan S, Krajewski S, Reed JC and Gottlieb RA (2001) Bid 
is cleaved by calpain to an active fragment in vitro and during 
myocardial ischemia/reperfusion. J Biol Chem 276:30724-30728. 
Cheng J and Haas M (1990) Frequent mutations in the p53 tumor 
suppressor gene in human leukemia T-cell lines. Mol Cell Biol 
10:5502-5509. 
 169  
Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L and Neckers L 
(2003) 17AAG: low target binding affinity and potent cell activity--
finding an explanation. Mol Cancer Ther 2:123-129. 
Chipuk JE, Bouchier-Hayes L and Green DR (2006) Mitochondrial outer 
membrane permeabilization during apoptosis: the innocent 
bystander scenario. Cell Death Differ 13:1396-1402. 
Chipuk JE and Green DR (2008) How do BCL-2 proteins induce 
mitochondrial outer membrane permeabilization? Trends Cell Biol 
18:157-164. 
Choi YE, Butterworth M, Malladi S, Duckett CS, Cohen GM and Bratton 
SB (2009) The E3 ubiquitin ligase cIAP1 binds and ubiquitinates 
caspase-3 and -7 via unique mechanisms at distinct steps in their 
processing. J Biol Chem 284:12772-12782. 
Christofori G and Semb H (1999) The role of the cell-adhesion molecule 
E-cadherin as a tumour-suppressor gene. Trends Biochem Sci 
24:73-76. 
Cippitelli M, Fionda C, Di Bona D, Piccoli M, Frati L and Santoni A (2005) 
Hyperthermia enhances CD95-ligand gene expression in T 
lymphocytes. J Immunol 174:223-232. 
Cleary ML, Smith SD and Sklar J (1986) Cloning and structural analysis of 
cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript 
resulting from the t(14;18) translocation. Cell 47:19-28. 
 170  
Clem RJ, Fechheimer M and Miller LK (1991) Prevention of apoptosis by a 
baculovirus gene during infection of insect cells. Science 254:1388-
1390. 
Cohen GM (1997) Caspases: the executioners of apoptosis. Biochem J 
326 ( Pt 1):1-16. 
Danial NN and Korsmeyer SJ (2004) Cell death: critical control points. Cell 
116:205-219. 
Denault JB, Eckelman BP, Shin H, Pop C and Salvesen GS (2007) 
Caspase 3 attenuates XIAP (X-linked inhibitor of apoptosis protein)-
mediated inhibition of caspase 9. Biochem J 405:11-19. 
Donnelly AC, Mays JR, Burlison JA, Nelson JT, Vielhauer G, Holzbeierlein 
J and Blagg BS (2008) The design, synthesis, and evaluation of 
coumarin ring derivatives of the novobiocin scaffold that exhibit 
antiproliferative activity. J Org Chem 73:8901-8920. 
Downward J (2006) Signal transduction. Prelude to an anniversary for the 
RAS oncogene. Science 314:433-434. 
Droga-Mazovec G, Bojic L, Petelin A, Ivanova S, Romih R, Repnik U, 
Salvesen GS, Stoka V, Turk V and Turk B (2008) Cysteine 
cathepsins trigger caspase-dependent cell death through cleavage 
of bid and antiapoptotic Bcl-2 homologues. J Biol Chem 283:19140-
19150. 
 171  
Du C, Fang M, Li Y, Li L and Wang X (2000) Smac, a mitochondrial 
protein that promotes cytochrome c-dependent caspase activation 
by eliminating IAP inhibition. Cell 102:33-42. 
Duan H and Dixit VM (1997) RAIDD is a new 'death' adaptor molecule. 
Nature 385:86-89. 
Eckelman BP, Salvesen GS and Scott FL (2006) Human inhibitor of 
apoptosis proteins: why XIAP is the black sheep of the family. 
EMBO Rep 7:988-994. 
Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM and Eiseman JL 
(1998) Metabolism of 17-(allylamino)-17-demethoxygeldanamycin 
(NSC 330507) by murine and human hepatic preparations. Cancer 
Res 58:2385-2396. 
Evan G and Littlewood T (1998) A matter of life and cell death. Science 
281:1317-1322. 
Felix CA, Kolaris CP and Osheroff N (2006) Topoisomerase II and the 
etiology of chromosomal translocations. DNA Repair (Amst) 
5:1093-1108. 
Folkman J (1997) Addressing tumor blood vessels. Nat Biotechnol 15:510. 
Franklin EE and Robertson JD (2007) Requirement of Apaf-1 for 
mitochondrial events and the cleavage or activation of all 
procaspases during genotoxic stress-induced apoptosis. Biochem J 
405:115-122. 
 172  
Friesen C, Herr I, Krammer PH and Debatin KM (1996) Involvement of the 
CD95 (APO-1/FAS) receptor/ligand system in drug-induced 
apoptosis in leukemia cells. Nat Med 2:574-577. 
Fuentes-Prior P and Salvesen GS (2004) The protein structures that 
shape caspase activity, specificity, activation and inhibition. 
Biochem J 384:201-232. 
Georgakis GV and Younes A (2005) Heat-shock protein 90 inhibitors in 
cancer therapy: 17AAG and beyond. Future Oncol 1:273-281. 
Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, 
Sloan J, Atherton P, Vasile V, Salazaar S, Adjei A, Croghan G and 
Erlichman C (2005) Phase I trial of 17-allylamino-17-
demethoxygeldanamycin in patients with advanced cancer. J Clin 
Oncol 23:1078-1087. 
Goldstein JC, Munoz-Pinedo C, Ricci JE, Adams SR, Kelekar A, Schuler 
M, Tsien RY and Green DR (2005) Cytochrome c is released in a 
single step during apoptosis. Cell Death Differ 12:453-462. 
Goldstein JC, Waterhouse NJ, Juin P, Evan GI and Green DR (2000) The 
coordinate release of cytochrome c during apoptosis is rapid, 
complete and kinetically invariant. Nat Cell Biol 2:156-162. 
Green DR (2000) Apoptotic pathways: paper wraps stone blunts scissors. 
Cell 102:1-4. 
 173  
Grenert JP, Sullivan WP, Fadden P, Haystead TA, Clark J, Mimnaugh E, 
Krutzsch H, Ochel HJ, Schulte TW, Sausville E, Neckers LM and 
Toft DO (1997) The amino-terminal domain of heat shock protein 
90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain 
that regulates hsp90 conformation. J Biol Chem 272:23843-23850. 
Guo Y, Srinivasula SM, Druilhe A, Fernandes-Alnemri T and Alnemri ES 
(2002) Caspase-2 induces apoptosis by releasing proapoptotic 
proteins from mitochondria. J Biol Chem 277:13430-13437. 
Hacker G and Vaux DL (1997) A chronology of cell death. Apoptosis 
2:247-256. 
Hahn JS (2009) The Hsp90 chaperone machinery: from structure to drug 
development. BMB Rep 42:623-630. 
Hanahan D and Folkman J (1996) Patterns and emerging mechanisms of 
the angiogenic switch during tumorigenesis. Cell 86:353-364. 
Hanahan D and Weinberg RA (2000) The hallmarks of cancer. Cell 
100:57-70. 
Hande KR (1998) Etoposide: four decades of development of a 
topoisomerase II inhibitor. Eur J Cancer 34:1514-1521. 
Hao Z, Duncan GS, Chang CC, Elia A, Fang M, Wakeham A, Okada H, 
Calzascia T, Jang Y, You-Ten A, Yeh WC, Ohashi P, Wang X and 
Mak TW (2005) Specific ablation of the apoptotic functions of 
 174  
cytochrome C reveals a differential requirement for cytochrome C 
and Apaf-1 in apoptosis. Cell 121:579-591. 
Harris CC (1996a) p53 tumor suppressor gene: from the basic research 
laboratory to the clinic--an abridged historical perspective. 
Carcinogenesis 17:1187-1198. 
Harris CC (1996b) Structure and function of the p53 tumor suppressor 
gene: clues for rational cancer therapeutic strategies. J Natl Cancer 
Inst 88:1442-1455. 
Hartson SD, Thulasiraman V, Huang W, Whitesell L and Matts RL (1999) 
Molybdate inhibits hsp90, induces structural changes in its C-
terminal domain, and alters its interactions with substrates. 
Biochemistry 38:3837-3849. 
Hayflick L (1997) Mortality and immortality at the cellular level. A review. 
Biochemistry (Mosc) 62:1180-1190. 
Huang HC, Rege K and Heys JJ Spatiotemporal Temperature Distribution 
and Cancer Cell Death in Response to Extracellular Hyperthermia 
Induced by Gold Nanorods. ACS Nano. 
Isaacs JS, Xu W and Neckers L (2003) Heat shock protein 90 as a 
molecular target for cancer therapeutics. Cancer Cell 3:213-217. 
Ito A, Honda H and Kobayashi T (2006) Cancer immunotherapy based on 
intracellular hyperthermia using magnetite nanoparticles: a novel 
 175  
concept of "heat-controlled necrosis" with heat shock protein 
expression. Cancer Immunol Immunother 55:320-328. 
Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J, MacLean 
KH, Han J, Chittenden T, Ihle JN, McKinnon PJ, Cleveland JL and 
Zambetti GP (2003) Puma is an essential mediator of p53-
dependent and -independent apoptotic pathways. Cancer Cell 
4:321-328. 
Jiang X and Wang X (2004) Cytochrome C-mediated apoptosis. Annu Rev 
Biochem 73:87-106. 
Johnstone RW, Ruefli AA and Lowe SW (2002) Apoptosis: a link between 
cancer genetics and chemotherapy. Cell 108:153-164. 
Jolly C and Morimoto RI (2000) Role of the heat shock response and 
molecular chaperones in oncogenesis and cell death. J Natl Cancer 
Inst 92:1564-1572. 
Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC and 
Burrows FJ (2003) A high-affinity conformation of Hsp90 confers 
tumour selectivity on Hsp90 inhibitors. Nature 425:407-410. 
Kamer I, Sarig R, Zaltsman Y, Niv H, Oberkovitz G, Regev L, Haimovich 
G, Lerenthal Y, Marcellus RC and Gross A (2005) Proapoptotic BID 
is an ATM effector in the DNA-damage response. Cell 122:593-
603. 
 176  
Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A and Green 
DR (1998) DNA damaging agents induce expression of Fas ligand 
and subsequent apoptosis in T lymphocytes via the activation of 
NF-kappa B and AP-1. Mol Cell 1:543-551. 
Kaufmann T, Tai L, Ekert PG, Huang DC, Norris F, Lindemann RK, 
Johnstone RW, Dixit VM and Strasser A (2007) The BH3-only 
protein bid is dispensable for DNA damage- and replicative stress-
induced apoptosis or cell-cycle arrest. Cell 129:423-433. 
Kerr JF, Wyllie AH and Currie AR (1972) Apoptosis: a basic biological 
phenomenon with wide-ranging implications in tissue kinetics. Br J 
Cancer 26:239-257. 
Kim H, Rafiuddin-Shah M, Tu HC, Jeffers JR, Zambetti GP, Hsieh JJ and 
Cheng EH (2006a) Hierarchical regulation of mitochondrion-
dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 8:1348-
1358. 
Kim H, Rafiuddin-Shah M, Tu HC, Jeffers JR, Zambetti GP, Hsieh JJ and 
Cheng EH (2006b) Hierarchical regulation of mitochondrion-
dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 8:1348-
1358. 
Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH 
and Peter ME (1995) Cytotoxicity-dependent APO-1 (Fas/CD95)-
 177  
associated proteins form a death-inducing signaling complex 
(DISC) with the receptor. Embo J 14:5579-5588. 
Knudson AG, Jr. (1971) Mutation and cancer: statistical study of 
retinoblastoma. Proc Natl Acad Sci U S A 68:820-823. 
Kouloulias V, Plataniotis G, Kouvaris J, Dardoufas C, Gennatas C, 
Uzunoglu N, Papavasiliou C and Vlahos L (2005) 
Chemoradiotherapy combined with intracavitary hyperthermia for 
anal cancer: feasibility and long-term results from a phase II 
randomized trial. Am J Clin Oncol 28:91-99. 
Kregel KC (2002) Heat shock proteins: modifying factors in physiological 
stress responses and acquired thermotolerance. J Appl Physiol 
92:2177-2186. 
Lakhani SA, Masud A, Kuida K, Porter GA, Jr., Booth CJ, Mehal WZ, 
Inayat I and Flavell RA (2006) Caspases 3 and 7: key mediators of 
mitochondrial events of apoptosis. Science 311:847-851. 
Lassus P, Opitz-Araya X and Lazebnik Y (2002) Requirement for 
caspase-2 in stress-induced apoptosis before mitochondrial 
permeabilization. Science 297:1352-1354. 
Letai AG (2008) Diagnosing and exploiting cancer's addiction to blocks in 
apoptosis. Nat Rev Cancer 8:121-132. 
 178  
Li H, Zhu H, Xu CJ and Yuan J (1998) Cleavage of BID by caspase 8 
mediates the mitochondrial damage in the Fas pathway of 
apoptosis. Cell 94:491-501. 
Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and 
Wang X (1997) Cytochrome c and dATP-dependent formation of 
Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. 
Cell 91:479-489. 
Lindsten T, Ross AJ, King A, Zong WX, Rathmell JC, Shiels HA, Ulrich E, 
Waymire KG, Mahar P, Frauwirth K, Chen Y, Wei M, Eng VM, 
Adelman DM, Simon MC, Ma A, Golden JA, Evan G, Korsmeyer 
SJ, MacGregor GR and Thompson CB (2000) The combined 
functions of proapoptotic Bcl-2 family members bak and bax are 
essential for normal development of multiple tissues. Mol Cell 
6:1389-1399. 
Lockshin RA and Zakeri Z (2001) Programmed cell death and apoptosis: 
origins of the theory. Nat Rev Mol Cell Biol 2:545-550. 
Lowe SW and Lin AW (2000) Apoptosis in cancer. Carcinogenesis 
21:485-495. 
Luo X, Budihardjo I, Zou H, Slaughter C and Wang X (1998) Bid, a Bcl2 
interacting protein, mediates cytochrome c release from 
mitochondria in response to activation of cell surface death 
receptors. Cell 94:481-490. 
 179  
Mandic A, Viktorsson K, Strandberg L, Heiden T, Hansson J, Linder S and 
Shoshan MC (2002) Calpain-mediated Bid cleavage and calpain-
independent Bak modulation: two separate pathways in cisplatin-
induced apoptosis. Mol Cell Biol 22:3003-3013. 
Marcu MG, Chadli A, Bouhouche I, Catelli M and Neckers LM (2000a) The 
heat shock protein 90 antagonist novobiocin interacts with a 
previously unrecognized ATP-binding domain in the carboxyl 
terminus of the chaperone. J Biol Chem 275:37181-37186. 
Marcu MG, Schulte TW and Neckers L (2000b) Novobiocin and related 
coumarins and depletion of heat shock protein 90-dependent 
signaling proteins. J Natl Cancer Inst 92:242-248. 
Martincic D and Hande KR (2005) Topoisomerase II inhibitors. Cancer 
Chemother Biol Response Modif 22:101-121. 
McStay GP, Salvesen GS and Green DR (2008) Overlapping cleavage 
motif selectivity of caspases: implications for analysis of apoptotic 
pathways. Cell Death Differ 15:322-331. 
Metzstein MM, Stanfield GM and Horvitz HR (1998) Genetics of 
programmed cell death in C. elegans: past, present and future. 
Trends Genet 14:410-416. 
Milleron RS and Bratton SB (2006) Heat shock induces apoptosis 
independently of any known initiator caspase-activating complex. J 
Biol Chem 281:16991-17000. 
 180  
Milleron RS and Bratton SB (2007a) 'Heated' Debates in Apoptosis. Cell 
Mol Life Sci. 
Milleron RS and Bratton SB (2007b) 'Heated' debates in apoptosis. Cell 
Mol Life Sci 64:2329-2333. 
Morimoto RI and Santoro MG (1998) Stress-inducible responses and heat 
shock proteins: new pharmacologic targets for cytoprotection. Nat 
Biotechnol 16:833-838. 
Nitiss JL (2009) Targeting DNA topoisomerase II in cancer chemotherapy. 
Nat Rev Cancer 9:338-350. 
Nitiss JL and Beck WT (1996) Antitopoisomerase drug action and 
resistance. Eur J Cancer 32A:958-966. 
Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei 
AA, Toft DO, Safgren SL and Erlichman C (2006) A phase I trial of 
twice-weekly 17-allylamino-demethoxy-geldanamycin in patients 
with advanced cancer. Clin Cancer Res 12:6087-6093. 
Nunez G, Benedict MA, Hu Y and Inohara N (1998) Caspases: the 
proteases of the apoptotic pathway. Oncogene 17:3237-3245. 
Oberst A, Pop C, Tremblay AG, Blais V, Denault JB, Salvesen GS and 
Green DR Inducible dimerization and inducible cleavage reveal a 
requirement for both processes in caspase-8 activation. J Biol 
Chem. 
 181  
Ow YL, Green DR, Hao Z and Mak TW (2008) Cytochrome c: functions 
beyond respiration. Nat Rev Mol Cell Biol 9:532-542. 
Owen BA, Sullivan WP, Felts SJ and Toft DO (2002) Regulation of heat 
shock protein 90 ATPase activity by sequences in the carboxyl 
terminus. J Biol Chem 277:7086-7091. 
Pagliari LJ, Kuwana T, Bonzon C, Newmeyer DD, Tu S, Beere HM and 
Green DR (2005) The multidomain proapoptotic molecules Bax and 
Bak are directly activated by heat. Proc Natl Acad Sci U S A 
102:17975-17980. 
Park HH, Logette E, Raunser S, Cuenin S, Walz T, Tschopp J and Wu H 
(2007) Death domain assembly mechanism revealed by crystal 
structure of the oligomeric PIDDosome core complex. Cell 128:533-
546. 
Parsell DA, Taulien J and Lindquist S (1993) The role of heat-shock 
proteins in thermotolerance. Philos Trans R Soc Lond B Biol Sci 
339:279-285; discussion 285-276. 
Petak I, Tillman DM, Harwood FG, Mihalik R and Houghton JA (2000) 
Fas-dependent and -independent mechanisms of cell death 
following DNA damage in human colon carcinoma cells. Cancer 
Res 60:2643-2650. 
 182  
Pissuwan D, Valenzuela SM and Cortie MB (2006) Therapeutic 
possibilities of plasmonically heated gold nanoparticles. Trends 
Biotechnol 24:62-67. 
Powers MV and Workman P (2007) Inhibitors of the heat shock response: 
biology and pharmacology. FEBS Lett 581:3758-3769. 
Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P and Grant S (2003) 
Coadministration of the heat shock protein 90 antagonist 17-
allylamino- 17-demethoxygeldanamycin with suberoylanilide 
hydroxamic acid or sodium butyrate synergistically induces 
apoptosis in human leukemia cells. Cancer Res 63:8420-8427. 
Rensing-Ehl A, Frei K, Flury R, Matiba B, Mariani SM, Weller M, 
Aebischer P, Krammer PH and Fontana A (1995) Local Fas/APO-1 
(CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 
25:2253-2258. 
Ritossa F (1996) Discovery of the heat shock response. Cell Stress 
Chaperones 1:97-98. 
Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW and Pearl LH 
(1999) Structural basis for inhibition of the Hsp90 molecular 
chaperone by the antitumor antibiotics radicicol and geldanamycin. 
J Med Chem 42:260-266. 
Samraj AK, Keil E, Ueffing N, Schulze-Osthoff K and Schmitz I (2006) 
Loss of caspase-9 provides genetic evidence for the type I/II 
 183  
concept of CD95-mediated apoptosis. J Biol Chem 281:29652-
29659. 
Sarig R, Zaltsman Y, Marcellus RC, Flavell R, Mak TW and Gross A 
(2003) BID-D59A is a potent inducer of apoptosis in primary 
embryonic fibroblasts. J Biol Chem 278:10707-10715. 
Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin 
KM, Krammer PH and Peter ME (1998) Two CD95 (APO-1/Fas) 
signaling pathways. Embo J 17:1675-1687. 
Schimmer AD (2004) Inhibitor of apoptosis proteins: translating basic 
knowledge into clinical practice. Cancer Res 64:7183-7190. 
Schmitt E, Gehrmann M, Brunet M, Multhoff G and Garrido C (2007) 
Intracellular and extracellular functions of heat shock proteins: 
repercussions in cancer therapy. J Leukoc Biol 81:15-27. 
Schmitz I, Walczak H, Krammer PH and Peter ME (1999) Differences 
between CD95 type I and II cells detected with the CD95 ligand. 
Cell Death Differ 6:821-822. 
Schulte TW, Blagosklonny MV, Ingui C and Neckers L (1995) Disruption of 
the Raf-1-Hsp90 molecular complex results in destabilization of 
Raf-1 and loss of Raf-1-Ras association. J Biol Chem 270:24585-
24588. 
 184  
Scott FL, Denault JB, Riedl SJ, Shin H, Renatus M and Salvesen GS 
(2005) XIAP inhibits caspase-3 and -7 using two binding sites: 
evolutionarily conserved mechanism of IAPs. EMBO J 24:645-655. 
Sharma SV, Agatsuma T and Nakano H (1998) Targeting of the protein 
chaperone, HSP90, by the transformation suppressing agent, 
radicicol. Oncogene 16:2639-2645. 
Shawgo ME, Shelton SN and Robertson JD (2008a) Caspase-mediated 
Bak Activation and Cytochrome c Release during Intrinsic Apoptotic 
Cell Death in Jurkat Cells. J Biol Chem 283:35532-35538. 
Shawgo ME, Shelton SN and Robertson JD (2008b) Caspase-mediated 
Bak activation and cytochrome c release during intrinsic apoptotic 
cell death in Jurkat cells. J Biol Chem 283:35532-35538. 
Shawgo ME, Shelton SN and Robertson JD (2009) Caspase-9 activation 
by the apoptosome is not required for fas-mediated apoptosis in 
type II Jurkat cells. J Biol Chem 284:33447-33455. 
Shay JW and Bacchetti S (1997) A survey of telomerase activity in human 
cancer. Eur J Cancer 33:787-791. 
Shelton SN, Shawgo ME and Robertson JD (2009) Cleavage of Bid by 
executioner caspases mediates feed forward amplification of 
mitochondrial outer membrane permeabilization during genotoxic 
stress-induced apoptosis in Jurkat cells. J Biol Chem 284:11247-
11255. 
 185  
Shi M, Vivian CJ, Lee KJ, Ge C, Morotomi-Yano K, Manzl C, Bock F, Sato 
S, Tomomori-Sato C, Zhu R, Haug JS, Swanson SK, Washburn 
MP, Chen DJ, Chen BP, Villunger A, Florens L and Du C (2009) 
DNA-PKcs-PIDDosome: a nuclear caspase-2-activating complex 
with role in G2/M checkpoint maintenance. Cell 136:508-520. 
Shiozaki EN, Chai J, Rigotti DJ, Riedl SJ, Li P, Srinivasula SM, Alnemri 
ES, Fairman R and Shi Y (2003) Mechanism of XIAP-mediated 
inhibition of caspase-9. Mol Cell 11:519-527. 
Shiozaki EN and Shi Y (2004) Caspases, IAPs and Smac/DIABLO: 
mechanisms from structural biology. Trends Biochem Sci 29:486-
494. 
Slee EA, Keogh SA and Martin SJ (2000) Cleavage of BID during 
cytotoxic drug and UV radiation-induced apoptosis occurs 
downstream of the point of Bcl-2 action and is catalysed by 
caspase-3: a potential feedback loop for amplification of apoptosis-
associated mitochondrial cytochrome c release. Cell Death Differ 
7:556-565. 
Solit DB and Chiosis G (2008) Development and application of Hsp90 
inhibitors. Drug Discov Today 13:38-43. 
Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, Kelly WK, 
DeLaCruz A, Curley T, Heller G, Larson S, Schwartz L, Egorin MJ, 
Rosen N and Scher HI (2007) Phase I trial of 17-allylamino-17-
 186  
demethoxygeldanamycin in patients with advanced cancer. Clin 
Cancer Res 13:1775-1782. 
Solit DB and Rosen N (2006) Hsp90: a novel target for cancer therapy. 
Curr Top Med Chem 6:1205-1214. 
Solit DB, Scher HI and Rosen N (2003) Hsp90 as a therapeutic target in 
prostate cancer. Semin Oncol 30:709-716. 
Sporn MB (1996) The war on cancer. Lancet 347:1377-1381. 
Srinivasula SM, Ahmad M, Fernandes-Alnemri T and Alnemri ES (1998) 
Autoactivation of procaspase-9 by Apaf-1-mediated 
oligomerization. Mol Cell 1:949-957. 
Srinivasula SM and Ashwell JD (2008) IAPs: what's in a name? Mol Cell 
30:123-135. 
Stankiewicz AR, Livingstone AM, Mohseni N and Mosser DD (2009) 
Regulation of heat-induced apoptosis by Mcl-1 degradation and its 
inhibition by Hsp70. Cell Death Differ 16:638-647. 
Stoka V, Turk B, Schendel SL, Kim TH, Cirman T, Snipas SJ, Ellerby LM, 
Bredesen D, Freeze H, Abrahamson M, Bromme D, Krajewski S, 
Reed JC, Yin XM, Turk V and Salvesen GS (2001) Lysosomal 
protease pathways to apoptosis. Cleavage of bid, not pro-
caspases, is the most likely route. J Biol Chem 276:3149-3157. 
 187  
Strasser A, Harris AW, Jacks T and Cory S (1994) DNA damage can 
induce apoptosis in proliferating lymphoid cells via p53-independent 
mechanisms inhibitable by Bcl-2. Cell 79:329-339. 
Sun XM, Bratton SB, Butterworth M, MacFarlane M and Cohen GM (2002) 
Bcl-2 and Bcl-xL inhibit CD95-mediated apoptosis by preventing 
mitochondrial release of Smac/DIABLO and subsequent 
inactivation of X-linked inhibitor-of-apoptosis protein. J Biol Chem 
277:11345-11351. 
Tafani M, Karpinich NO, Hurster KA, Pastorino JG, Schneider T, Russo 
MA and Farber JL (2002) Cytochrome c release upon Fas receptor 
activation depends on translocation of full-length bid and the 
induction of the mitochondrial permeability transition. J Biol Chem 
277:10073-10082. 
Tait SW, de Vries E, Maas C, Keller AM, D'Santos CS and Borst J (2007) 
Apoptosis induction by Bid requires unconventional ubiquitination 
and degradation of its N-terminal fragment. J Cell Biol 179:1453-
1466. 
Thompson CB (1995) Apoptosis in the pathogenesis and treatment of 
disease. Science 267:1456-1462. 
Tinel A and Tschopp J (2004) The PIDDosome, a protein complex 
implicated in activation of caspase-2 in response to genotoxic 
stress. Science 304:843-846. 
 188  
Tu S, McStay GP, Boucher LM, Mak T, Beere HM and Green DR (2006) 
In situ trapping of activated initiator caspases reveals a role for 
caspase-2 in heat shock-induced apoptosis. Nat Cell Biol 8:72-77. 
Valentijn AJ and Gilmore AP (2004) Translocation of full-length Bid to 
mitochondria during anoikis. J Biol Chem 279:32848-32857. 
Vande Walle L, Lamkanfi M and Vandenabeele P (2008) The 
mitochondrial serine protease HtrA2/Omi: an overview. Cell Death 
Differ 15:453-460. 
Veikkola T and Alitalo K (1999) VEGFs, receptors and angiogenesis. 
Semin Cancer Biol 9:211-220. 
Vempati UD, Diaz F, Barrientos A, Narisawa S, Mian AM, Millan JL, Boise 
LH and Moraes CT (2007) Role of cytochrome C in apoptosis: 
increased sensitivity to tumor necrosis factor alpha is associated 
with respiratory defects but not with lack of cytochrome C release. 
Mol Cell Biol 27:1771-1783. 
Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, 
Moritz RL, Simpson RJ and Vaux DL (2000) Identification of 
DIABLO, a mammalian protein that promotes apoptosis by binding 
to and antagonizing IAP proteins. Cell 102:43-53. 
Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner 
MJ, Adams JM and Strasser A (2003) p53- and drug-induced 
 189  
apoptotic responses mediated by BH3-only proteins puma and 
noxa. Science 302:1036-1038. 
Volpert OV, Dameron KM and Bouck N (1997) Sequential development of 
an angiogenic phenotype by human fibroblasts progressing to 
tumorigenicity. Oncogene 14:1495-1502. 
Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular 
perspective. Nat Rev Mol Cell Biol 3:430-440. 
Wang K, Yin XM, Chao DT, Milliman CL and Korsmeyer SJ (1996) BID: a 
novel BH3 domain-only death agonist. Genes Dev 10:2859-2869. 
Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross 
AJ, Roth KA, MacGregor GR, Thompson CB and Korsmeyer SJ 
(2001) Proapoptotic BAX and BAK: a requisite gateway to 
mitochondrial dysfunction and death. Science 292:727-730. 
Weinberg RA (1995) The retinoblastoma protein and cell cycle control. 
Cell 81:323-330. 
Werner AB, Tait SW, de Vries E, Eldering E and Borst J (2004) 
Requirement for aspartate-cleaved bid in apoptosis signaling by 
DNA-damaging anti-cancer regimens. J Biol Chem 279:28771-
28780. 
Whitesell L, Bagatell R and Falsey R (2003) The stress response: 
implications for the clinical development of hsp90 inhibitors. Curr 
Cancer Drug Targets 3:349-358. 
 190  
Whitesell L and Lindquist SL (2005) HSP90 and the chaperoning of 
cancer. Nat Rev Cancer 5:761-772. 
Whitesell L, Mimnaugh EG, De Costa B, Myers CE and Neckers LM 
(1994) Inhibition of heat shock protein HSP90-pp60v-src 
heteroprotein complex formation by benzoquinone ansamycins: 
essential role for stress proteins in oncogenic transformation. Proc 
Natl Acad Sci U S A 91:8324-8328. 
Wilkinson JC, Cepero E, Boise LH and Duckett CS (2004) Upstream 
regulatory role for XIAP in receptor-mediated apoptosis. Mol Cell 
Biol 24:7003-7014. 
Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, 
Ierino H, Lee EF, Fairlie WD, Bouillet P, Strasser A, Kluck RM, 
Adams JM and Huang DC (2007) Apoptosis initiated when BH3 
ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 
315:856-859. 
Workman P and Powers MV (2007) Chaperoning cell death: a critical dual 
role for Hsp90 in small-cell lung cancer. Nat Chem Biol 3:455-457. 
Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, 
Felix R and Schlag PM (2002) Hyperthermia in combined treatment 
of cancer. Lancet Oncol 3:487-497. 
Wyllie AH, Kerr JF and Currie AR (1980) Cell death: the significance of 
apoptosis. Int Rev Cytol 68:251-306. 
 191  
Yang QH, Church-Hajduk R, Ren J, Newton ML and Du C (2003) 
Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) 
irreversibly inactivates IAPs and facilitates caspase activity in 
apoptosis. Genes Dev 17:1487-1496. 
Yang X, Li W, Prescott ED, Burden SJ and Wang JC (2000) DNA 
topoisomerase IIbeta and neural development. Science 287:131-
134. 
Yin XM (2006) Bid, a BH3-only multi-functional molecule, is at the cross 
road of life and death. Gene 369:7-19. 
Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, Roth KA and 
Korsmeyer SJ (1999) Bid-deficient mice are resistant to Fas-
induced hepatocellular apoptosis. Nature 400:886-891. 
Youle RJ and Strasser A (2008) The BCL-2 protein family: opposing 
activities that mediate cell death. Nat Rev Mol Cell Biol 9:47-59. 
Yu XM, Shen G, Neckers L, Blake H, Holzbeierlein J, Cronk B and Blagg 
BS (2005) Hsp90 inhibitors identified from a library of novobiocin 
analogues. J Am Chem Soc 127:12778-12779. 
Yun BG, Huang W, Leach N, Hartson SD and Matts RL (2004) Novobiocin 
induces a distinct conformation of Hsp90 and alters Hsp90-
cochaperone-client interactions. Biochemistry 43:8217-8229. 
 192  
Zha J, Weiler S, Oh KJ, Wei MC and Korsmeyer SJ (2000) 
Posttranslational N-myristoylation of BID as a molecular switch for 
targeting mitochondria and apoptosis. Science 290:1761-1765. 
Zinkel SS, Hurov KE and Gross A (2007) Bid plays a role in the DNA 
damage response. Cell 130:9-10; author reply 10-11. 
Zinkel SS, Hurov KE, Ong C, Abtahi FM, Gross A and Korsmeyer SJ 
(2005) A role for proapoptotic BID in the DNA-damage response. 
Cell 122:579-591. 
Zou J, Guo Y, Guettouche T, Smith DF and Voellmy R (1998) Repression 
of heat shock transcription factor HSF1 activation by HSP90 
(HSP90 complex) that forms a stress-sensitive complex with HSF1. 
Cell 94:471-480. 
 
 
